#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Alterations in intrinsic fronto-thalamo-parietal connectivity are associated with cognitive control deficits in psychotic disorders
#Text=Despite a growing number of reports about alterations in intrinsic/resting brain activity observed in patients with psychotic disorders, their relevance to well-established cognitive control deficits in this patient group is not well understood. 88 clinically stabilized patients with a psychotic disorder and 50 healthy controls participated in a resting-state magnetic resonance imaging study (rs-MRI) and performed an antisaccade task in the laboratory to assess voluntary inhibitory control ability.
1-1	0-11	Alterations	_	
1-2	12-14	in	_	
1-3	15-24	intrinsic	_	
1-4	25-48	fronto-thalamo-parietal	_	
1-5	49-61	connectivity	_	
1-6	62-65	are	_	
1-7	66-76	associated	_	
1-8	77-81	with	_	
1-9	82-91	cognitive	_	
1-10	92-99	control	_	
1-11	100-108	deficits	_	
1-12	109-111	in	_	
1-13	112-121	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[1]	
1-14	122-131	disorders	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[1]	
1-15	132-139	Despite	_	
1-16	140-141	a	_	
1-17	142-149	growing	_	
1-18	150-156	number	_	
1-19	157-159	of	_	
1-20	160-167	reports	_	
1-21	168-173	about	_	
1-22	174-185	alterations	_	
1-23	186-188	in	_	
1-24	189-198	intrinsic	_	
1-25	198-199	/	_	
1-26	199-206	resting	_	
1-27	207-212	brain	_	
1-28	213-221	activity	_	
1-29	222-230	observed	_	
1-30	231-233	in	_	
1-31	234-242	patients	_	
1-32	243-247	with	_	
1-33	248-257	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[2]	
1-34	258-267	disorders	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[2]	
1-35	267-268	,	_	
1-36	269-274	their	_	
1-37	275-284	relevance	_	
1-38	285-287	to	_	
1-39	288-304	well-established	_	
1-40	305-314	cognitive	_	
1-41	315-322	control	_	
1-42	323-331	deficits	_	
1-43	332-334	in	_	
1-44	335-339	this	_	
1-45	340-347	patient	_	
1-46	348-353	group	_	
1-47	354-356	is	_	
1-48	357-360	not	_	
1-49	361-365	well	_	
1-50	366-376	understood	_	
1-51	376-377	.	_	
1-52	378-380	88	_	
1-53	381-391	clinically	_	
1-54	392-402	stabilized	_	
1-55	403-411	patients	_	
1-56	412-416	with	_	
1-57	417-418	a	_	
1-58	419-428	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[3]	
1-59	429-437	disorder	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[3]	
1-60	438-441	and	_	
1-61	442-444	50	_	
1-62	445-452	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
1-63	453-461	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
1-64	462-474	participated	_	
1-65	475-477	in	_	
1-66	478-479	a	_	
1-67	480-493	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
1-68	494-502	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
1-69	503-512	resonance	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
1-70	513-520	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
1-71	521-526	study	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
1-72	527-528	(	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
1-73	528-534	rs-MRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
1-74	534-535	)	_	
1-75	536-539	and	_	
1-76	540-549	performed	_	
1-77	550-552	an	_	
1-78	553-564	antisaccade	_	
1-79	565-569	task	_	
1-80	570-572	in	_	
1-81	573-576	the	_	
1-82	577-587	laboratory	_	
1-83	588-590	to	_	
1-84	591-597	assess	_	
1-85	598-607	voluntary	_	
1-86	608-618	inhibitory	_	
1-87	619-626	control	_	
1-88	627-634	ability	_	
1-89	634-635	.	_	

#Text=Deficits on this task are a well-established biomarker across psychotic disorders as we found in the present patient sample.
2-1	636-644	Deficits	_	
2-2	645-647	on	_	
2-3	648-652	this	_	
2-4	653-657	task	_	
2-5	658-661	are	_	
2-6	662-663	a	_	
2-7	664-680	well-established	_	
2-8	681-690	biomarker	_	
2-9	691-697	across	_	
2-10	698-707	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[6]	
2-11	708-717	disorders	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[6]	
2-12	718-720	as	_	
2-13	721-723	we	_	
2-14	724-729	found	_	
2-15	730-732	in	_	
2-16	733-736	the	_	
2-17	737-744	present	_	
2-18	745-752	patient	_	
2-19	753-759	sample	_	
2-20	759-760	.	_	

#Text=First, regional cerebral function was evaluated by measuring the amplitude of low frequency fluctuations (ALFF) in rs-MRI BOLD signals.
3-1	761-766	First	_	
3-2	766-767	,	_	
3-3	768-776	regional	_	
3-4	777-785	cerebral	_	
3-5	786-794	function	_	
3-6	795-798	was	_	
3-7	799-808	evaluated	_	
3-8	809-811	by	_	
3-9	812-821	measuring	_	
3-10	822-825	the	_	
3-11	826-835	amplitude	_	
3-12	836-838	of	_	
3-13	839-842	low	_	
3-14	843-852	frequency	_	
3-15	853-865	fluctuations	_	
3-16	866-867	(	_	
3-17	867-871	ALFF	_	
3-18	871-872	)	_	
3-19	873-875	in	_	
3-20	876-882	rs-MRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	
3-21	883-887	BOLD	_	
3-22	888-895	signals	_	
3-23	895-896	.	_	

#Text=We found reduced ALFF in patients in regions known to be relevant to antisaccade task performance including bilateral frontal eye fields (FEF), supplementary eye fields (SEF) and thalamus.
4-1	897-899	We	_	
4-2	900-905	found	_	
4-3	906-913	reduced	_	
4-4	914-918	ALFF	_	
4-5	919-921	in	_	
4-6	922-930	patients	_	
4-7	931-933	in	_	
4-8	934-941	regions	_	
4-9	942-947	known	_	
4-10	948-950	to	_	
4-11	951-953	be	_	
4-12	954-962	relevant	_	
4-13	963-965	to	_	
4-14	966-977	antisaccade	_	
4-15	978-982	task	_	
4-16	983-994	performance	_	
4-17	995-1004	including	_	
4-18	1005-1014	bilateral	_	
4-19	1015-1022	frontal	_	
4-20	1023-1026	eye	_	
4-21	1027-1033	fields	_	
4-22	1034-1035	(	_	
4-23	1035-1038	FEF	_	
4-24	1038-1039	)	_	
4-25	1039-1040	,	_	
4-26	1041-1054	supplementary	_	
4-27	1055-1058	eye	_	
4-28	1059-1065	fields	_	
4-29	1066-1067	(	_	
4-30	1067-1070	SEF	_	
4-31	1070-1071	)	_	
4-32	1072-1075	and	_	
4-33	1076-1084	thalamus	_	
4-34	1084-1085	.	_	

#Text=Second, areas with ALFF alterations were used as seed areas in whole-brain functional connectivity (FC) analysis.
5-1	1086-1092	Second	_	
5-2	1092-1093	,	_	
5-3	1094-1099	areas	_	
5-4	1100-1104	with	_	
5-5	1105-1109	ALFF	_	
5-6	1110-1121	alterations	_	
5-7	1122-1126	were	_	
5-8	1127-1131	used	_	
5-9	1132-1134	as	_	
5-10	1135-1139	seed	_	
5-11	1140-1145	areas	_	
5-12	1146-1148	in	_	
5-13	1149-1160	whole-brain	_	
5-14	1161-1171	functional	_	
5-15	1172-1184	connectivity	_	
5-16	1185-1186	(	_	
5-17	1186-1188	FC	_	
5-18	1188-1189	)	_	
5-19	1190-1198	analysis	_	
5-20	1198-1199	.	_	

#Text=Altered FC was observed in a fronto-thalamo-parietal network that was associated with inhibition error rate in patients but not in controls.
6-1	1200-1207	Altered	_	
6-2	1208-1210	FC	_	
6-3	1211-1214	was	_	
6-4	1215-1223	observed	_	
6-5	1224-1226	in	_	
6-6	1227-1228	a	_	
6-7	1229-1252	fronto-thalamo-parietal	_	
6-8	1253-1260	network	_	
6-9	1261-1265	that	_	
6-10	1266-1269	was	_	
6-11	1270-1280	associated	_	
6-12	1281-1285	with	_	
6-13	1286-1296	inhibition	_	
6-14	1297-1302	error	_	
6-15	1303-1307	rate	_	
6-16	1308-1310	in	_	
6-17	1311-1319	patients	_	
6-18	1320-1323	but	_	
6-19	1324-1327	not	_	
6-20	1328-1330	in	_	
6-21	1331-1339	controls	_	
6-22	1339-1340	.	_	

#Text=In contrast, faster time to generate a correct antisaccade was associated with FC in FEF and SEF in controls but this effect was not seen in patients.
7-1	1341-1343	In	_	
7-2	1344-1352	contrast	_	
7-3	1352-1353	,	_	
7-4	1354-1360	faster	_	
7-5	1361-1365	time	_	
7-6	1366-1368	to	_	
7-7	1369-1377	generate	_	
7-8	1378-1379	a	_	
7-9	1380-1387	correct	_	
7-10	1388-1399	antisaccade	_	
7-11	1400-1403	was	_	
7-12	1404-1414	associated	_	
7-13	1415-1419	with	_	
7-14	1420-1422	FC	_	
7-15	1423-1425	in	_	
7-16	1426-1429	FEF	_	
7-17	1430-1433	and	_	
7-18	1434-1437	SEF	_	
7-19	1438-1440	in	_	
7-20	1441-1449	controls	_	
7-21	1450-1453	but	_	
7-22	1454-1458	this	_	
7-23	1459-1465	effect	_	
7-24	1466-1469	was	_	
7-25	1470-1473	not	_	
7-26	1474-1478	seen	_	
7-27	1479-1481	in	_	
7-28	1482-1490	patients	_	
7-29	1490-1491	.	_	

#Text=These findings establish a behavioural relevance of resting-state fMRI findings in psychotic disorders, and extend previous reports of alterations in fronto-thalamo-parietal network activation during antisaccade performance seen in task-based fMRI studies.
8-1	1492-1497	These	_	
8-2	1498-1506	findings	_	
8-3	1507-1516	establish	_	
8-4	1517-1518	a	_	
8-5	1519-1530	behavioural	_	
8-6	1531-1540	relevance	_	
8-7	1541-1543	of	_	
8-8	1544-1557	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[7]	
8-9	1558-1562	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[7]	
8-10	1563-1571	findings	_	
8-11	1572-1574	in	_	
8-12	1575-1584	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[8]	
8-13	1585-1594	disorders	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[8]	
8-14	1594-1595	,	_	
8-15	1596-1599	and	_	
8-16	1600-1606	extend	_	
8-17	1607-1615	previous	_	
8-18	1616-1623	reports	_	
8-19	1624-1626	of	_	
8-20	1627-1638	alterations	_	
8-21	1639-1641	in	_	
8-22	1642-1665	fronto-thalamo-parietal	_	
8-23	1666-1673	network	_	
8-24	1674-1684	activation	_	
8-25	1685-1691	during	_	
8-26	1692-1703	antisaccade	_	
8-27	1704-1715	performance	_	
8-28	1716-1720	seen	_	
8-29	1721-1723	in	_	
8-30	1724-1734	task-based	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[9]	
8-31	1735-1739	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[9]	
8-32	1740-1747	studies	_	
8-33	1747-1748	.	_	

#Text=Introduction
#Text=There is an increasing number of reports from patients with psychotic disorders of altered resting state physiology and functional connectivity in intrinsic brain systems.
9-1	1749-1761	Introduction	_	
9-2	1762-1767	There	_	
9-3	1768-1770	is	_	
9-4	1771-1773	an	_	
9-5	1774-1784	increasing	_	
9-6	1785-1791	number	_	
9-7	1792-1794	of	_	
9-8	1795-1802	reports	_	
9-9	1803-1807	from	_	
9-10	1808-1816	patients	_	
9-11	1817-1821	with	_	
9-12	1822-1831	psychotic	_	
9-13	1832-1841	disorders	_	
9-14	1842-1844	of	_	
9-15	1845-1852	altered	_	
9-16	1853-1860	resting	_	
9-17	1861-1866	state	_	
9-18	1867-1877	physiology	_	
9-19	1878-1881	and	_	
9-20	1882-1892	functional	_	
9-21	1893-1905	connectivity	_	
9-22	1906-1908	in	_	
9-23	1909-1918	intrinsic	_	
9-24	1919-1924	brain	_	
9-25	1925-1932	systems	_	
9-26	1932-1933	.	_	

#Text=Several studies suggest alterations in thalamo-cortical networks characterized by a pattern of reduced prefrontal-thalamic connectivity and increased motor and sensorimotor system connectivity with the thalamus.
10-1	1934-1941	Several	_	
10-2	1942-1949	studies	_	
10-3	1950-1957	suggest	_	
10-4	1958-1969	alterations	_	
10-5	1970-1972	in	_	
10-6	1973-1989	thalamo-cortical	_	
10-7	1990-1998	networks	_	
10-8	1999-2012	characterized	_	
10-9	2013-2015	by	_	
10-10	2016-2017	a	_	
10-11	2018-2025	pattern	_	
10-12	2026-2028	of	_	
10-13	2029-2036	reduced	_	
10-14	2037-2056	prefrontal-thalamic	_	
10-15	2057-2069	connectivity	_	
10-16	2070-2073	and	_	
10-17	2074-2083	increased	_	
10-18	2084-2089	motor	_	
10-19	2090-2093	and	_	
10-20	2094-2106	sensorimotor	_	
10-21	2107-2113	system	_	
10-22	2114-2126	connectivity	_	
10-23	2127-2131	with	_	
10-24	2132-2135	the	_	
10-25	2136-2144	thalamus	_	
10-26	2144-2145	.	_	

#Text=In line with this, we previously reported altered functional connectivity in fronto-thalamo-striatal circuitry as part of the Bipolar and Schizophrenia Network on Intermediate Phenotypes (B-SNIP) consortium study that was identified across patients with schizophrenia-spectrum disorders and psychotic bipolar disorder.
11-1	2146-2148	In	_	
11-2	2149-2153	line	_	
11-3	2154-2158	with	_	
11-4	2159-2163	this	_	
11-5	2163-2164	,	_	
11-6	2165-2167	we	_	
11-7	2168-2178	previously	_	
11-8	2179-2187	reported	_	
11-9	2188-2195	altered	_	
11-10	2196-2206	functional	_	
11-11	2207-2219	connectivity	_	
11-12	2220-2222	in	_	
11-13	2223-2246	fronto-thalamo-striatal	_	
11-14	2247-2256	circuitry	_	
11-15	2257-2259	as	_	
11-16	2260-2264	part	_	
11-17	2265-2267	of	_	
11-18	2268-2271	the	_	
11-19	2272-2279	Bipolar	_	
11-20	2280-2283	and	_	
11-21	2284-2297	Schizophrenia	_	
11-22	2298-2305	Network	_	
11-23	2306-2308	on	_	
11-24	2309-2321	Intermediate	_	
11-25	2322-2332	Phenotypes	_	
11-26	2333-2334	(	_	
11-27	2334-2340	B-SNIP	_	
11-28	2340-2341	)	_	
11-29	2342-2352	consortium	_	
11-30	2353-2358	study	_	
11-31	2359-2363	that	_	
11-32	2364-2367	was	_	
11-33	2368-2378	identified	_	
11-34	2379-2385	across	_	
11-35	2386-2394	patients	_	
11-36	2395-2399	with	_	
11-37	2400-2422	schizophrenia-spectrum	_	
11-38	2423-2432	disorders	_	
11-39	2433-2436	and	_	
11-40	2437-2446	psychotic	_	
11-41	2447-2454	bipolar	_	
11-42	2455-2463	disorder	_	
11-43	2463-2464	.	_	

#Text=While there are now many studies indicating altered resting brain physiology in psychotic disorders, the neurocognitive significance of these deficits such as in cognitive control remains to be well established.
12-1	2465-2470	While	_	
12-2	2471-2476	there	_	
12-3	2477-2480	are	_	
12-4	2481-2484	now	_	
12-5	2485-2489	many	_	
12-6	2490-2497	studies	_	
12-7	2498-2508	indicating	_	
12-8	2509-2516	altered	_	
12-9	2517-2524	resting	_	
12-10	2525-2530	brain	_	
12-11	2531-2541	physiology	_	
12-12	2542-2544	in	_	
12-13	2545-2554	psychotic	_	
12-14	2555-2564	disorders	_	
12-15	2564-2565	,	_	
12-16	2566-2569	the	_	
12-17	2570-2584	neurocognitive	_	
12-18	2585-2597	significance	_	
12-19	2598-2600	of	_	
12-20	2601-2606	these	_	
12-21	2607-2615	deficits	_	
12-22	2616-2620	such	_	
12-23	2621-2623	as	_	
12-24	2624-2626	in	_	
12-25	2627-2636	cognitive	_	
12-26	2637-2644	control	_	
12-27	2645-2652	remains	_	
12-28	2653-2655	to	_	
12-29	2656-2658	be	_	
12-30	2659-2663	well	_	
12-31	2664-2675	established	_	
12-32	2675-2676	.	_	

#Text=One widely used approach to study voluntary cognitive control in psychiatric patients has been the antisaccade task, which requires the suppression of a reflexive saccadic eye movement to a visual target presented in the periphery, and then a voluntary saccade in opposite direction.
13-1	2677-2680	One	_	
13-2	2681-2687	widely	_	
13-3	2688-2692	used	_	
13-4	2693-2701	approach	_	
13-5	2702-2704	to	_	
13-6	2705-2710	study	_	
13-7	2711-2720	voluntary	_	
13-8	2721-2730	cognitive	_	
13-9	2731-2738	control	_	
13-10	2739-2741	in	_	
13-11	2742-2753	psychiatric	_	
13-12	2754-2762	patients	_	
13-13	2763-2766	has	_	
13-14	2767-2771	been	_	
13-15	2772-2775	the	_	
13-16	2776-2787	antisaccade	_	
13-17	2788-2792	task	_	
13-18	2792-2793	,	_	
13-19	2794-2799	which	_	
13-20	2800-2808	requires	_	
13-21	2809-2812	the	_	
13-22	2813-2824	suppression	_	
13-23	2825-2827	of	_	
13-24	2828-2829	a	_	
13-25	2830-2839	reflexive	_	
13-26	2840-2848	saccadic	_	
13-27	2849-2852	eye	_	
13-28	2853-2861	movement	_	
13-29	2862-2864	to	_	
13-30	2865-2866	a	_	
13-31	2867-2873	visual	_	
13-32	2874-2880	target	_	
13-33	2881-2890	presented	_	
13-34	2891-2893	in	_	
13-35	2894-2897	the	_	
13-36	2898-2907	periphery	_	
13-37	2907-2908	,	_	
13-38	2909-2912	and	_	
13-39	2913-2917	then	_	
13-40	2918-2919	a	_	
13-41	2920-2929	voluntary	_	
13-42	2930-2937	saccade	_	
13-43	2938-2940	in	_	
13-44	2941-2949	opposite	_	
13-45	2950-2959	direction	_	
13-46	2959-2960	.	_	

#Text=Increased antisaccade error rates have been consistently reported across untreated first-episode and chronically ill medicated patients with schizophrenia, schizoaffective disorder and psychotic bipolar disorder as well as in their unaffected relatives, supporting its use as a biomarker for psychotic disorders.
14-1	2961-2970	Increased	_	
14-2	2971-2982	antisaccade	_	
14-3	2983-2988	error	_	
14-4	2989-2994	rates	_	
14-5	2995-2999	have	_	
14-6	3000-3004	been	_	
14-7	3005-3017	consistently	_	
14-8	3018-3026	reported	_	
14-9	3027-3033	across	_	
14-10	3034-3043	untreated	_	
14-11	3044-3057	first-episode	_	
14-12	3058-3061	and	_	
14-13	3062-3073	chronically	_	
14-14	3074-3077	ill	_	
14-15	3078-3087	medicated	_	
14-16	3088-3096	patients	_	
14-17	3097-3101	with	_	
14-18	3102-3115	schizophrenia	_	
14-19	3115-3116	,	_	
14-20	3117-3132	schizoaffective	_	
14-21	3133-3141	disorder	_	
14-22	3142-3145	and	_	
14-23	3146-3155	psychotic	_	
14-24	3156-3163	bipolar	_	
14-25	3164-3172	disorder	_	
14-26	3173-3175	as	_	
14-27	3176-3180	well	_	
14-28	3181-3183	as	_	
14-29	3184-3186	in	_	
14-30	3187-3192	their	_	
14-31	3193-3203	unaffected	_	
14-32	3204-3213	relatives	_	
14-33	3213-3214	,	_	
14-34	3215-3225	supporting	_	
14-35	3226-3229	its	_	
14-36	3230-3233	use	_	
14-37	3234-3236	as	_	
14-38	3237-3238	a	_	
14-39	3239-3248	biomarker	_	
14-40	3249-3252	for	_	
14-41	3253-3262	psychotic	_	
14-42	3263-3272	disorders	_	
14-43	3272-3273	.	_	

#Text=We recently replicated and extended these findings in a large cohort of patients with psychotic disorders from the B-SNIP consortium.
15-1	3274-3276	We	_	
15-2	3277-3285	recently	_	
15-3	3286-3296	replicated	_	
15-4	3297-3300	and	_	
15-5	3301-3309	extended	_	
15-6	3310-3315	these	_	
15-7	3316-3324	findings	_	
15-8	3325-3327	in	_	
15-9	3328-3329	a	_	
15-10	3330-3335	large	_	
15-11	3336-3342	cohort	_	
15-12	3343-3345	of	_	
15-13	3346-3354	patients	_	
15-14	3355-3359	with	_	
15-15	3360-3369	psychotic	_	
15-16	3370-3379	disorders	_	
15-17	3380-3384	from	_	
15-18	3385-3388	the	_	
15-19	3389-3395	B-SNIP	_	
15-20	3396-3406	consortium	_	
15-21	3406-3407	.	_	

#Text=From neurophysiological studies of nonhuman primates and human brain imaging studies, the specific neural networks supporting antisaccade performance have been established.
16-1	3408-3412	From	_	
16-2	3413-3431	neurophysiological	_	
16-3	3432-3439	studies	_	
16-4	3440-3442	of	_	
16-5	3443-3451	nonhuman	_	
16-6	3452-3460	primates	_	
16-7	3461-3464	and	_	
16-8	3465-3470	human	_	
16-9	3471-3476	brain	_	
16-10	3477-3484	imaging	_	
16-11	3485-3492	studies	_	
16-12	3492-3493	,	_	
16-13	3494-3497	the	_	
16-14	3498-3506	specific	_	
16-15	3507-3513	neural	_	
16-16	3514-3522	networks	_	
16-17	3523-3533	supporting	_	
16-18	3534-3545	antisaccade	_	
16-19	3546-3557	performance	_	
16-20	3558-3562	have	_	
16-21	3563-3567	been	_	
16-22	3568-3579	established	_	
16-23	3579-3580	.	_	

#Text=This network includes the frontal and supplementary eye fields (FEF and SEF, respectively), the dorsolateral prefrontal cortex (DLPFC), posterior parietal cortex (PPC), precuneus, anterior cingulate (ACC), and subcortical structures including the thalamus, basal ganglia, midbrain superior colliculus (SC) and cerebellum.
17-1	3581-3585	This	_	
17-2	3586-3593	network	_	
17-3	3594-3602	includes	_	
17-4	3603-3606	the	_	
17-5	3607-3614	frontal	_	
17-6	3615-3618	and	_	
17-7	3619-3632	supplementary	_	
17-8	3633-3636	eye	_	
17-9	3637-3643	fields	_	
17-10	3644-3645	(	_	
17-11	3645-3648	FEF	_	
17-12	3649-3652	and	_	
17-13	3653-3656	SEF	_	
17-14	3656-3657	,	_	
17-15	3658-3670	respectively	_	
17-16	3670-3671	)	_	
17-17	3671-3672	,	_	
17-18	3673-3676	the	_	
17-19	3677-3689	dorsolateral	_	
17-20	3690-3700	prefrontal	_	
17-21	3701-3707	cortex	_	
17-22	3708-3709	(	_	
17-23	3709-3714	DLPFC	_	
17-24	3714-3715	)	_	
17-25	3715-3716	,	_	
17-26	3717-3726	posterior	_	
17-27	3727-3735	parietal	_	
17-28	3736-3742	cortex	_	
17-29	3743-3744	(	_	
17-30	3744-3747	PPC	_	
17-31	3747-3748	)	_	
17-32	3748-3749	,	_	
17-33	3750-3759	precuneus	_	
17-34	3759-3760	,	_	
17-35	3761-3769	anterior	_	
17-36	3770-3779	cingulate	_	
17-37	3780-3781	(	_	
17-38	3781-3784	ACC	_	
17-39	3784-3785	)	_	
17-40	3785-3786	,	_	
17-41	3787-3790	and	_	
17-42	3791-3802	subcortical	_	
17-43	3803-3813	structures	_	
17-44	3814-3823	including	_	
17-45	3824-3827	the	_	
17-46	3828-3836	thalamus	_	
17-47	3836-3837	,	_	
17-48	3838-3843	basal	_	
17-49	3844-3851	ganglia	_	
17-50	3851-3852	,	_	
17-51	3853-3861	midbrain	_	
17-52	3862-3870	superior	_	
17-53	3871-3881	colliculus	_	
17-54	3882-3883	(	_	
17-55	3883-3885	SC	_	
17-56	3885-3886	)	_	
17-57	3887-3890	and	_	
17-58	3891-3901	cerebellum	_	
17-59	3901-3902	.	_	

#Text=Additionally, studies of nonhuman primates using single cell recordings have pointed out the importance of intrinsic brain activity in prefrontal-subcortical circuitry prior to trial onset as being critical for task performance.
18-1	3903-3915	Additionally	_	
18-2	3915-3916	,	_	
18-3	3917-3924	studies	_	
18-4	3925-3927	of	_	
18-5	3928-3936	nonhuman	_	
18-6	3937-3945	primates	_	
18-7	3946-3951	using	_	
18-8	3952-3958	single	_	
18-9	3959-3963	cell	_	
18-10	3964-3974	recordings	_	
18-11	3975-3979	have	_	
18-12	3980-3987	pointed	_	
18-13	3988-3991	out	_	
18-14	3992-3995	the	_	
18-15	3996-4006	importance	_	
18-16	4007-4009	of	_	
18-17	4010-4019	intrinsic	_	
18-18	4020-4025	brain	_	
18-19	4026-4034	activity	_	
18-20	4035-4037	in	_	
18-21	4038-4060	prefrontal-subcortical	_	
18-22	4061-4070	circuitry	_	
18-23	4071-4076	prior	_	
18-24	4077-4079	to	_	
18-25	4080-4085	trial	_	
18-26	4086-4091	onset	_	
18-27	4092-4094	as	_	
18-28	4095-4100	being	_	
18-29	4101-4109	critical	_	
18-30	4110-4113	for	_	
18-31	4114-4118	task	_	
18-32	4119-4130	performance	_	
18-33	4130-4131	.	_	

#Text=In healthy human participants, antisaccade error rate and the latency of correct antisaccades have been associated with task-related changes in fronto-thalamo-parietal networks during active task performance.
19-1	4132-4134	In	_	
19-2	4135-4142	healthy	_	
19-3	4143-4148	human	_	
19-4	4149-4161	participants	_	
19-5	4161-4162	,	_	
19-6	4163-4174	antisaccade	_	
19-7	4175-4180	error	_	
19-8	4181-4185	rate	_	
19-9	4186-4189	and	_	
19-10	4190-4193	the	_	
19-11	4194-4201	latency	_	
19-12	4202-4204	of	_	
19-13	4205-4212	correct	_	
19-14	4213-4225	antisaccades	_	
19-15	4226-4230	have	_	
19-16	4231-4235	been	_	
19-17	4236-4246	associated	_	
19-18	4247-4251	with	_	
19-19	4252-4264	task-related	_	
19-20	4265-4272	changes	_	
19-21	4273-4275	in	_	
19-22	4276-4299	fronto-thalamo-parietal	_	
19-23	4300-4308	networks	_	
19-24	4309-4315	during	_	
19-25	4316-4322	active	_	
19-26	4323-4327	task	_	
19-27	4328-4339	performance	_	
19-28	4339-4340	.	_	

#Text=Resting state activity has only recently been related to antisaccade performance in healthy participants revealing associations of antisaccade error rate and response latency with modulations of resting state activity in orbitofrontal and ventrolateral prefrontal cortex as well as medial premotor regions.
20-1	4341-4348	Resting	_	
20-2	4349-4354	state	_	
20-3	4355-4363	activity	_	
20-4	4364-4367	has	_	
20-5	4368-4372	only	_	
20-6	4373-4381	recently	_	
20-7	4382-4386	been	_	
20-8	4387-4394	related	_	
20-9	4395-4397	to	_	
20-10	4398-4409	antisaccade	_	
20-11	4410-4421	performance	_	
20-12	4422-4424	in	_	
20-13	4425-4432	healthy	_	
20-14	4433-4445	participants	_	
20-15	4446-4455	revealing	_	
20-16	4456-4468	associations	_	
20-17	4469-4471	of	_	
20-18	4472-4483	antisaccade	_	
20-19	4484-4489	error	_	
20-20	4490-4494	rate	_	
20-21	4495-4498	and	_	
20-22	4499-4507	response	_	
20-23	4508-4515	latency	_	
20-24	4516-4520	with	_	
20-25	4521-4532	modulations	_	
20-26	4533-4535	of	_	
20-27	4536-4543	resting	_	
20-28	4544-4549	state	_	
20-29	4550-4558	activity	_	
20-30	4559-4561	in	_	
20-31	4562-4575	orbitofrontal	_	
20-32	4576-4579	and	_	
20-33	4580-4593	ventrolateral	_	
20-34	4594-4604	prefrontal	_	
20-35	4605-4611	cortex	_	
20-36	4612-4614	as	_	
20-37	4615-4619	well	_	
20-38	4620-4622	as	_	
20-39	4623-4629	medial	_	
20-40	4630-4638	premotor	_	
20-41	4639-4646	regions	_	
20-42	4646-4647	.	_	

#Text=By taking advantage of noninvasive imaging approaches, the psychoradiology (https://radiopaedia.org/articles/psychoradiology), a subfield of radiology, is increasingly of clinical importance in guiding diagnostic and therapeutic decision making in patients with mental disorders.This prior literature indicates the potential utility of using antisaccade task performance to establish the neurobehavioral relevance of resting-state fMRI data for cognitive control deficits in patients with serious mental illness.
21-1	4648-4650	By	_	
21-2	4651-4657	taking	_	
21-3	4658-4667	advantage	_	
21-4	4668-4670	of	_	
21-5	4671-4682	noninvasive	_	
21-6	4683-4690	imaging	_	
21-7	4691-4701	approaches	_	
21-8	4701-4702	,	_	
21-9	4703-4706	the	_	
21-10	4707-4722	psychoradiology	_	
21-11	4723-4724	(	_	
21-12	4724-4729	https	_	
21-13	4729-4730	:	_	
21-14	4730-4731	/	_	
21-15	4731-4732	/	_	
21-16	4732-4747	radiopaedia.org	_	
21-17	4747-4748	/	_	
21-18	4748-4756	articles	_	
21-19	4756-4757	/	_	
21-20	4757-4772	psychoradiology	_	
21-21	4772-4773	)	_	
21-22	4773-4774	,	_	
21-23	4775-4776	a	_	
21-24	4777-4785	subfield	_	
21-25	4786-4788	of	_	
21-26	4789-4798	radiology	_	
21-27	4798-4799	,	_	
21-28	4800-4802	is	_	
21-29	4803-4815	increasingly	_	
21-30	4816-4818	of	_	
21-31	4819-4827	clinical	_	
21-32	4828-4838	importance	_	
21-33	4839-4841	in	_	
21-34	4842-4849	guiding	_	
21-35	4850-4860	diagnostic	_	
21-36	4861-4864	and	_	
21-37	4865-4876	therapeutic	_	
21-38	4877-4885	decision	_	
21-39	4886-4892	making	_	
21-40	4893-4895	in	_	
21-41	4896-4904	patients	_	
21-42	4905-4909	with	_	
21-43	4910-4916	mental	_	
21-44	4917-4931	disorders.This	_	
21-45	4932-4937	prior	_	
21-46	4938-4948	literature	_	
21-47	4949-4958	indicates	_	
21-48	4959-4962	the	_	
21-49	4963-4972	potential	_	
21-50	4973-4980	utility	_	
21-51	4981-4983	of	_	
21-52	4984-4989	using	_	
21-53	4990-5001	antisaccade	_	
21-54	5002-5006	task	_	
21-55	5007-5018	performance	_	
21-56	5019-5021	to	_	
21-57	5022-5031	establish	_	
21-58	5032-5035	the	_	
21-59	5036-5051	neurobehavioral	_	
21-60	5052-5061	relevance	_	
21-61	5062-5064	of	_	
21-62	5065-5078	resting-state	_	
21-63	5079-5083	fMRI	_	
21-64	5084-5088	data	_	
21-65	5089-5092	for	_	
21-66	5093-5102	cognitive	_	
21-67	5103-5110	control	_	
21-68	5111-5119	deficits	_	
21-69	5120-5122	in	_	
21-70	5123-5131	patients	_	
21-71	5132-5136	with	_	
21-72	5137-5144	serious	_	
21-73	5145-5151	mental	_	
21-74	5152-5159	illness	_	
21-75	5159-5160	.	_	

#Text=In patients with psychotic disorders, functional brain imaging studies have revealed abnormalities in fronto-thalamo-parietal networks during active antisaccade task performance that were associated with increased error rates independent from medication status.
22-1	5161-5163	In	_	
22-2	5164-5172	patients	_	
22-3	5173-5177	with	_	
22-4	5178-5187	psychotic	_	
22-5	5188-5197	disorders	_	
22-6	5197-5198	,	_	
22-7	5199-5209	functional	_	
22-8	5210-5215	brain	_	
22-9	5216-5223	imaging	_	
22-10	5224-5231	studies	_	
22-11	5232-5236	have	_	
22-12	5237-5245	revealed	_	
22-13	5246-5259	abnormalities	_	
22-14	5260-5262	in	_	
22-15	5263-5286	fronto-thalamo-parietal	_	
22-16	5287-5295	networks	_	
22-17	5296-5302	during	_	
22-18	5303-5309	active	_	
22-19	5310-5321	antisaccade	_	
22-20	5322-5326	task	_	
22-21	5327-5338	performance	_	
22-22	5339-5343	that	_	
22-23	5344-5348	were	_	
22-24	5349-5359	associated	_	
22-25	5360-5364	with	_	
22-26	5365-5374	increased	_	
22-27	5375-5380	error	_	
22-28	5381-5386	rates	_	
22-29	5387-5398	independent	_	
22-30	5399-5403	from	_	
22-31	5404-5414	medication	_	
22-32	5415-5421	status	_	
22-33	5421-5422	.	_	

#Text=However, whether impairments of antisaccade performance in patients with psychotic disorders are also related to alterations of resting brain activity in fronto-thalamo-parietal brain systems remains to be established.
23-1	5423-5430	However	_	
23-2	5430-5431	,	_	
23-3	5432-5439	whether	_	
23-4	5440-5451	impairments	_	
23-5	5452-5454	of	_	
23-6	5455-5466	antisaccade	_	
23-7	5467-5478	performance	_	
23-8	5479-5481	in	_	
23-9	5482-5490	patients	_	
23-10	5491-5495	with	_	
23-11	5496-5505	psychotic	_	
23-12	5506-5515	disorders	_	
23-13	5516-5519	are	_	
23-14	5520-5524	also	_	
23-15	5525-5532	related	_	
23-16	5533-5535	to	_	
23-17	5536-5547	alterations	_	
23-18	5548-5550	of	_	
23-19	5551-5558	resting	_	
23-20	5559-5564	brain	_	
23-21	5565-5573	activity	_	
23-22	5574-5576	in	_	
23-23	5577-5600	fronto-thalamo-parietal	_	
23-24	5601-5606	brain	_	
23-25	5607-5614	systems	_	
23-26	5615-5622	remains	_	
23-27	5623-5625	to	_	
23-28	5626-5628	be	_	
23-29	5629-5640	established	_	
23-30	5640-5641	.	_	

#Text=There were two hypotheses driving the present study.
24-1	5642-5647	There	_	
24-2	5648-5652	were	_	
24-3	5653-5656	two	_	
24-4	5657-5667	hypotheses	_	
24-5	5668-5675	driving	_	
24-6	5676-5679	the	_	
24-7	5680-5687	present	_	
24-8	5688-5693	study	_	
24-9	5693-5694	.	_	

#Text=First, we predicted that increased antisaccade error rates in patients would be associated with reduced coherent activity in distinct brain regions associated with antisaccade performance, e.g.
25-1	5695-5700	First	_	
25-2	5700-5701	,	_	
25-3	5702-5704	we	_	
25-4	5705-5714	predicted	_	
25-5	5715-5719	that	_	
25-6	5720-5729	increased	_	
25-7	5730-5741	antisaccade	_	
25-8	5742-5747	error	_	
25-9	5748-5753	rates	_	
25-10	5754-5756	in	_	
25-11	5757-5765	patients	_	
25-12	5766-5771	would	_	
25-13	5772-5774	be	_	
25-14	5775-5785	associated	_	
25-15	5786-5790	with	_	
25-16	5791-5798	reduced	_	
25-17	5799-5807	coherent	_	
25-18	5808-5816	activity	_	
25-19	5817-5819	in	_	
25-20	5820-5828	distinct	_	
25-21	5829-5834	brain	_	
25-22	5835-5842	regions	_	
25-23	5843-5853	associated	_	
25-24	5854-5858	with	_	
25-25	5859-5870	antisaccade	_	
25-26	5871-5882	performance	_	
25-27	5882-5883	,	_	
25-28	5884-5887	e.g	_	
25-29	5887-5888	.	_	

#Text=FEF, SEF and thalamus, and second that error rates would also be related to alterations of functional connectivity within this circuitry.
26-1	5889-5892	FEF	_	
26-2	5892-5893	,	_	
26-3	5894-5897	SEF	_	
26-4	5898-5901	and	_	
26-5	5902-5910	thalamus	_	
26-6	5910-5911	,	_	
26-7	5912-5915	and	_	
26-8	5916-5922	second	_	
26-9	5923-5927	that	_	
26-10	5928-5933	error	_	
26-11	5934-5939	rates	_	
26-12	5940-5945	would	_	
26-13	5946-5950	also	_	
26-14	5951-5953	be	_	
26-15	5954-5961	related	_	
26-16	5962-5964	to	_	
26-17	5965-5976	alterations	_	
26-18	5977-5979	of	_	
26-19	5980-5990	functional	_	
26-20	5991-6003	connectivity	_	
26-21	6004-6010	within	_	
26-22	6011-6015	this	_	
26-23	6016-6025	circuitry	_	
26-24	6025-6026	.	_	

#Text=Based on our previous findings of elevated antisaccade error rates across psychotic disorders in the B-SNIP sample and similar disturbances of resting state measures in task-relevant fronto-thalamo-striatal circuitry in clinically stable patients with schizophrenia-spectrum and bipolar disorders, we tested these hypotheses in a combined patient sample with both affective and non-affective psychotic disorders.
27-1	6027-6032	Based	_	
27-2	6033-6035	on	_	
27-3	6036-6039	our	_	
27-4	6040-6048	previous	_	
27-5	6049-6057	findings	_	
27-6	6058-6060	of	_	
27-7	6061-6069	elevated	_	
27-8	6070-6081	antisaccade	_	
27-9	6082-6087	error	_	
27-10	6088-6093	rates	_	
27-11	6094-6100	across	_	
27-12	6101-6110	psychotic	_	
27-13	6111-6120	disorders	_	
27-14	6121-6123	in	_	
27-15	6124-6127	the	_	
27-16	6128-6134	B-SNIP	_	
27-17	6135-6141	sample	_	
27-18	6142-6145	and	_	
27-19	6146-6153	similar	_	
27-20	6154-6166	disturbances	_	
27-21	6167-6169	of	_	
27-22	6170-6177	resting	_	
27-23	6178-6183	state	_	
27-24	6184-6192	measures	_	
27-25	6193-6195	in	_	
27-26	6196-6209	task-relevant	_	
27-27	6210-6233	fronto-thalamo-striatal	_	
27-28	6234-6243	circuitry	_	
27-29	6244-6246	in	_	
27-30	6247-6257	clinically	_	
27-31	6258-6264	stable	_	
27-32	6265-6273	patients	_	
27-33	6274-6278	with	_	
27-34	6279-6301	schizophrenia-spectrum	_	
27-35	6302-6305	and	_	
27-36	6306-6313	bipolar	_	
27-37	6314-6323	disorders	_	
27-38	6323-6324	,	_	
27-39	6325-6327	we	_	
27-40	6328-6334	tested	_	
27-41	6335-6340	these	_	
27-42	6341-6351	hypotheses	_	
27-43	6352-6354	in	_	
27-44	6355-6356	a	_	
27-45	6357-6365	combined	_	
27-46	6366-6373	patient	_	
27-47	6374-6380	sample	_	
27-48	6381-6385	with	_	
27-49	6386-6390	both	_	
27-50	6391-6400	affective	_	
27-51	6401-6404	and	_	
27-52	6405-6418	non-affective	_	
27-53	6419-6428	psychotic	_	
27-54	6429-6438	disorders	_	
27-55	6438-6439	.	_	

#Text=Material and methods
#Text=Subjects
#Text=Antisaccade performance was assessed in 88 patients with a psychotic disorder (schizophrenia N=32, schizoaffective disorder N=13, and bipolar disorder with psychotic features N=43) and 50 healthy control participants studied at the Chicago site of the B-SNIP consortium as described previously.
28-1	6440-6448	Material	http://www.case.edu/ProvCaRe/provcare#StudyMethod[10]	
28-2	6449-6452	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[10]	
28-3	6453-6460	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[10]	
28-4	6461-6469	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-5	6470-6481	Antisaccade	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-6	6482-6493	performance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-7	6494-6497	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-8	6498-6506	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-9	6507-6509	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-10	6510-6512	88	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-11	6513-6521	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-12	6522-6526	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-13	6527-6528	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-14	6529-6538	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[12]	
28-15	6539-6547	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[12]	
28-16	6548-6549	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-17	6549-6562	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[13]	
28-18	6563-6564	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-19	6564-6565	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-20	6565-6567	32	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-21	6567-6568	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-22	6569-6584	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[14]	
28-23	6585-6593	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[14]	
28-24	6594-6595	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-25	6595-6596	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-26	6596-6598	13	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-27	6598-6599	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-28	6600-6603	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-29	6604-6611	bipolar	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder[15]	
28-30	6612-6620	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder[15]	
28-31	6621-6625	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-32	6626-6635	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-33	6636-6644	features	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-34	6645-6646	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-35	6646-6647	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-36	6647-6649	43	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-37	6649-6650	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-38	6651-6654	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-39	6655-6657	50	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-40	6658-6665	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[16]	
28-41	6666-6673	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[16]	
28-42	6674-6686	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-43	6687-6694	studied	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-44	6695-6697	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-45	6698-6701	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-46	6702-6709	Chicago	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-47	6710-6714	site	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-48	6715-6717	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-49	6718-6721	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-50	6722-6728	B-SNIP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-51	6729-6739	consortium	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-52	6740-6742	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-53	6743-6752	described	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-54	6753-6763	previously	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
28-55	6763-6764	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Diagnoses were made by a consensus process using all available clinical information including the Structured Clinical Interview for DSM IV.
29-1	6765-6774	Diagnoses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-2	6775-6779	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-3	6780-6784	made	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-4	6785-6787	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-5	6788-6789	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-6	6790-6799	consensus	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-7	6800-6807	process	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-8	6808-6813	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-9	6814-6817	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-10	6818-6827	available	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-11	6828-6836	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-12	6837-6848	information	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-13	6849-6858	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-14	6859-6862	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-15	6863-6873	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[17]	
29-16	6874-6882	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[17]	
29-17	6883-6892	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[17]	
29-18	6893-6896	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[17]	
29-19	6897-6900	DSM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[17]	
29-20	6901-6903	IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[17]	
29-21	6903-6904	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Patients were clinically stable and receiving consistent psychopharmacological treatment for at least one month.
30-1	6905-6913	Patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-2	6914-6918	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-3	6919-6929	clinically	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-4	6930-6936	stable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-5	6937-6940	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-6	6941-6950	receiving	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-7	6951-6961	consistent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-8	6962-6983	psychopharmacological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-9	6984-6993	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-10	6994-6997	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-11	6998-7000	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-12	7001-7006	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-13	7007-7010	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-14	7011-7016	month	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-15	7016-7017	.	_	

#Text=Current symptoms and cognitive status were assessed using standard rating scales, Table I (Table I S).
31-1	7018-7025	Current	_	
31-2	7026-7034	symptoms	_	
31-3	7035-7038	and	_	
31-4	7039-7048	cognitive	_	
31-5	7049-7055	status	_	
31-6	7056-7060	were	_	
31-7	7061-7069	assessed	_	
31-8	7070-7075	using	_	
31-9	7076-7084	standard	_	
31-10	7085-7091	rating	_	
31-11	7092-7098	scales	_	
31-12	7098-7099	,	_	
31-13	7100-7105	Table	_	
31-14	7106-7107	I	_	
31-15	7108-7109	(	_	
31-16	7109-7114	Table	_	
31-17	7115-7116	I	_	
31-18	7117-7118	S	_	
31-19	7118-7119	)	_	
31-20	7119-7120	.	_	

#Text=Inclusion criteria for all subjects were: (1) age 15–65; (2) WRAT reading score ≥ 65; (3) no history of neurologic illness or systemic disease; (4) minimum of 20/40 acuity (with or without correction), (5) no history of substance abuse within the last month or substance dependence within the last three months, and negative urine toxicology on assessment day, (6) no potentially sedating medication, i.e. benzodiazepines, and (7) head translation <1.5mm and rotation <1.5° during fMRI scanning.
32-1	7121-7130	Inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-2	7131-7139	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-3	7140-7143	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-4	7144-7147	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-5	7148-7156	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-6	7157-7161	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-7	7161-7162	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-8	7163-7164	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-9	7164-7165	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-10	7165-7166	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-11	7167-7170	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-12	7171-7173	15	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-13	7173-7174	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-14	7174-7176	65	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-15	7176-7177	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-16	7178-7179	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-17	7179-7180	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-18	7180-7181	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-19	7182-7186	WRAT	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-20	7187-7194	reading	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-21	7195-7200	score	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-22	7201-7202	≥	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-23	7203-7205	65	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-24	7205-7206	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-25	7207-7208	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-26	7208-7209	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-27	7209-7210	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-28	7211-7213	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-29	7214-7221	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-30	7222-7224	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-31	7225-7235	neurologic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-32	7236-7243	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-33	7244-7246	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-34	7247-7255	systemic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-35	7256-7263	disease	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-36	7263-7264	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-37	7265-7266	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-38	7266-7267	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-39	7267-7268	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-40	7269-7276	minimum	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-41	7277-7279	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-42	7280-7282	20	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-43	7282-7283	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-44	7283-7285	40	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-45	7286-7292	acuity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-46	7293-7294	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-47	7294-7298	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-48	7299-7301	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-49	7302-7309	without	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-50	7310-7320	correction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-51	7320-7321	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-52	7321-7322	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-53	7323-7324	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-54	7324-7325	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-55	7325-7326	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-56	7327-7329	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-57	7330-7337	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-58	7338-7340	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-59	7341-7350	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-60	7351-7356	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-61	7357-7363	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-62	7364-7367	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-63	7368-7372	last	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-64	7373-7378	month	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-65	7379-7381	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-66	7382-7391	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-67	7392-7402	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-68	7403-7409	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-69	7410-7413	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-70	7414-7418	last	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-71	7419-7424	three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-72	7425-7431	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-73	7431-7432	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-74	7433-7436	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-75	7437-7445	negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-76	7446-7451	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-77	7452-7462	toxicology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-78	7463-7465	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-79	7466-7476	assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-80	7477-7480	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-81	7480-7481	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-82	7482-7483	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-83	7483-7484	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-84	7484-7485	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-85	7486-7488	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-86	7489-7500	potentially	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-87	7501-7509	sedating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-88	7510-7520	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-89	7520-7521	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-90	7522-7525	i.e	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-91	7525-7526	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-92	7527-7542	benzodiazepines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-93	7542-7543	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-94	7544-7547	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-95	7548-7549	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-96	7549-7550	7	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-97	7550-7551	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-98	7552-7556	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-99	7557-7568	translation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-100	7569-7570	<	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-101	7570-7575	1.5mm	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-102	7576-7579	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-103	7580-7588	rotation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-104	7589-7590	<	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-105	7590-7593	1.5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-106	7593-7594	°	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-107	7595-7601	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-108	7602-7606	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[19]	
32-109	7607-7615	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-110	7615-7616	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=Inclusion criteria for control subjects additionally included: (1) no personal or family history (first-degree relative) of psychotic or bipolar disorder; (2) no history of recurrent depression; and (3) no history of psychosis spectrum personality traits defined as meeting full or within one criteria of a Cluster A (psychosis spectrum) Axis-II diagnosis.
33-1	7617-7626	Inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-2	7627-7635	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-3	7636-7639	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-4	7640-7647	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-5	7648-7656	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-6	7657-7669	additionally	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-7	7670-7678	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-8	7678-7679	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-9	7680-7681	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-10	7681-7682	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-11	7682-7683	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-12	7684-7686	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-13	7687-7695	personal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-14	7696-7698	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-15	7699-7705	family	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-16	7706-7713	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-17	7714-7715	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-18	7715-7727	first-degree	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-19	7728-7736	relative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-20	7736-7737	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-21	7738-7740	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-22	7741-7750	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-23	7751-7753	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-24	7754-7761	bipolar	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-25	7762-7770	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-26	7770-7771	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-27	7772-7773	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-28	7773-7774	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-29	7774-7775	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-30	7776-7778	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-31	7779-7786	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-32	7787-7789	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-33	7790-7799	recurrent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-34	7800-7810	depression	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-35	7810-7811	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-36	7812-7815	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-37	7816-7817	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-38	7817-7818	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-39	7818-7819	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-40	7820-7822	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-41	7823-7830	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-42	7831-7833	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-43	7834-7843	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-44	7844-7852	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-45	7853-7864	personality	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-46	7865-7871	traits	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-47	7872-7879	defined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-48	7880-7882	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-49	7883-7890	meeting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-50	7891-7895	full	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-51	7896-7898	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-52	7899-7905	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-53	7906-7909	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-54	7910-7918	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-55	7919-7921	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-56	7922-7923	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-57	7924-7931	Cluster	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-58	7932-7933	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-59	7934-7935	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-60	7935-7944	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-61	7945-7953	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-62	7953-7954	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-63	7955-7962	Axis-II	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-64	7963-7972	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
33-65	7972-7973	.	_	

#Text=The median time for completion of the full protocol was two days.
34-1	7974-7977	The	_	
34-2	7978-7984	median	_	
34-3	7985-7989	time	_	
34-4	7990-7993	for	_	
34-5	7994-8004	completion	_	
34-6	8005-8007	of	_	
34-7	8008-8011	the	_	
34-8	8012-8016	full	_	
34-9	8017-8025	protocol	_	
34-10	8026-8029	was	_	
34-11	8030-8033	two	_	
34-12	8034-8038	days	_	
34-13	8038-8039	.	_	

#Text=T1 and T2 weighted magnetic resonance images were inspected by an experienced neuroradiologist to exclude significant structural abnormalities, e.g. tumors, in all participants.
35-1	8040-8042	T1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[22]	
35-2	8043-8046	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
35-3	8047-8049	T2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[23]	
35-4	8050-8058	weighted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[23]	
35-5	8059-8067	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[24]	
35-6	8068-8077	resonance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[24]	
35-7	8078-8084	images	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[24]	
35-8	8085-8089	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
35-9	8090-8099	inspected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
35-10	8100-8102	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
35-11	8103-8105	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
35-12	8106-8117	experienced	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
35-13	8118-8134	neuroradiologist	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
35-14	8135-8137	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
35-15	8138-8145	exclude	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
35-16	8146-8157	significant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
35-17	8158-8168	structural	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
35-18	8169-8182	abnormalities	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
35-19	8182-8183	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
35-20	8184-8187	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
35-21	8187-8188	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
35-22	8189-8195	tumors	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
35-23	8195-8196	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
35-24	8197-8199	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
35-25	8200-8203	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
35-26	8204-8216	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
35-27	8216-8217	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	

#Text=The study was approved by the institutional review board of the University of Illinois at Chicago and written informed consent was obtained prior to study participation.
36-1	8218-8221	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-2	8222-8227	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-3	8228-8231	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-4	8232-8240	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-5	8241-8243	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-6	8244-8247	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-7	8248-8261	institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-8	8262-8268	review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-9	8269-8274	board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-10	8275-8277	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-11	8278-8281	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-12	8282-8292	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-13	8293-8295	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-14	8296-8304	Illinois	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-15	8305-8307	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-16	8308-8315	Chicago	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-17	8316-8319	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-18	8320-8327	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-19	8328-8336	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-20	8337-8344	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-21	8345-8348	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-22	8349-8357	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-23	8358-8363	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-24	8364-8366	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-25	8367-8372	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-26	8373-8386	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
36-27	8386-8387	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	

#Text=Eye movement testing
#Text=Antisaccade testing and analysis procedures have been described in detail previously.
37-1	8388-8391	Eye	_	
37-2	8392-8400	movement	_	
37-3	8401-8408	testing	_	
37-4	8409-8420	Antisaccade	_	
37-5	8421-8428	testing	_	
37-6	8429-8432	and	_	
37-7	8433-8441	analysis	_	
37-8	8442-8452	procedures	_	
37-9	8453-8457	have	_	
37-10	8458-8462	been	_	
37-11	8463-8472	described	_	
37-12	8473-8475	in	_	
37-13	8476-8482	detail	_	
37-14	8483-8493	previously	_	
37-15	8493-8494	.	_	

#Text=Eye movements were acquired with a video-based eye tracker in a darkened room (Eyelink II, SR Research Ltd., Ontario/Canada, sampling rate 500 Hz).
38-1	8495-8498	Eye	_	
38-2	8499-8508	movements	_	
38-3	8509-8513	were	_	
38-4	8514-8522	acquired	_	
38-5	8523-8527	with	_	
38-6	8528-8529	a	_	
38-7	8530-8541	video-based	_	
38-8	8542-8545	eye	_	
38-9	8546-8553	tracker	_	
38-10	8554-8556	in	_	
38-11	8557-8558	a	_	
38-12	8559-8567	darkened	_	
38-13	8568-8572	room	_	
38-14	8573-8574	(	_	
38-15	8574-8581	Eyelink	_	
38-16	8582-8584	II	_	
38-17	8584-8585	,	_	
38-18	8586-8588	SR	_	
38-19	8589-8597	Research	_	
38-20	8598-8601	Ltd	_	
38-21	8601-8602	.	_	
38-22	8602-8603	,	_	
38-23	8604-8611	Ontario	_	
38-24	8611-8612	/	_	
38-25	8612-8618	Canada	_	
38-26	8618-8619	,	_	
38-27	8620-8628	sampling	_	
38-28	8629-8633	rate	_	
38-29	8634-8637	500	_	
38-30	8638-8640	Hz	_	
38-31	8640-8641	)	_	
38-32	8641-8642	.	_	

#Text=Before testing, participants refrained from nicotine or caffeine exposure for at least 30 minutes.
39-1	8643-8649	Before	_	
39-2	8650-8657	testing	_	
39-3	8657-8658	,	_	
39-4	8659-8671	participants	_	
39-5	8672-8681	refrained	_	
39-6	8682-8686	from	_	
39-7	8687-8695	nicotine	_	
39-8	8696-8698	or	_	
39-9	8699-8707	caffeine	_	
39-10	8708-8716	exposure	_	
39-11	8717-8720	for	_	
39-12	8721-8723	at	_	
39-13	8724-8729	least	_	
39-14	8730-8732	30	_	
39-15	8733-8740	minutes	_	
39-16	8740-8741	.	_	

#Text=They were seated 60 cm from a 22-inch CRT monitor (1360 × 768 resolution; 150 Hz refresh rate) with their heads stabilized with a chin and forehead restraint.
40-1	8742-8746	They	_	
40-2	8747-8751	were	_	
40-3	8752-8758	seated	_	
40-4	8759-8761	60	_	
40-5	8762-8764	cm	_	
40-6	8765-8769	from	_	
40-7	8770-8771	a	_	
40-8	8772-8774	22	_	
40-9	8774-8775	-	_	
40-10	8775-8779	inch	_	
40-11	8780-8783	CRT	_	
40-12	8784-8791	monitor	_	
40-13	8792-8793	(	_	
40-14	8793-8797	1360	_	
40-15	8798-8799	×	_	
40-16	8800-8803	768	_	
40-17	8804-8814	resolution	_	
40-18	8814-8815	;	_	
40-19	8816-8819	150	_	
40-20	8820-8822	Hz	_	
40-21	8823-8830	refresh	_	
40-22	8831-8835	rate	_	
40-23	8835-8836	)	_	
40-24	8837-8841	with	_	
40-25	8842-8847	their	_	
40-26	8848-8853	heads	_	
40-27	8854-8864	stabilized	_	
40-28	8865-8869	with	_	
40-29	8870-8871	a	_	
40-30	8872-8876	chin	_	
40-31	8877-8880	and	_	
40-32	8881-8889	forehead	_	
40-33	8890-8899	restraint	_	
40-34	8899-8900	.	_	

#Text=The target was a red cross in a box covering 0.5°.
41-1	8901-8904	The	_	
41-2	8905-8911	target	_	
41-3	8912-8915	was	_	
41-4	8916-8917	a	_	
41-5	8918-8921	red	_	
41-6	8922-8927	cross	_	
41-7	8928-8930	in	_	
41-8	8931-8932	a	_	
41-9	8933-8936	box	_	
41-10	8937-8945	covering	_	
41-11	8946-8949	0.5	_	
41-12	8949-8950	°	_	
41-13	8950-8951	.	_	

#Text=The antisaccade task consisted of 80 overlap trials divided into four blocks.
42-1	8952-8955	The	_	
42-2	8956-8967	antisaccade	_	
42-3	8968-8972	task	_	
42-4	8973-8982	consisted	_	
42-5	8983-8985	of	_	
42-6	8986-8988	80	_	
42-7	8989-8996	overlap	_	
42-8	8997-9003	trials	_	
42-9	9004-9011	divided	_	
42-10	9012-9016	into	_	
42-11	9017-9021	four	_	
42-12	9022-9028	blocks	_	
42-13	9028-9029	.	_	

#Text=After a period of central fixation (1500 – 2500 msec), the central target was extinguished 200ms after peripheral target appearance at either 10° or 15° to the left or right from center.
43-1	9030-9035	After	_	
43-2	9036-9037	a	_	
43-3	9038-9044	period	_	
43-4	9045-9047	of	_	
43-5	9048-9055	central	_	
43-6	9056-9064	fixation	_	
43-7	9065-9066	(	_	
43-8	9066-9070	1500	_	
43-9	9071-9072	–	_	
43-10	9073-9077	2500	_	
43-11	9078-9082	msec	_	
43-12	9082-9083	)	_	
43-13	9083-9084	,	_	
43-14	9085-9088	the	_	
43-15	9089-9096	central	_	
43-16	9097-9103	target	_	
43-17	9104-9107	was	_	
43-18	9108-9120	extinguished	_	
43-19	9121-9126	200ms	_	
43-20	9127-9132	after	_	
43-21	9133-9143	peripheral	_	
43-22	9144-9150	target	_	
43-23	9151-9161	appearance	_	
43-24	9162-9164	at	_	
43-25	9165-9171	either	_	
43-26	9172-9174	10	_	
43-27	9174-9175	°	_	
43-28	9176-9178	or	_	
43-29	9179-9181	15	_	
43-30	9181-9182	°	_	
43-31	9183-9185	to	_	
43-32	9186-9189	the	_	
43-33	9190-9194	left	_	
43-34	9195-9197	or	_	
43-35	9198-9203	right	_	
43-36	9204-9208	from	_	
43-37	9209-9215	center	_	
43-38	9215-9216	.	_	

#Text=Subjects were instructed to not look to the peripheral target (antisaccade error) but instead immediately look to the mirror image location in the opposite hemi-field.
44-1	9217-9225	Subjects	_	
44-2	9226-9230	were	_	
44-3	9231-9241	instructed	_	
44-4	9242-9244	to	_	
44-5	9245-9248	not	_	
44-6	9249-9253	look	_	
44-7	9254-9256	to	_	
44-8	9257-9260	the	_	
44-9	9261-9271	peripheral	_	
44-10	9272-9278	target	_	
44-11	9279-9280	(	_	
44-12	9280-9291	antisaccade	_	
44-13	9292-9297	error	_	
44-14	9297-9298	)	_	
44-15	9299-9302	but	_	
44-16	9303-9310	instead	_	
44-17	9311-9322	immediately	_	
44-18	9323-9327	look	_	
44-19	9328-9330	to	_	
44-20	9331-9334	the	_	
44-21	9335-9341	mirror	_	
44-22	9342-9347	image	_	
44-23	9348-9356	location	_	
44-24	9357-9359	in	_	
44-25	9360-9363	the	_	
44-26	9364-9372	opposite	_	
44-27	9373-9383	hemi-field	_	
44-28	9383-9384	.	_	

#Text=The percentage of trials with antisaccade errors was recorded indicating failed inhibitory control.
45-1	9385-9388	The	_	
45-2	9389-9399	percentage	_	
45-3	9400-9402	of	_	
45-4	9403-9409	trials	_	
45-5	9410-9414	with	_	
45-6	9415-9426	antisaccade	_	
45-7	9427-9433	errors	_	
45-8	9434-9437	was	_	
45-9	9438-9446	recorded	_	
45-10	9447-9457	indicating	_	
45-11	9458-9464	failed	_	
45-12	9465-9475	inhibitory	_	
45-13	9476-9483	control	_	
45-14	9483-9484	.	_	

#Text=The mean latency of correct antisaccades for each subject was also determined, which reflects time to inhibit an antisaccade error and implement of task-appropriate correct goal-directed voluntary behavior.
46-1	9485-9488	The	_	
46-2	9489-9493	mean	_	
46-3	9494-9501	latency	_	
46-4	9502-9504	of	_	
46-5	9505-9512	correct	_	
46-6	9513-9525	antisaccades	_	
46-7	9526-9529	for	_	
46-8	9530-9534	each	_	
46-9	9535-9542	subject	_	
46-10	9543-9546	was	_	
46-11	9547-9551	also	_	
46-12	9552-9562	determined	_	
46-13	9562-9563	,	_	
46-14	9564-9569	which	_	
46-15	9570-9578	reflects	_	
46-16	9579-9583	time	_	
46-17	9584-9586	to	_	
46-18	9587-9594	inhibit	_	
46-19	9595-9597	an	_	
46-20	9598-9609	antisaccade	_	
46-21	9610-9615	error	_	
46-22	9616-9619	and	_	
46-23	9620-9629	implement	_	
46-24	9630-9632	of	_	
46-25	9633-9649	task-appropriate	_	
46-26	9650-9657	correct	_	
46-27	9658-9671	goal-directed	_	
46-28	9672-9681	voluntary	_	
46-29	9682-9690	behavior	_	
46-30	9690-9691	.	_	

#Text=Resting State fMRI Data Acquisition
#Text=Brain scans were conducted using a GE Signa EXCITE 3.0 Tesla MR imaging system and an 8-channel phased array head coil.
47-1	9692-9699	Resting	_	
47-2	9700-9705	State	_	
47-3	9706-9710	fMRI	_	
47-4	9711-9715	Data	_	
47-5	9716-9727	Acquisition	_	
47-6	9728-9733	Brain	_	
47-7	9734-9739	scans	_	
47-8	9740-9744	were	_	
47-9	9745-9754	conducted	_	
47-10	9755-9760	using	_	
47-11	9761-9762	a	_	
47-12	9763-9765	GE	_	
47-13	9766-9771	Signa	_	
47-14	9772-9778	EXCITE	_	
47-15	9779-9782	3.0	_	
47-16	9783-9788	Tesla	_	
47-17	9789-9791	MR	_	
47-18	9792-9799	imaging	_	
47-19	9800-9806	system	_	
47-20	9807-9810	and	_	
47-21	9811-9813	an	_	
47-22	9814-9815	8	_	
47-23	9815-9816	-	_	
47-24	9816-9823	channel	_	
47-25	9824-9830	phased	_	
47-26	9831-9836	array	_	
47-27	9837-9841	head	_	
47-28	9842-9846	coil	_	
47-29	9846-9847	.	_	

#Text=Resting-state MR scanning was performed while subjects fixated a central crosshair for the duration of a 5-minute scan.
48-1	9848-9861	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[25]	
48-2	9862-9864	MR	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[25]	
48-3	9865-9873	scanning	_	
48-4	9874-9877	was	_	
48-5	9878-9887	performed	_	
48-6	9888-9893	while	_	
48-7	9894-9902	subjects	_	
48-8	9903-9910	fixated	_	
48-9	9911-9912	a	_	
48-10	9913-9920	central	_	
48-11	9921-9930	crosshair	_	
48-12	9931-9934	for	_	
48-13	9935-9938	the	_	
48-14	9939-9947	duration	_	
48-15	9948-9950	of	_	
48-16	9951-9952	a	_	
48-17	9953-9954	5	_	
48-18	9954-9955	-	_	
48-19	9955-9961	minute	_	
48-20	9962-9966	scan	_	
48-21	9966-9967	.	_	

#Text=Video monitoring of participants’ eyes confirmed adherence to this instruction.
49-1	9968-9973	Video	_	
49-2	9974-9984	monitoring	_	
49-3	9985-9987	of	_	
49-4	9988-10000	participants	_	
49-5	10000-10001	’	_	
49-6	10002-10006	eyes	_	
49-7	10007-10016	confirmed	_	
49-8	10017-10026	adherence	_	
49-9	10027-10029	to	_	
49-10	10030-10034	this	_	
49-11	10035-10046	instruction	_	
49-12	10046-10047	.	_	

#Text=Soft ear plugs were used to reduce scan noise, and head motion was minimized with head cushions.
50-1	10048-10052	Soft	_	
50-2	10053-10056	ear	_	
50-3	10057-10062	plugs	_	
50-4	10063-10067	were	_	
50-5	10068-10072	used	_	
50-6	10073-10075	to	_	
50-7	10076-10082	reduce	_	
50-8	10083-10087	scan	_	
50-9	10088-10093	noise	_	
50-10	10093-10094	,	_	
50-11	10095-10098	and	_	
50-12	10099-10103	head	_	
50-13	10104-10110	motion	_	
50-14	10111-10114	was	_	
50-15	10115-10124	minimized	_	
50-16	10125-10129	with	_	
50-17	10130-10134	head	_	
50-18	10135-10143	cushions	_	
50-19	10143-10144	.	_	

#Text=During scanning, subjects were instructed to relax with eyes closed, without falling asleep and without directed, systematic thought.
51-1	10145-10151	During	_	
51-2	10152-10160	scanning	_	
51-3	10160-10161	,	_	
51-4	10162-10170	subjects	_	
51-5	10171-10175	were	_	
51-6	10176-10186	instructed	_	
51-7	10187-10189	to	_	
51-8	10190-10195	relax	_	
51-9	10196-10200	with	_	
51-10	10201-10205	eyes	_	
51-11	10206-10212	closed	_	
51-12	10212-10213	,	_	
51-13	10214-10221	without	_	
51-14	10222-10229	falling	_	
51-15	10230-10236	asleep	_	
51-16	10237-10240	and	_	
51-17	10241-10248	without	_	
51-18	10249-10257	directed	_	
51-19	10257-10258	,	_	
51-20	10259-10269	systematic	_	
51-21	10270-10277	thought	_	
51-22	10277-10278	.	_	

#Text=Echo-planar imaging (repetition time= 1775msec, echo time= 27msec, flip angle= 60°) was performed with slice thickness of 4 mm (1mm gap), a matrix size of 64×64 and a field of view of 220×220 mm², resulting in a voxel size for analysis of 3.44×3.44×5 mm.
52-1	10279-10290	Echo-planar	_	
52-2	10291-10298	imaging	_	
52-3	10299-10300	(	_	
52-4	10300-10310	repetition	_	
52-5	10311-10315	time	_	
52-6	10315-10316	=	_	
52-7	10317-10325	1775msec	_	
52-8	10325-10326	,	_	
52-9	10327-10331	echo	_	
52-10	10332-10336	time	_	
52-11	10336-10337	=	_	
52-12	10338-10344	27msec	_	
52-13	10344-10345	,	_	
52-14	10346-10350	flip	_	
52-15	10351-10356	angle	_	
52-16	10356-10357	=	_	
52-17	10358-10360	60	_	
52-18	10360-10361	°	_	
52-19	10361-10362	)	_	
52-20	10363-10366	was	_	
52-21	10367-10376	performed	_	
52-22	10377-10381	with	_	
52-23	10382-10387	slice	_	
52-24	10388-10397	thickness	_	
52-25	10398-10400	of	_	
52-26	10401-10402	4	_	
52-27	10403-10405	mm	_	
52-28	10406-10407	(	_	
52-29	10407-10410	1mm	_	
52-30	10411-10414	gap	_	
52-31	10414-10415	)	_	
52-32	10415-10416	,	_	
52-33	10417-10418	a	_	
52-34	10419-10425	matrix	_	
52-35	10426-10430	size	_	
52-36	10431-10433	of	_	
52-37	10434-10436	64	_	
52-38	10436-10437	×	_	
52-39	10437-10439	64	_	
52-40	10440-10443	and	_	
52-41	10444-10445	a	_	
52-42	10446-10451	field	_	
52-43	10452-10454	of	_	
52-44	10455-10459	view	_	
52-45	10460-10462	of	_	
52-46	10463-10466	220	_	
52-47	10466-10467	×	_	
52-48	10467-10470	220	_	
52-49	10471-10474	mm²	_	
52-50	10474-10475	,	_	
52-51	10476-10485	resulting	_	
52-52	10486-10488	in	_	
52-53	10489-10490	a	_	
52-54	10491-10496	voxel	_	
52-55	10497-10501	size	_	
52-56	10502-10505	for	_	
52-57	10506-10514	analysis	_	
52-58	10515-10517	of	_	
52-59	10518-10522	3.44	_	
52-60	10522-10523	×	_	
52-61	10523-10527	3.44	_	
52-62	10527-10528	×	_	
52-63	10528-10529	5	_	
52-64	10530-10532	mm	_	
52-65	10532-10533	.	_	

#Text=Each brain volume was comprised of 29 axial slices, and each functional run contained 210 image volumes.
53-1	10534-10538	Each	_	
53-2	10539-10544	brain	_	
53-3	10545-10551	volume	_	
53-4	10552-10555	was	_	
53-5	10556-10565	comprised	_	
53-6	10566-10568	of	_	
53-7	10569-10571	29	_	
53-8	10572-10577	axial	_	
53-9	10578-10584	slices	_	
53-10	10584-10585	,	_	
53-11	10586-10589	and	_	
53-12	10590-10594	each	_	
53-13	10595-10605	functional	_	
53-14	10606-10609	run	_	
53-15	10610-10619	contained	_	
53-16	10620-10623	210	_	
53-17	10624-10629	image	_	
53-18	10630-10637	volumes	_	
53-19	10637-10638	.	_	

#Text=Resting State Data Analyses
#Text=Amplitude of low frequency fluctuations (ALFF)
#Text=Pre-processing steps were performed using the Data Processing Assistant for Resting-State fMRI (DPARSF) toolbox that runs on the REST software platform (http://resting-fmri.sourceforge.net).
54-1	10639-10646	Resting	_	
54-2	10647-10652	State	_	
54-3	10653-10657	Data	_	
54-4	10658-10666	Analyses	_	
54-5	10667-10676	Amplitude	_	
54-6	10677-10679	of	_	
54-7	10680-10683	low	_	
54-8	10684-10693	frequency	_	
54-9	10694-10706	fluctuations	_	
54-10	10707-10708	(	_	
54-11	10708-10712	ALFF	_	
54-12	10712-10713	)	_	
54-13	10714-10728	Pre-processing	_	
54-14	10729-10734	steps	_	
54-15	10735-10739	were	_	
54-16	10740-10749	performed	_	
54-17	10750-10755	using	_	
54-18	10756-10759	the	_	
54-19	10760-10764	Data	_	
54-20	10765-10775	Processing	_	
54-21	10776-10785	Assistant	_	
54-22	10786-10789	for	_	
54-23	10790-10803	Resting-State	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[26]	
54-24	10804-10808	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[26]	
54-25	10809-10810	(	_	
54-26	10810-10816	DPARSF	_	
54-27	10816-10817	)	_	
54-28	10818-10825	toolbox	_	
54-29	10826-10830	that	_	
54-30	10831-10835	runs	_	
54-31	10836-10838	on	_	
54-32	10839-10842	the	_	
54-33	10843-10847	REST	_	
54-34	10848-10856	software	_	
54-35	10857-10865	platform	_	
54-36	10866-10867	(	_	
54-37	10867-10871	http	_	
54-38	10871-10872	:	_	
54-39	10872-10873	/	_	
54-40	10873-10874	/	_	
54-41	10874-10902	resting-fmri.sourceforge.net	_	
54-42	10902-10903	)	_	
54-43	10903-10904	.	_	

#Text=The first five scans were discarded to establish magnetization stabilization.
55-1	10905-10908	The	_	
55-2	10909-10914	first	_	
55-3	10915-10919	five	_	
55-4	10920-10925	scans	_	
55-5	10926-10930	were	_	
55-6	10931-10940	discarded	_	
55-7	10941-10943	to	_	
55-8	10944-10953	establish	_	
55-9	10954-10967	magnetization	_	
55-10	10968-10981	stabilization	_	
55-11	10981-10982	.	_	

#Text=For each subject, EPI images were slice-timing corrected, and realigned to the middle slice.
56-1	10983-10986	For	_	
56-2	10987-10991	each	_	
56-3	10992-10999	subject	_	
56-4	10999-11000	,	_	
56-5	11001-11004	EPI	_	
56-6	11005-11011	images	_	
56-7	11012-11016	were	_	
56-8	11017-11029	slice-timing	_	
56-9	11030-11039	corrected	_	
56-10	11039-11040	,	_	
56-11	11041-11044	and	_	
56-12	11045-11054	realigned	_	
56-13	11055-11057	to	_	
56-14	11058-11061	the	_	
56-15	11062-11068	middle	_	
56-16	11069-11074	slice	_	
56-17	11074-11075	.	_	

#Text=The Friston 24-parameter model was used to regress out head motion effects from the realigned data, which has demonstrated benefits in removing head motion effects in recent reports.
57-1	11076-11079	The	_	
57-2	11080-11087	Friston	_	
57-3	11088-11090	24	_	
57-4	11090-11091	-	_	
57-5	11091-11100	parameter	_	
57-6	11101-11106	model	_	
57-7	11107-11110	was	_	
57-8	11111-11115	used	_	
57-9	11116-11118	to	_	
57-10	11119-11126	regress	_	
57-11	11127-11130	out	_	
57-12	11131-11135	head	_	
57-13	11136-11142	motion	_	
57-14	11143-11150	effects	_	
57-15	11151-11155	from	_	
57-16	11156-11159	the	_	
57-17	11160-11169	realigned	_	
57-18	11170-11174	data	_	
57-19	11174-11175	,	_	
57-20	11176-11181	which	_	
57-21	11182-11185	has	_	
57-22	11186-11198	demonstrated	_	
57-23	11199-11207	benefits	_	
57-24	11208-11210	in	_	
57-25	11211-11219	removing	_	
57-26	11220-11224	head	_	
57-27	11225-11231	motion	_	
57-28	11232-11239	effects	_	
57-29	11240-11242	in	_	
57-30	11243-11249	recent	_	
57-31	11250-11257	reports	_	
57-32	11257-11258	.	_	

#Text=Motion scrubbing was not applied to avoid the possibility of losing data leading to a biased estimate of further distant connectivity, specifically in visual and posterior parietal regions.
58-1	11259-11265	Motion	_	
58-2	11266-11275	scrubbing	_	
58-3	11276-11279	was	_	
58-4	11280-11283	not	_	
58-5	11284-11291	applied	_	
58-6	11292-11294	to	_	
58-7	11295-11300	avoid	_	
58-8	11301-11304	the	_	
58-9	11305-11316	possibility	_	
58-10	11317-11319	of	_	
58-11	11320-11326	losing	_	
58-12	11327-11331	data	_	
58-13	11332-11339	leading	_	
58-14	11340-11342	to	_	
58-15	11343-11344	a	_	
58-16	11345-11351	biased	_	
58-17	11352-11360	estimate	_	
58-18	11361-11363	of	_	
58-19	11364-11371	further	_	
58-20	11372-11379	distant	_	
58-21	11380-11392	connectivity	_	
58-22	11392-11393	,	_	
58-23	11394-11406	specifically	_	
58-24	11407-11409	in	_	
58-25	11410-11416	visual	_	
58-26	11417-11420	and	_	
58-27	11421-11430	posterior	_	
58-28	11431-11439	parietal	_	
58-29	11440-11447	regions	_	
58-30	11447-11448	.	_	

#Text=Next, functional images were spatially normalized to the Montreal Neurological Institute (MNI) EPI template in SPM8, resampled to 3×3×3mm³, and smoothed with an 6-mm full-width at half-maximum (FWHM) Gaussian kernel.
59-1	11449-11453	Next	_	
59-2	11453-11454	,	_	
59-3	11455-11465	functional	_	
59-4	11466-11472	images	_	
59-5	11473-11477	were	_	
59-6	11478-11487	spatially	_	
59-7	11488-11498	normalized	_	
59-8	11499-11501	to	_	
59-9	11502-11505	the	_	
59-10	11506-11514	Montreal	_	
59-11	11515-11527	Neurological	_	
59-12	11528-11537	Institute	_	
59-13	11538-11539	(	_	
59-14	11539-11542	MNI	_	
59-15	11542-11543	)	_	
59-16	11544-11547	EPI	_	
59-17	11548-11556	template	_	
59-18	11557-11559	in	_	
59-19	11560-11564	SPM8	_	
59-20	11564-11565	,	_	
59-21	11566-11575	resampled	_	
59-22	11576-11578	to	_	
59-23	11579-11580	3	_	
59-24	11580-11581	×	_	
59-25	11581-11582	3	_	
59-26	11582-11583	×	_	
59-27	11583-11587	3mm³	_	
59-28	11587-11588	,	_	
59-29	11589-11592	and	_	
59-30	11593-11601	smoothed	_	
59-31	11602-11606	with	_	
59-32	11607-11609	an	_	
59-33	11610-11611	6	_	
59-34	11611-11612	-	_	
59-35	11612-11614	mm	_	
59-36	11615-11625	full-width	_	
59-37	11626-11628	at	_	
59-38	11629-11641	half-maximum	_	
59-39	11642-11643	(	_	
59-40	11643-11647	FWHM	_	
59-41	11647-11648	)	_	
59-42	11649-11657	Gaussian	_	
59-43	11658-11664	kernel	_	
59-44	11664-11665	.	_	

#Text=Measurement of the amplitude of low-frequency fluctuations of the BOLD signal (ALFF), considered to be related to regional spontaneous neural activity, was used to identify differences between the patient group and controls in regional resting cerebral function.
60-1	11666-11677	Measurement	_	
60-2	11678-11680	of	_	
60-3	11681-11684	the	_	
60-4	11685-11694	amplitude	_	
60-5	11695-11697	of	_	
60-6	11698-11711	low-frequency	_	
60-7	11712-11724	fluctuations	_	
60-8	11725-11727	of	_	
60-9	11728-11731	the	_	
60-10	11732-11736	BOLD	_	
60-11	11737-11743	signal	_	
60-12	11744-11745	(	_	
60-13	11745-11749	ALFF	_	
60-14	11749-11750	)	_	
60-15	11750-11751	,	_	
60-16	11752-11762	considered	_	
60-17	11763-11765	to	_	
60-18	11766-11768	be	_	
60-19	11769-11776	related	_	
60-20	11777-11779	to	_	
60-21	11780-11788	regional	_	
60-22	11789-11800	spontaneous	_	
60-23	11801-11807	neural	_	
60-24	11808-11816	activity	_	
60-25	11816-11817	,	_	
60-26	11818-11821	was	_	
60-27	11822-11826	used	_	
60-28	11827-11829	to	_	
60-29	11830-11838	identify	_	
60-30	11839-11850	differences	_	
60-31	11851-11858	between	_	
60-32	11859-11862	the	_	
60-33	11863-11870	patient	_	
60-34	11871-11876	group	_	
60-35	11877-11880	and	_	
60-36	11881-11889	controls	_	
60-37	11890-11892	in	_	
60-38	11893-11901	regional	_	
60-39	11902-11909	resting	_	
60-40	11910-11918	cerebral	_	
60-41	11919-11927	function	_	
60-42	11927-11928	.	_	

#Text=After bandpass filtering (0.01–0.08 Hz), signals from white matter and cerebrospinal fluid were removed.
61-1	11929-11934	After	_	
61-2	11935-11943	bandpass	_	
61-3	11944-11953	filtering	_	
61-4	11954-11955	(	_	
61-5	11955-11959	0.01	_	
61-6	11959-11960	–	_	
61-7	11960-11964	0.08	_	
61-8	11965-11967	Hz	_	
61-9	11967-11968	)	_	
61-10	11968-11969	,	_	
61-11	11970-11977	signals	_	
61-12	11978-11982	from	_	
61-13	11983-11988	white	_	
61-14	11989-11995	matter	_	
61-15	11996-11999	and	_	
61-16	12000-12013	cerebrospinal	_	
61-17	12014-12019	fluid	_	
61-18	12020-12024	were	_	
61-19	12025-12032	removed	_	
61-20	12032-12033	.	_	

#Text=Following linear detrending, the voxel-wise time series were transformed to the frequency domain using fast Fourier transformation to obtain the power spectrum.
62-1	12034-12043	Following	_	
62-2	12044-12050	linear	_	
62-3	12051-12061	detrending	_	
62-4	12061-12062	,	_	
62-5	12063-12066	the	_	
62-6	12067-12077	voxel-wise	_	
62-7	12078-12082	time	_	
62-8	12083-12089	series	_	
62-9	12090-12094	were	_	
62-10	12095-12106	transformed	_	
62-11	12107-12109	to	_	
62-12	12110-12113	the	_	
62-13	12114-12123	frequency	_	
62-14	12124-12130	domain	_	
62-15	12131-12136	using	_	
62-16	12137-12141	fast	_	
62-17	12142-12149	Fourier	_	
62-18	12150-12164	transformation	_	
62-19	12165-12167	to	_	
62-20	12168-12174	obtain	_	
62-21	12175-12178	the	_	
62-22	12179-12184	power	_	
62-23	12185-12193	spectrum	_	
62-24	12193-12194	.	_	

#Text=The ALFF measure at each voxel represents the square root of the power across a low-frequency range.
63-1	12195-12198	The	_	
63-2	12199-12203	ALFF	_	
63-3	12204-12211	measure	_	
63-4	12212-12214	at	_	
63-5	12215-12219	each	_	
63-6	12220-12225	voxel	_	
63-7	12226-12236	represents	_	
63-8	12237-12240	the	_	
63-9	12241-12247	square	_	
63-10	12248-12252	root	_	
63-11	12253-12255	of	_	
63-12	12256-12259	the	_	
63-13	12260-12265	power	_	
63-14	12266-12272	across	_	
63-15	12273-12274	a	_	
63-16	12275-12288	low-frequency	_	
63-17	12289-12294	range	_	
63-18	12294-12295	.	_	

#Text=The ALFF value of each voxel was divided by the global mean ALFF value of each individual subject to standardize data for comparisons across subjects.
64-1	12296-12299	The	_	
64-2	12300-12304	ALFF	_	
64-3	12305-12310	value	_	
64-4	12311-12313	of	_	
64-5	12314-12318	each	_	
64-6	12319-12324	voxel	_	
64-7	12325-12328	was	_	
64-8	12329-12336	divided	_	
64-9	12337-12339	by	_	
64-10	12340-12343	the	_	
64-11	12344-12350	global	_	
64-12	12351-12355	mean	_	
64-13	12356-12360	ALFF	_	
64-14	12361-12366	value	_	
64-15	12367-12369	of	_	
64-16	12370-12374	each	_	
64-17	12375-12385	individual	_	
64-18	12386-12393	subject	_	
64-19	12394-12396	to	_	
64-20	12397-12408	standardize	_	
64-21	12409-12413	data	_	
64-22	12414-12417	for	_	
64-23	12418-12429	comparisons	_	
64-24	12430-12436	across	_	
64-25	12437-12445	subjects	_	
64-26	12445-12446	.	_	

#Text=Functional connectivity analysis
#Text=To investigate functional circuitry alterations, we first identified regional group differences of ALFF values.
65-1	12447-12457	Functional	_	
65-2	12458-12470	connectivity	_	
65-3	12471-12479	analysis	_	
65-4	12480-12482	To	_	
65-5	12483-12494	investigate	_	
65-6	12495-12505	functional	_	
65-7	12506-12515	circuitry	_	
65-8	12516-12527	alterations	_	
65-9	12527-12528	,	_	
65-10	12529-12531	we	_	
65-11	12532-12537	first	_	
65-12	12538-12548	identified	_	
65-13	12549-12557	regional	_	
65-14	12558-12563	group	_	
65-15	12564-12575	differences	_	
65-16	12576-12578	of	_	
65-17	12579-12583	ALFF	_	
65-18	12584-12590	values	_	
65-19	12590-12591	.	_	

#Text=These were used to create seed regions for functional connectivity analyses by creating a spherical region of interest centered on the voxel with peak group difference in ALFF data that had a radius of 3mm.
66-1	12592-12597	These	_	
66-2	12598-12602	were	_	
66-3	12603-12607	used	_	
66-4	12608-12610	to	_	
66-5	12611-12617	create	_	
66-6	12618-12622	seed	_	
66-7	12623-12630	regions	_	
66-8	12631-12634	for	_	
66-9	12635-12645	functional	_	
66-10	12646-12658	connectivity	_	
66-11	12659-12667	analyses	_	
66-12	12668-12670	by	_	
66-13	12671-12679	creating	_	
66-14	12680-12681	a	_	
66-15	12682-12691	spherical	_	
66-16	12692-12698	region	_	
66-17	12699-12701	of	_	
66-18	12702-12710	interest	_	
66-19	12711-12719	centered	_	
66-20	12720-12722	on	_	
66-21	12723-12726	the	_	
66-22	12727-12732	voxel	_	
66-23	12733-12737	with	_	
66-24	12738-12742	peak	_	
66-25	12743-12748	group	_	
66-26	12749-12759	difference	_	
66-27	12760-12762	in	_	
66-28	12763-12767	ALFF	_	
66-29	12768-12772	data	_	
66-30	12773-12777	that	_	
66-31	12778-12781	had	_	
66-32	12782-12783	a	_	
66-33	12784-12790	radius	_	
66-34	12791-12793	of	_	
66-35	12794-12797	3mm	_	
66-36	12797-12798	.	_	

#Text=Voxels in the region of interest sphere were averaged to create the seed for FC analysis between eye movement relevant regions with altered ALFF values and the remainder of the brain.
67-1	12799-12805	Voxels	_	
67-2	12806-12808	in	_	
67-3	12809-12812	the	_	
67-4	12813-12819	region	_	
67-5	12820-12822	of	_	
67-6	12823-12831	interest	_	
67-7	12832-12838	sphere	_	
67-8	12839-12843	were	_	
67-9	12844-12852	averaged	_	
67-10	12853-12855	to	_	
67-11	12856-12862	create	_	
67-12	12863-12866	the	_	
67-13	12867-12871	seed	_	
67-14	12872-12875	for	_	
67-15	12876-12878	FC	_	
67-16	12879-12887	analysis	_	
67-17	12888-12895	between	_	
67-18	12896-12899	eye	_	
67-19	12900-12908	movement	_	
67-20	12909-12917	relevant	_	
67-21	12918-12925	regions	_	
67-22	12926-12930	with	_	
67-23	12931-12938	altered	_	
67-24	12939-12943	ALFF	_	
67-25	12944-12950	values	_	
67-26	12951-12954	and	_	
67-27	12955-12958	the	_	
67-28	12959-12968	remainder	_	
67-29	12969-12971	of	_	
67-30	12972-12975	the	_	
67-31	12976-12981	brain	_	
67-32	12981-12982	.	_	

#Text=The first step in the analysis was to extract a reference time series by obtaining the average of the time series of voxels within each sphere as described above.
68-1	12983-12986	The	_	
68-2	12987-12992	first	_	
68-3	12993-12997	step	_	
68-4	12998-13000	in	_	
68-5	13001-13004	the	_	
68-6	13005-13013	analysis	_	
68-7	13014-13017	was	_	
68-8	13018-13020	to	_	
68-9	13021-13028	extract	_	
68-10	13029-13030	a	_	
68-11	13031-13040	reference	_	
68-12	13041-13045	time	_	
68-13	13046-13052	series	_	
68-14	13053-13055	by	_	
68-15	13056-13065	obtaining	_	
68-16	13066-13069	the	_	
68-17	13070-13077	average	_	
68-18	13078-13080	of	_	
68-19	13081-13084	the	_	
68-20	13085-13089	time	_	
68-21	13090-13096	series	_	
68-22	13097-13099	of	_	
68-23	13100-13106	voxels	_	
68-24	13107-13113	within	_	
68-25	13114-13118	each	_	
68-26	13119-13125	sphere	_	
68-27	13126-13128	as	_	
68-28	13129-13138	described	_	
68-29	13139-13144	above	_	
68-30	13144-13145	.	_	

#Text=Correlations were then computed between the time series of the seed reference and all brain voxels outside the seed region.
69-1	13146-13158	Correlations	_	
69-2	13159-13163	were	_	
69-3	13164-13168	then	_	
69-4	13169-13177	computed	_	
69-5	13178-13185	between	_	
69-6	13186-13189	the	_	
69-7	13190-13194	time	_	
69-8	13195-13201	series	_	
69-9	13202-13204	of	_	
69-10	13205-13208	the	_	
69-11	13209-13213	seed	_	
69-12	13214-13223	reference	_	
69-13	13224-13227	and	_	
69-14	13228-13231	all	_	
69-15	13232-13237	brain	_	
69-16	13238-13244	voxels	_	
69-17	13245-13252	outside	_	
69-18	13253-13256	the	_	
69-19	13257-13261	seed	_	
69-20	13262-13268	region	_	
69-21	13268-13269	.	_	

#Text=Finally, these correlation coefficients were transformed by Fisher r-to-z transformation to increase their normality before averaging correlations across participants and testing for associations with antisaccade task performance.
70-1	13270-13277	Finally	_	
70-2	13277-13278	,	_	
70-3	13279-13284	these	_	
70-4	13285-13296	correlation	_	
70-5	13297-13309	coefficients	_	
70-6	13310-13314	were	_	
70-7	13315-13326	transformed	_	
70-8	13327-13329	by	_	
70-9	13330-13336	Fisher	_	
70-10	13337-13343	r-to-z	_	
70-11	13344-13358	transformation	_	
70-12	13359-13361	to	_	
70-13	13362-13370	increase	_	
70-14	13371-13376	their	_	
70-15	13377-13386	normality	_	
70-16	13387-13393	before	_	
70-17	13394-13403	averaging	_	
70-18	13404-13416	correlations	_	
70-19	13417-13423	across	_	
70-20	13424-13436	participants	_	
70-21	13437-13440	and	_	
70-22	13441-13448	testing	_	
70-23	13449-13452	for	_	
70-24	13453-13465	associations	_	
70-25	13466-13470	with	_	
70-26	13471-13482	antisaccade	_	
70-27	13483-13487	task	_	
70-28	13488-13499	performance	_	
70-29	13499-13500	.	_	

#Text=Statistical analyses
#Text=Voxel-based comparison of ALFF maps from patient and control groups was performed using pairwise t tests in SPM8 (http://www.fil.ion.ecl.ac.uk/spm).
71-1	13501-13512	Statistical	_	
71-2	13513-13521	analyses	_	
71-3	13522-13533	Voxel-based	_	
71-4	13534-13544	comparison	_	
71-5	13545-13547	of	_	
71-6	13548-13552	ALFF	_	
71-7	13553-13557	maps	_	
71-8	13558-13562	from	_	
71-9	13563-13570	patient	_	
71-10	13571-13574	and	_	
71-11	13575-13582	control	_	
71-12	13583-13589	groups	_	
71-13	13590-13593	was	_	
71-14	13594-13603	performed	_	
71-15	13604-13609	using	_	
71-16	13610-13618	pairwise	_	
71-17	13619-13620	t	_	
71-18	13621-13626	tests	_	
71-19	13627-13629	in	_	
71-20	13630-13634	SPM8	_	
71-21	13635-13636	(	_	
71-22	13636-13640	http	_	
71-23	13640-13641	:	_	
71-24	13641-13642	/	_	
71-25	13642-13643	/	_	
71-26	13643-13664	www.fil.ion.ecl.ac.uk	_	
71-27	13664-13665	/	_	
71-28	13665-13668	spm	_	
71-29	13668-13669	)	_	
71-30	13669-13670	.	_	

#Text=Age, sex and race were used as covariates in group comparisons.
72-1	13671-13674	Age	_	
72-2	13674-13675	,	_	
72-3	13676-13679	sex	_	
72-4	13680-13683	and	_	
72-5	13684-13688	race	_	
72-6	13689-13693	were	_	
72-7	13694-13698	used	_	
72-8	13699-13701	as	_	
72-9	13702-13712	covariates	_	
72-10	13713-13715	in	_	
72-11	13716-13721	group	_	
72-12	13722-13733	comparisons	_	
72-13	13733-13734	.	_	

#Text=Connectivity was examined from the selected seed areas using pairwise t-tests comparing patients and controls.
73-1	13735-13747	Connectivity	_	
73-2	13748-13751	was	_	
73-3	13752-13760	examined	_	
73-4	13761-13765	from	_	
73-5	13766-13769	the	_	
73-6	13770-13778	selected	_	
73-7	13779-13783	seed	_	
73-8	13784-13789	areas	_	
73-9	13790-13795	using	_	
73-10	13796-13804	pairwise	_	
73-11	13805-13812	t-tests	_	
73-12	13813-13822	comparing	_	
73-13	13823-13831	patients	_	
73-14	13832-13835	and	_	
73-15	13836-13844	controls	_	
73-16	13844-13845	.	_	

#Text=In all image analyses, a threshold of p=0.05 after AlphaSim correction was used to correct for multiple comparisons corresponding to a minimum cluster size of 80 contiguous voxels significant individually at a threshold of p<0.01.
74-1	13846-13848	In	_	
74-2	13849-13852	all	_	
74-3	13853-13858	image	_	
74-4	13859-13867	analyses	_	
74-5	13867-13868	,	_	
74-6	13869-13870	a	_	
74-7	13871-13880	threshold	_	
74-8	13881-13883	of	_	
74-9	13884-13885	p	_	
74-10	13885-13886	=	_	
74-11	13886-13890	0.05	_	
74-12	13891-13896	after	_	
74-13	13897-13905	AlphaSim	_	
74-14	13906-13916	correction	_	
74-15	13917-13920	was	_	
74-16	13921-13925	used	_	
74-17	13926-13928	to	_	
74-18	13929-13936	correct	_	
74-19	13937-13940	for	_	
74-20	13941-13949	multiple	_	
74-21	13950-13961	comparisons	_	
74-22	13962-13975	corresponding	_	
74-23	13976-13978	to	_	
74-24	13979-13980	a	_	
74-25	13981-13988	minimum	_	
74-26	13989-13996	cluster	_	
74-27	13997-14001	size	_	
74-28	14002-14004	of	_	
74-29	14005-14007	80	_	
74-30	14008-14018	contiguous	_	
74-31	14019-14025	voxels	_	
74-32	14026-14037	significant	_	
74-33	14038-14050	individually	_	
74-34	14051-14053	at	_	
74-35	14054-14055	a	_	
74-36	14056-14065	threshold	_	
74-37	14066-14068	of	_	
74-38	14069-14070	p	_	
74-39	14070-14071	<	_	
74-40	14071-14075	0.01	_	
74-41	14075-14076	.	_	

#Text=The AlphaSim calculation based on Monte Carlo simulations was conducted using REST software (http://restfmri.net/forum/index.php).
75-1	14077-14080	The	_	
75-2	14081-14089	AlphaSim	_	
75-3	14090-14101	calculation	_	
75-4	14102-14107	based	_	
75-5	14108-14110	on	_	
75-6	14111-14116	Monte	_	
75-7	14117-14122	Carlo	_	
75-8	14123-14134	simulations	_	
75-9	14135-14138	was	_	
75-10	14139-14148	conducted	_	
75-11	14149-14154	using	_	
75-12	14155-14159	REST	_	
75-13	14160-14168	software	_	
75-14	14169-14170	(	_	
75-15	14170-14174	http	_	
75-16	14174-14175	:	_	
75-17	14175-14176	/	_	
75-18	14176-14177	/	_	
75-19	14177-14189	restfmri.net	_	
75-20	14189-14190	/	_	
75-21	14190-14195	forum	_	
75-22	14195-14196	/	_	
75-23	14196-14205	index.php	_	
75-24	14205-14206	)	_	
75-25	14206-14207	.	_	

#Text=To determine relations between alterations of mean ALFF and FC values with antisaccade performance measures, we used stepwise backward regression analysis that allows for consideration of several independent variables simultaneously.
76-1	14208-14210	To	_	
76-2	14211-14220	determine	_	
76-3	14221-14230	relations	_	
76-4	14231-14238	between	_	
76-5	14239-14250	alterations	_	
76-6	14251-14253	of	_	
76-7	14254-14258	mean	_	
76-8	14259-14263	ALFF	_	
76-9	14264-14267	and	_	
76-10	14268-14270	FC	_	
76-11	14271-14277	values	_	
76-12	14278-14282	with	_	
76-13	14283-14294	antisaccade	_	
76-14	14295-14306	performance	_	
76-15	14307-14315	measures	_	
76-16	14315-14316	,	_	
76-17	14317-14319	we	_	
76-18	14320-14324	used	_	
76-19	14325-14333	stepwise	_	
76-20	14334-14342	backward	_	
76-21	14343-14353	regression	_	
76-22	14354-14362	analysis	_	
76-23	14363-14367	that	_	
76-24	14368-14374	allows	_	
76-25	14375-14378	for	_	
76-26	14379-14392	consideration	_	
76-27	14393-14395	of	_	
76-28	14396-14403	several	_	
76-29	14404-14415	independent	_	
76-30	14416-14425	variables	_	
76-31	14426-14440	simultaneously	_	
76-32	14440-14441	.	_	

#Text=This procedure yielded a regression model using imaging parameters to predict antisaccade performance with a significance threshold for entry of 0.05 and that for removal of 0.10.
77-1	14442-14446	This	_	
77-2	14447-14456	procedure	_	
77-3	14457-14464	yielded	_	
77-4	14465-14466	a	_	
77-5	14467-14477	regression	_	
77-6	14478-14483	model	_	
77-7	14484-14489	using	_	
77-8	14490-14497	imaging	_	
77-9	14498-14508	parameters	_	
77-10	14509-14511	to	_	
77-11	14512-14519	predict	_	
77-12	14520-14531	antisaccade	_	
77-13	14532-14543	performance	_	
77-14	14544-14548	with	_	
77-15	14549-14550	a	_	
77-16	14551-14563	significance	_	
77-17	14564-14573	threshold	_	
77-18	14574-14577	for	_	
77-19	14578-14583	entry	_	
77-20	14584-14586	of	_	
77-21	14587-14591	0.05	_	
77-22	14592-14595	and	_	
77-23	14596-14600	that	_	
77-24	14601-14604	for	_	
77-25	14605-14612	removal	_	
77-26	14613-14615	of	_	
77-27	14616-14620	0.10	_	
77-28	14620-14621	.	_	

#Text=Standardized z-scores for antisaccade error rate and latency, derived from a normative regression approach described previously, were entered as dependent variables while mean values of peak coordinate-defined spherical regions of altered ALFF and altered FC clusters in patients were used as independent variables in these analyses.
78-1	14622-14634	Standardized	_	
78-2	14635-14643	z-scores	_	
78-3	14644-14647	for	_	
78-4	14648-14659	antisaccade	_	
78-5	14660-14665	error	_	
78-6	14666-14670	rate	_	
78-7	14671-14674	and	_	
78-8	14675-14682	latency	_	
78-9	14682-14683	,	_	
78-10	14684-14691	derived	_	
78-11	14692-14696	from	_	
78-12	14697-14698	a	_	
78-13	14699-14708	normative	_	
78-14	14709-14719	regression	_	
78-15	14720-14728	approach	_	
78-16	14729-14738	described	_	
78-17	14739-14749	previously	_	
78-18	14749-14750	,	_	
78-19	14751-14755	were	_	
78-20	14756-14763	entered	_	
78-21	14764-14766	as	_	
78-22	14767-14776	dependent	_	
78-23	14777-14786	variables	_	
78-24	14787-14792	while	_	
78-25	14793-14797	mean	_	
78-26	14798-14804	values	_	
78-27	14805-14807	of	_	
78-28	14808-14812	peak	_	
78-29	14813-14831	coordinate-defined	_	
78-30	14832-14841	spherical	_	
78-31	14842-14849	regions	_	
78-32	14850-14852	of	_	
78-33	14853-14860	altered	_	
78-34	14861-14865	ALFF	_	
78-35	14866-14869	and	_	
78-36	14870-14877	altered	_	
78-37	14878-14880	FC	_	
78-38	14881-14889	clusters	_	
78-39	14890-14892	in	_	
78-40	14893-14901	patients	_	
78-41	14902-14906	were	_	
78-42	14907-14911	used	_	
78-43	14912-14914	as	_	
78-44	14915-14926	independent	_	
78-45	14927-14936	variables	_	
78-46	14937-14939	in	_	
78-47	14940-14945	these	_	
78-48	14946-14954	analyses	_	
78-49	14954-14955	.	_	

#Text=Results
#Text=Behavioral findings
#Text=As expected following our previous studies including the full B-SNIP sample, antisaccade error rate was considerably increased in patients compared to controls in the sample available for this study (Table I).
79-1	14956-14963	Results	_	
79-2	14964-14974	Behavioral	_	
79-3	14975-14983	findings	_	
79-4	14984-14986	As	_	
79-5	14987-14995	expected	_	
79-6	14996-15005	following	_	
79-7	15006-15009	our	_	
79-8	15010-15018	previous	_	
79-9	15019-15026	studies	_	
79-10	15027-15036	including	_	
79-11	15037-15040	the	_	
79-12	15041-15045	full	_	
79-13	15046-15052	B-SNIP	_	
79-14	15053-15059	sample	_	
79-15	15059-15060	,	_	
79-16	15061-15072	antisaccade	_	
79-17	15073-15078	error	_	
79-18	15079-15083	rate	_	
79-19	15084-15087	was	_	
79-20	15088-15100	considerably	_	
79-21	15101-15110	increased	_	
79-22	15111-15113	in	_	
79-23	15114-15122	patients	_	
79-24	15123-15131	compared	_	
79-25	15132-15134	to	_	
79-26	15135-15143	controls	_	
79-27	15144-15146	in	_	
79-28	15147-15150	the	_	
79-29	15151-15157	sample	_	
79-30	15158-15167	available	_	
79-31	15168-15171	for	_	
79-32	15172-15176	this	_	
79-33	15177-15182	study	_	
79-34	15183-15184	(	_	
79-35	15184-15189	Table	_	
79-36	15190-15191	I	_	
79-37	15191-15192	)	_	
79-38	15192-15193	.	_	

#Text=Error rate did not differ between the three patient groups (F(2,82) = 2.04, p = 0.14, Table I S).
80-1	15194-15199	Error	_	
80-2	15200-15204	rate	_	
80-3	15205-15208	did	_	
80-4	15209-15212	not	_	
80-5	15213-15219	differ	_	
80-6	15220-15227	between	_	
80-7	15228-15231	the	_	
80-8	15232-15237	three	_	
80-9	15238-15245	patient	_	
80-10	15246-15252	groups	_	
80-11	15253-15254	(	_	
80-12	15254-15255	F	_	
80-13	15255-15256	(	_	
80-14	15256-15260	2,82	_	
80-15	15260-15261	)	_	
80-16	15262-15263	=	_	
80-17	15264-15268	2.04	_	
80-18	15268-15269	,	_	
80-19	15270-15271	p	_	
80-20	15272-15273	=	_	
80-21	15274-15278	0.14	_	
80-22	15278-15279	,	_	
80-23	15280-15285	Table	_	
80-24	15286-15287	I	_	
80-25	15288-15289	S	_	
80-26	15289-15290	)	_	
80-27	15290-15291	.	_	

#Text=Despite increased antisaccade errors in patients, latencies of correct antisaccade responses did not differ between patients and controls, indicating that patients planned and initiated correct antisaccades as quickly as controls.
81-1	15292-15299	Despite	_	
81-2	15300-15309	increased	_	
81-3	15310-15321	antisaccade	_	
81-4	15322-15328	errors	_	
81-5	15329-15331	in	_	
81-6	15332-15340	patients	_	
81-7	15340-15341	,	_	
81-8	15342-15351	latencies	_	
81-9	15352-15354	of	_	
81-10	15355-15362	correct	_	
81-11	15363-15374	antisaccade	_	
81-12	15375-15384	responses	_	
81-13	15385-15388	did	_	
81-14	15389-15392	not	_	
81-15	15393-15399	differ	_	
81-16	15400-15407	between	_	
81-17	15408-15416	patients	_	
81-18	15417-15420	and	_	
81-19	15421-15429	controls	_	
81-20	15429-15430	,	_	
81-21	15431-15441	indicating	_	
81-22	15442-15446	that	_	
81-23	15447-15455	patients	_	
81-24	15456-15463	planned	_	
81-25	15464-15467	and	_	
81-26	15468-15477	initiated	_	
81-27	15478-15485	correct	_	
81-28	15486-15498	antisaccades	_	
81-29	15499-15501	as	_	
81-30	15502-15509	quickly	_	
81-31	15510-15512	as	_	
81-32	15513-15521	controls	_	
81-33	15521-15522	.	_	

#Text=Alterations of ALFF and FC in patients
#Text=ALFF was reduced in patients compared to controls in FEF regions bilaterally, SEF region, and thalamus bilaterally, and in left orbitofrontal gyrus and left superior temporal gyrus (Table II).
82-1	15523-15534	Alterations	_	
82-2	15535-15537	of	_	
82-3	15538-15542	ALFF	_	
82-4	15543-15546	and	_	
82-5	15547-15549	FC	_	
82-6	15550-15552	in	_	
82-7	15553-15561	patients	_	
82-8	15562-15566	ALFF	_	
82-9	15567-15570	was	_	
82-10	15571-15578	reduced	_	
82-11	15579-15581	in	_	
82-12	15582-15590	patients	_	
82-13	15591-15599	compared	_	
82-14	15600-15602	to	_	
82-15	15603-15611	controls	_	
82-16	15612-15614	in	_	
82-17	15615-15618	FEF	_	
82-18	15619-15626	regions	_	
82-19	15627-15638	bilaterally	_	
82-20	15638-15639	,	_	
82-21	15640-15643	SEF	_	
82-22	15644-15650	region	_	
82-23	15650-15651	,	_	
82-24	15652-15655	and	_	
82-25	15656-15664	thalamus	_	
82-26	15665-15676	bilaterally	_	
82-27	15676-15677	,	_	
82-28	15678-15681	and	_	
82-29	15682-15684	in	_	
82-30	15685-15689	left	_	
82-31	15690-15703	orbitofrontal	_	
82-32	15704-15709	gyrus	_	
82-33	15710-15713	and	_	
82-34	15714-15718	left	_	
82-35	15719-15727	superior	_	
82-36	15728-15736	temporal	_	
82-37	15737-15742	gyrus	_	
82-38	15743-15744	(	_	
82-39	15744-15749	Table	_	
82-40	15750-15752	II	_	
82-41	15752-15753	)	_	
82-42	15753-15754	.	_	

#Text=Given their adjacent midline location, left and right SEF were considered as one SEF region.
83-1	15755-15760	Given	_	
83-2	15761-15766	their	_	
83-3	15767-15775	adjacent	_	
83-4	15776-15783	midline	_	
83-5	15784-15792	location	_	
83-6	15792-15793	,	_	
83-7	15794-15798	left	_	
83-8	15799-15802	and	_	
83-9	15803-15808	right	_	
83-10	15809-15812	SEF	_	
83-11	15813-15817	were	_	
83-12	15818-15828	considered	_	
83-13	15829-15831	as	_	
83-14	15832-15835	one	_	
83-15	15836-15839	SEF	_	
83-16	15840-15846	region	_	
83-17	15846-15847	.	_	

#Text=Based on the established roles in eye movement activity of FEF, SEF and thalamus, these regions were selected as seed areas for FC analyses.
84-1	15848-15853	Based	_	
84-2	15854-15856	on	_	
84-3	15857-15860	the	_	
84-4	15861-15872	established	_	
84-5	15873-15878	roles	_	
84-6	15879-15881	in	_	
84-7	15882-15885	eye	_	
84-8	15886-15894	movement	_	
84-9	15895-15903	activity	_	
84-10	15904-15906	of	_	
84-11	15907-15910	FEF	_	
84-12	15910-15911	,	_	
84-13	15912-15915	SEF	_	
84-14	15916-15919	and	_	
84-15	15920-15928	thalamus	_	
84-16	15928-15929	,	_	
84-17	15930-15935	these	_	
84-18	15936-15943	regions	_	
84-19	15944-15948	were	_	
84-20	15949-15957	selected	_	
84-21	15958-15960	as	_	
84-22	15961-15965	seed	_	
84-23	15966-15971	areas	_	
84-24	15972-15975	for	_	
84-25	15976-15978	FC	_	
84-26	15979-15987	analyses	_	
84-27	15987-15988	.	_	

#Text=Note that clusters of voxels in FC analyses with these seeds include areas defined previously in task-based fMRI studies using antisaccade paradigms but were in some instances larger.
85-1	15989-15993	Note	_	
85-2	15994-15998	that	_	
85-3	15999-16007	clusters	_	
85-4	16008-16010	of	_	
85-5	16011-16017	voxels	_	
85-6	16018-16020	in	_	
85-7	16021-16023	FC	_	
85-8	16024-16032	analyses	_	
85-9	16033-16037	with	_	
85-10	16038-16043	these	_	
85-11	16044-16049	seeds	_	
85-12	16050-16057	include	_	
85-13	16058-16063	areas	_	
85-14	16064-16071	defined	_	
85-15	16072-16082	previously	_	
85-16	16083-16085	in	_	
85-17	16086-16096	task-based	_	
85-18	16097-16101	fMRI	_	
85-19	16102-16109	studies	_	
85-20	16110-16115	using	_	
85-21	16116-16127	antisaccade	_	
85-22	16128-16137	paradigms	_	
85-23	16138-16141	but	_	
85-24	16142-16146	were	_	
85-25	16147-16149	in	_	
85-26	16150-16154	some	_	
85-27	16155-16164	instances	_	
85-28	16165-16171	larger	_	
85-29	16171-16172	.	_	

#Text=FC analyses revealed a pattern of both increased and decreased connectivity in patients compared to controls.
86-1	16173-16175	FC	_	
86-2	16176-16184	analyses	_	
86-3	16185-16193	revealed	_	
86-4	16194-16195	a	_	
86-5	16196-16203	pattern	_	
86-6	16204-16206	of	_	
86-7	16207-16211	both	_	
86-8	16212-16221	increased	_	
86-9	16222-16225	and	_	
86-10	16226-16235	decreased	_	
86-11	16236-16248	connectivity	_	
86-12	16249-16251	in	_	
86-13	16252-16260	patients	_	
86-14	16261-16269	compared	_	
86-15	16270-16272	to	_	
86-16	16273-16281	controls	_	
86-17	16281-16282	.	_	

#Text=Table III lists all FC that differed between patients and controls.
87-1	16283-16288	Table	_	
87-2	16289-16292	III	_	
87-3	16293-16298	lists	_	
87-4	16299-16302	all	_	
87-5	16303-16305	FC	_	
87-6	16306-16310	that	_	
87-7	16311-16319	differed	_	
87-8	16320-16327	between	_	
87-9	16328-16336	patients	_	
87-10	16337-16340	and	_	
87-11	16341-16349	controls	_	
87-12	16349-16350	.	_	

#Text=Associations with antisaccade performance
#Text=Antisaccade error rate
#Text=In patients, ALFF power was not associated with antisaccade error rate in any oculomotor region, including FEF, SEF or thalamus (adjusted R2=0.0, standard error (S.E.)=1.34, F=2.03.59, p>0.05).
88-1	16351-16363	Associations	_	
88-2	16364-16368	with	_	
88-3	16369-16380	antisaccade	_	
88-4	16381-16392	performance	_	
88-5	16393-16404	Antisaccade	_	
88-6	16405-16410	error	_	
88-7	16411-16415	rate	_	
88-8	16416-16418	In	_	
88-9	16419-16427	patients	_	
88-10	16427-16428	,	_	
88-11	16429-16433	ALFF	_	
88-12	16434-16439	power	_	
88-13	16440-16443	was	_	
88-14	16444-16447	not	_	
88-15	16448-16458	associated	_	
88-16	16459-16463	with	_	
88-17	16464-16475	antisaccade	_	
88-18	16476-16481	error	_	
88-19	16482-16486	rate	_	
88-20	16487-16489	in	_	
88-21	16490-16493	any	_	
88-22	16494-16504	oculomotor	_	
88-23	16505-16511	region	_	
88-24	16511-16512	,	_	
88-25	16513-16522	including	_	
88-26	16523-16526	FEF	_	
88-27	16526-16527	,	_	
88-28	16528-16531	SEF	_	
88-29	16532-16534	or	_	
88-30	16535-16543	thalamus	_	
88-31	16544-16545	(	_	
88-32	16545-16553	adjusted	_	
88-33	16554-16556	R2	_	
88-34	16556-16557	=	_	
88-35	16557-16560	0.0	_	
88-36	16560-16561	,	_	
88-37	16562-16570	standard	_	
88-38	16571-16576	error	_	
88-39	16577-16578	(	_	
88-40	16578-16581	S.E	_	
88-41	16581-16582	.	_	
88-42	16582-16583	)	_	
88-43	16583-16584	=	_	
88-44	16584-16588	1.34	_	
88-45	16588-16589	,	_	
88-46	16590-16591	F	_	
88-47	16591-16592	=	_	
88-48	16592-16599	2.03.59	_	
88-49	16599-16600	,	_	
88-50	16601-16602	p	_	
88-51	16602-16603	>	_	
88-52	16603-16607	0.05	_	
88-53	16607-16608	)	_	
88-54	16608-16609	.	_	

#Text=However, higher antisaccade error rate was associated with lower FC from left FEF to left inferior parietal gyrus (IPG), bilateral precuneus (PCUN), left middle temporal gyrus (MTG) and right fusiform gyrus (FFG), and higher FC from left FEF to left angular gyrus (ANG).
89-1	16610-16617	However	_	
89-2	16617-16618	,	_	
89-3	16619-16625	higher	_	
89-4	16626-16637	antisaccade	_	
89-5	16638-16643	error	_	
89-6	16644-16648	rate	_	
89-7	16649-16652	was	_	
89-8	16653-16663	associated	_	
89-9	16664-16668	with	_	
89-10	16669-16674	lower	_	
89-11	16675-16677	FC	_	
89-12	16678-16682	from	_	
89-13	16683-16687	left	_	
89-14	16688-16691	FEF	_	
89-15	16692-16694	to	_	
89-16	16695-16699	left	_	
89-17	16700-16708	inferior	_	
89-18	16709-16717	parietal	_	
89-19	16718-16723	gyrus	_	
89-20	16724-16725	(	_	
89-21	16725-16728	IPG	_	
89-22	16728-16729	)	_	
89-23	16729-16730	,	_	
89-24	16731-16740	bilateral	_	
89-25	16741-16750	precuneus	_	
89-26	16751-16752	(	_	
89-27	16752-16756	PCUN	_	
89-28	16756-16757	)	_	
89-29	16757-16758	,	_	
89-30	16759-16763	left	_	
89-31	16764-16770	middle	_	
89-32	16771-16779	temporal	_	
89-33	16780-16785	gyrus	_	
89-34	16786-16787	(	_	
89-35	16787-16790	MTG	_	
89-36	16790-16791	)	_	
89-37	16792-16795	and	_	
89-38	16796-16801	right	_	
89-39	16802-16810	fusiform	_	
89-40	16811-16816	gyrus	_	
89-41	16817-16818	(	_	
89-42	16818-16821	FFG	_	
89-43	16821-16822	)	_	
89-44	16822-16823	,	_	
89-45	16824-16827	and	_	
89-46	16828-16834	higher	_	
89-47	16835-16837	FC	_	
89-48	16838-16842	from	_	
89-49	16843-16847	left	_	
89-50	16848-16851	FEF	_	
89-51	16852-16854	to	_	
89-52	16855-16859	left	_	
89-53	16860-16867	angular	_	
89-54	16868-16873	gyrus	_	
89-55	16874-16875	(	_	
89-56	16875-16878	ANG	_	
89-57	16878-16879	)	_	
89-58	16879-16880	.	_	

#Text=Higher FC from SEF to bilateral thalamus (THA) and lower FC from right thalamus to right parahippocampus (PHG) and left middle frontal gyrus (MFG) were also associated with higher antisaccade error rate in patients.
90-1	16881-16887	Higher	_	
90-2	16888-16890	FC	_	
90-3	16891-16895	from	_	
90-4	16896-16899	SEF	_	
90-5	16900-16902	to	_	
90-6	16903-16912	bilateral	_	
90-7	16913-16921	thalamus	_	
90-8	16922-16923	(	_	
90-9	16923-16926	THA	_	
90-10	16926-16927	)	_	
90-11	16928-16931	and	_	
90-12	16932-16937	lower	_	
90-13	16938-16940	FC	_	
90-14	16941-16945	from	_	
90-15	16946-16951	right	_	
90-16	16952-16960	thalamus	_	
90-17	16961-16963	to	_	
90-18	16964-16969	right	_	
90-19	16970-16985	parahippocampus	_	
90-20	16986-16987	(	_	
90-21	16987-16990	PHG	_	
90-22	16990-16991	)	_	
90-23	16992-16995	and	_	
90-24	16996-17000	left	_	
90-25	17001-17007	middle	_	
90-26	17008-17015	frontal	_	
90-27	17016-17021	gyrus	_	
90-28	17022-17023	(	_	
90-29	17023-17026	MFG	_	
90-30	17026-17027	)	_	
90-31	17028-17032	were	_	
90-32	17033-17037	also	_	
90-33	17038-17048	associated	_	
90-34	17049-17053	with	_	
90-35	17054-17060	higher	_	
90-36	17061-17072	antisaccade	_	
90-37	17073-17078	error	_	
90-38	17079-17083	rate	_	
90-39	17084-17086	in	_	
90-40	17087-17095	patients	_	
90-41	17095-17096	.	_	

#Text=Together these alterations in FC explained 34% of the variance in antisaccade error rate in patients (adjusted R2=0.34, S.E.=1.12, F=6.59, p<0.001, Table IV).
91-1	17097-17105	Together	_	
91-2	17106-17111	these	_	
91-3	17112-17123	alterations	_	
91-4	17124-17126	in	_	
91-5	17127-17129	FC	_	
91-6	17130-17139	explained	_	
91-7	17140-17143	34%	_	
91-8	17144-17146	of	_	
91-9	17147-17150	the	_	
91-10	17151-17159	variance	_	
91-11	17160-17162	in	_	
91-12	17163-17174	antisaccade	_	
91-13	17175-17180	error	_	
91-14	17181-17185	rate	_	
91-15	17186-17188	in	_	
91-16	17189-17197	patients	_	
91-17	17198-17199	(	_	
91-18	17199-17207	adjusted	_	
91-19	17208-17210	R2	_	
91-20	17210-17211	=	_	
91-21	17211-17215	0.34	_	
91-22	17215-17216	,	_	
91-23	17217-17220	S.E	_	
91-24	17220-17221	.	_	
91-25	17221-17222	=	_	
91-26	17222-17226	1.12	_	
91-27	17226-17227	,	_	
91-28	17228-17229	F	_	
91-29	17229-17230	=	_	
91-30	17230-17234	6.59	_	
91-31	17234-17235	,	_	
91-32	17236-17237	p	_	
91-33	17237-17238	<	_	
91-34	17238-17243	0.001	_	
91-35	17243-17244	,	_	
91-36	17245-17250	Table	_	
91-37	17251-17253	IV	_	
91-38	17253-17254	)	_	
91-39	17254-17255	.	_	

#Text=Figure 1 illustrates the findings from regression analyses, note that FC in red indicate that stronger FC was associated with higher error rates while blue FC indicate weaker association with higher error rates.
92-1	17256-17262	Figure	_	
92-2	17263-17264	1	_	
92-3	17265-17276	illustrates	_	
92-4	17277-17280	the	_	
92-5	17281-17289	findings	_	
92-6	17290-17294	from	_	
92-7	17295-17305	regression	_	
92-8	17306-17314	analyses	_	
92-9	17314-17315	,	_	
92-10	17316-17320	note	_	
92-11	17321-17325	that	_	
92-12	17326-17328	FC	_	
92-13	17329-17331	in	_	
92-14	17332-17335	red	_	
92-15	17336-17344	indicate	_	
92-16	17345-17349	that	_	
92-17	17350-17358	stronger	_	
92-18	17359-17361	FC	_	
92-19	17362-17365	was	_	
92-20	17366-17376	associated	_	
92-21	17377-17381	with	_	
92-22	17382-17388	higher	_	
92-23	17389-17394	error	_	
92-24	17395-17400	rates	_	
92-25	17401-17406	while	_	
92-26	17407-17411	blue	_	
92-27	17412-17414	FC	_	
92-28	17415-17423	indicate	_	
92-29	17424-17430	weaker	_	
92-30	17431-17442	association	_	
92-31	17443-17447	with	_	
92-32	17448-17454	higher	_	
92-33	17455-17460	error	_	
92-34	17461-17466	rates	_	
92-35	17466-17467	.	_	

#Text=In controls, higher antisaccade error rate was predicted by higher ALFF in left thalamus (THA) and lower ALFF in left FEF (adjusted R2=0.18, S.E.=0.77, F=6.45, p=0.003), Figure 1.
93-1	17468-17470	In	_	
93-2	17471-17479	controls	_	
93-3	17479-17480	,	_	
93-4	17481-17487	higher	_	
93-5	17488-17499	antisaccade	_	
93-6	17500-17505	error	_	
93-7	17506-17510	rate	_	
93-8	17511-17514	was	_	
93-9	17515-17524	predicted	_	
93-10	17525-17527	by	_	
93-11	17528-17534	higher	_	
93-12	17535-17539	ALFF	_	
93-13	17540-17542	in	_	
93-14	17543-17547	left	_	
93-15	17548-17556	thalamus	_	
93-16	17557-17558	(	_	
93-17	17558-17561	THA	_	
93-18	17561-17562	)	_	
93-19	17563-17566	and	_	
93-20	17567-17572	lower	_	
93-21	17573-17577	ALFF	_	
93-22	17578-17580	in	_	
93-23	17581-17585	left	_	
93-24	17586-17589	FEF	_	
93-25	17590-17591	(	_	
93-26	17591-17599	adjusted	_	
93-27	17600-17602	R2	_	
93-28	17602-17603	=	_	
93-29	17603-17607	0.18	_	
93-30	17607-17608	,	_	
93-31	17609-17612	S.E	_	
93-32	17612-17613	.	_	
93-33	17613-17614	=	_	
93-34	17614-17618	0.77	_	
93-35	17618-17619	,	_	
93-36	17620-17621	F	_	
93-37	17621-17622	=	_	
93-38	17622-17626	6.45	_	
93-39	17626-17627	,	_	
93-40	17628-17629	p	_	
93-41	17629-17630	=	_	
93-42	17630-17635	0.003	_	
93-43	17635-17636	)	_	
93-44	17636-17637	,	_	
93-45	17638-17644	Figure	_	
93-46	17645-17646	1	_	
93-47	17646-17647	.	_	

#Text=In contrast to patients, error rates in controls were not associated with any FC differences between patients and controls (adjusted R2=0.0, S.E.=0.85, F=0.5, p>0.05).
94-1	17648-17650	In	_	
94-2	17651-17659	contrast	_	
94-3	17660-17662	to	_	
94-4	17663-17671	patients	_	
94-5	17671-17672	,	_	
94-6	17673-17678	error	_	
94-7	17679-17684	rates	_	
94-8	17685-17687	in	_	
94-9	17688-17696	controls	_	
94-10	17697-17701	were	_	
94-11	17702-17705	not	_	
94-12	17706-17716	associated	_	
94-13	17717-17721	with	_	
94-14	17722-17725	any	_	
94-15	17726-17728	FC	_	
94-16	17729-17740	differences	_	
94-17	17741-17748	between	_	
94-18	17749-17757	patients	_	
94-19	17758-17761	and	_	
94-20	17762-17770	controls	_	
94-21	17771-17772	(	_	
94-22	17772-17780	adjusted	_	
94-23	17781-17783	R2	_	
94-24	17783-17784	=	_	
94-25	17784-17787	0.0	_	
94-26	17787-17788	,	_	
94-27	17789-17792	S.E	_	
94-28	17792-17793	.	_	
94-29	17793-17794	=	_	
94-30	17794-17798	0.85	_	
94-31	17798-17799	,	_	
94-32	17800-17801	F	_	
94-33	17801-17802	=	_	
94-34	17802-17805	0.5	_	
94-35	17805-17806	,	_	
94-36	17807-17808	p	_	
94-37	17808-17809	>	_	
94-38	17809-17813	0.05	_	
94-39	17813-17814	)	_	
94-40	17814-17815	.	_	

#Text=Latency of correct antisaccades
#Text=There was only a weak association between antisaccade latency and resting state physiology in patients, Figure 2, with higher FC from right thalamus to bilateral cuneus (CUN) and lower FC from right thalamus to left middle frontal gyrus (MFG) predicting slower antisaccade processing speed (adjusted R2=0.09, S.E.=1.2, F=5.24, p=0.007).
95-1	17816-17823	Latency	_	
95-2	17824-17826	of	_	
95-3	17827-17834	correct	_	
95-4	17835-17847	antisaccades	_	
95-5	17848-17853	There	_	
95-6	17854-17857	was	_	
95-7	17858-17862	only	_	
95-8	17863-17864	a	_	
95-9	17865-17869	weak	_	
95-10	17870-17881	association	_	
95-11	17882-17889	between	_	
95-12	17890-17901	antisaccade	_	
95-13	17902-17909	latency	_	
95-14	17910-17913	and	_	
95-15	17914-17921	resting	_	
95-16	17922-17927	state	_	
95-17	17928-17938	physiology	_	
95-18	17939-17941	in	_	
95-19	17942-17950	patients	_	
95-20	17950-17951	,	_	
95-21	17952-17958	Figure	_	
95-22	17959-17960	2	_	
95-23	17960-17961	,	_	
95-24	17962-17966	with	_	
95-25	17967-17973	higher	_	
95-26	17974-17976	FC	_	
95-27	17977-17981	from	_	
95-28	17982-17987	right	_	
95-29	17988-17996	thalamus	_	
95-30	17997-17999	to	_	
95-31	18000-18009	bilateral	_	
95-32	18010-18016	cuneus	_	
95-33	18017-18018	(	_	
95-34	18018-18021	CUN	_	
95-35	18021-18022	)	_	
95-36	18023-18026	and	_	
95-37	18027-18032	lower	_	
95-38	18033-18035	FC	_	
95-39	18036-18040	from	_	
95-40	18041-18046	right	_	
95-41	18047-18055	thalamus	_	
95-42	18056-18058	to	_	
95-43	18059-18063	left	_	
95-44	18064-18070	middle	_	
95-45	18071-18078	frontal	_	
95-46	18079-18084	gyrus	_	
95-47	18085-18086	(	_	
95-48	18086-18089	MFG	_	
95-49	18089-18090	)	_	
95-50	18091-18101	predicting	_	
95-51	18102-18108	slower	_	
95-52	18109-18120	antisaccade	_	
95-53	18121-18131	processing	_	
95-54	18132-18137	speed	_	
95-55	18138-18139	(	_	
95-56	18139-18147	adjusted	_	
95-57	18148-18150	R2	_	
95-58	18150-18151	=	_	
95-59	18151-18155	0.09	_	
95-60	18155-18156	,	_	
95-61	18157-18160	S.E	_	
95-62	18160-18161	.	_	
95-63	18161-18162	=	_	
95-64	18162-18165	1.2	_	
95-65	18165-18166	,	_	
95-66	18167-18168	F	_	
95-67	18168-18169	=	_	
95-68	18169-18173	5.24	_	
95-69	18173-18174	,	_	
95-70	18175-18176	p	_	
95-71	18176-18177	=	_	
95-72	18177-18182	0.007	_	
95-73	18182-18183	)	_	
95-74	18183-18184	.	_	

#Text=In contrast, in controls, longer latency of correct antisaccades was predicted by lower FC from left FEF to right precuneus (PCUN) and to SEF and higher FC from left FEF to left MFG and left fusiform gyrus (FFG) (Figure 2).
96-1	18185-18187	In	_	
96-2	18188-18196	contrast	_	
96-3	18196-18197	,	_	
96-4	18198-18200	in	_	
96-5	18201-18209	controls	_	
96-6	18209-18210	,	_	
96-7	18211-18217	longer	_	
96-8	18218-18225	latency	_	
96-9	18226-18228	of	_	
96-10	18229-18236	correct	_	
96-11	18237-18249	antisaccades	_	
96-12	18250-18253	was	_	
96-13	18254-18263	predicted	_	
96-14	18264-18266	by	_	
96-15	18267-18272	lower	_	
96-16	18273-18275	FC	_	
96-17	18276-18280	from	_	
96-18	18281-18285	left	_	
96-19	18286-18289	FEF	_	
96-20	18290-18292	to	_	
96-21	18293-18298	right	_	
96-22	18299-18308	precuneus	_	
96-23	18309-18310	(	_	
96-24	18310-18314	PCUN	_	
96-25	18314-18315	)	_	
96-26	18316-18319	and	_	
96-27	18320-18322	to	_	
96-28	18323-18326	SEF	_	
96-29	18327-18330	and	_	
96-30	18331-18337	higher	_	
96-31	18338-18340	FC	_	
96-32	18341-18345	from	_	
96-33	18346-18350	left	_	
96-34	18351-18354	FEF	_	
96-35	18355-18357	to	_	
96-36	18358-18362	left	_	
96-37	18363-18366	MFG	_	
96-38	18367-18370	and	_	
96-39	18371-18375	left	_	
96-40	18376-18384	fusiform	_	
96-41	18385-18390	gyrus	_	
96-42	18391-18392	(	_	
96-43	18392-18395	FFG	_	
96-44	18395-18396	)	_	
96-45	18397-18398	(	_	
96-46	18398-18404	Figure	_	
96-47	18405-18406	2	_	
96-48	18406-18407	)	_	
96-49	18407-18408	.	_	

#Text=Additionally, longer antisaccade latency was predicted by higher FC from SEF to thalamus (THA) bilaterally and lower FC to anterior cingulate (ACC) bilaterally.
97-1	18409-18421	Additionally	_	
97-2	18421-18422	,	_	
97-3	18423-18429	longer	_	
97-4	18430-18441	antisaccade	_	
97-5	18442-18449	latency	_	
97-6	18450-18453	was	_	
97-7	18454-18463	predicted	_	
97-8	18464-18466	by	_	
97-9	18467-18473	higher	_	
97-10	18474-18476	FC	_	
97-11	18477-18481	from	_	
97-12	18482-18485	SEF	_	
97-13	18486-18488	to	_	
97-14	18489-18497	thalamus	_	
97-15	18498-18499	(	_	
97-16	18499-18502	THA	_	
97-17	18502-18503	)	_	
97-18	18504-18515	bilaterally	_	
97-19	18516-18519	and	_	
97-20	18520-18525	lower	_	
97-21	18526-18528	FC	_	
97-22	18529-18531	to	_	
97-23	18532-18540	anterior	_	
97-24	18541-18550	cingulate	_	
97-25	18551-18552	(	_	
97-26	18552-18555	ACC	_	
97-27	18555-18556	)	_	
97-28	18557-18568	bilaterally	_	
97-29	18568-18569	.	_	

#Text=Together, these FC patterns accounted for 27% of the variance in antisaccade latency in controls (adjusted R2=0.27, S.E.=0.78, F=3.95, p=0.003, Table IV).
98-1	18570-18578	Together	_	
98-2	18578-18579	,	_	
98-3	18580-18585	these	_	
98-4	18586-18588	FC	_	
98-5	18589-18597	patterns	_	
98-6	18598-18607	accounted	_	
98-7	18608-18611	for	_	
98-8	18612-18615	27%	_	
98-9	18616-18618	of	_	
98-10	18619-18622	the	_	
98-11	18623-18631	variance	_	
98-12	18632-18634	in	_	
98-13	18635-18646	antisaccade	_	
98-14	18647-18654	latency	_	
98-15	18655-18657	in	_	
98-16	18658-18666	controls	_	
98-17	18667-18668	(	_	
98-18	18668-18676	adjusted	_	
98-19	18677-18679	R2	_	
98-20	18679-18680	=	_	
98-21	18680-18684	0.27	_	
98-22	18684-18685	,	_	
98-23	18686-18689	S.E	_	
98-24	18689-18690	.	_	
98-25	18690-18691	=	_	
98-26	18691-18695	0.78	_	
98-27	18695-18696	,	_	
98-28	18697-18698	F	_	
98-29	18698-18699	=	_	
98-30	18699-18703	3.95	_	
98-31	18703-18704	,	_	
98-32	18705-18706	p	_	
98-33	18706-18707	=	_	
98-34	18707-18712	0.003	_	
98-35	18712-18713	,	_	
98-36	18714-18719	Table	_	
98-37	18720-18722	IV	_	
98-38	18722-18723	)	_	
98-39	18723-18724	.	_	

#Text=Note that in Figure 2, FC in red indicate that stronger FC was associated with longer latency while blue FC indicate weaker FC associated with longer latency.
99-1	18725-18729	Note	_	
99-2	18730-18734	that	_	
99-3	18735-18737	in	_	
99-4	18738-18744	Figure	_	
99-5	18745-18746	2	_	
99-6	18746-18747	,	_	
99-7	18748-18750	FC	_	
99-8	18751-18753	in	_	
99-9	18754-18757	red	_	
99-10	18758-18766	indicate	_	
99-11	18767-18771	that	_	
99-12	18772-18780	stronger	_	
99-13	18781-18783	FC	_	
99-14	18784-18787	was	_	
99-15	18788-18798	associated	_	
99-16	18799-18803	with	_	
99-17	18804-18810	longer	_	
99-18	18811-18818	latency	_	
99-19	18819-18824	while	_	
99-20	18825-18829	blue	_	
99-21	18830-18832	FC	_	
99-22	18833-18841	indicate	_	
99-23	18842-18848	weaker	_	
99-24	18849-18851	FC	_	
99-25	18852-18862	associated	_	
99-26	18863-18867	with	_	
99-27	18868-18874	longer	_	
99-28	18875-18882	latency	_	
99-29	18882-18883	.	_	

#Text=Antisaccade latency was not associated with ALFF in any oculomotor region in controls (adjusted R2=0.0, S.E.=0.90, F=1.3, p>0.05).
100-1	18884-18895	Antisaccade	_	
100-2	18896-18903	latency	_	
100-3	18904-18907	was	_	
100-4	18908-18911	not	_	
100-5	18912-18922	associated	_	
100-6	18923-18927	with	_	
100-7	18928-18932	ALFF	_	
100-8	18933-18935	in	_	
100-9	18936-18939	any	_	
100-10	18940-18950	oculomotor	_	
100-11	18951-18957	region	_	
100-12	18958-18960	in	_	
100-13	18961-18969	controls	_	
100-14	18970-18971	(	_	
100-15	18971-18979	adjusted	_	
100-16	18980-18982	R2	_	
100-17	18982-18983	=	_	
100-18	18983-18986	0.0	_	
100-19	18986-18987	,	_	
100-20	18988-18991	S.E	_	
100-21	18991-18992	.	_	
100-22	18992-18993	=	_	
100-23	18993-18997	0.90	_	
100-24	18997-18998	,	_	
100-25	18999-19000	F	_	
100-26	19000-19001	=	_	
100-27	19001-19004	1.3	_	
100-28	19004-19005	,	_	
100-29	19006-19007	p	_	
100-30	19007-19008	>	_	
100-31	19008-19012	0.05	_	
100-32	19012-19013	)	_	
100-33	19013-19014	.	_	

#Text=Associations with clinical variables
#Text=Alterations in regional ALFF and FC measures, which were associated with error rate and antisaccade latency, were not correlated with antipsychotic medication dosage, i.e. chlorpromazine equivalents.
101-1	19015-19027	Associations	_	
101-2	19028-19032	with	_	
101-3	19033-19041	clinical	_	
101-4	19042-19051	variables	_	
101-5	19052-19063	Alterations	_	
101-6	19064-19066	in	_	
101-7	19067-19075	regional	_	
101-8	19076-19080	ALFF	_	
101-9	19081-19084	and	_	
101-10	19085-19087	FC	_	
101-11	19088-19096	measures	_	
101-12	19096-19097	,	_	
101-13	19098-19103	which	_	
101-14	19104-19108	were	_	
101-15	19109-19119	associated	_	
101-16	19120-19124	with	_	
101-17	19125-19130	error	_	
101-18	19131-19135	rate	_	
101-19	19136-19139	and	_	
101-20	19140-19151	antisaccade	_	
101-21	19152-19159	latency	_	
101-22	19159-19160	,	_	
101-23	19161-19165	were	_	
101-24	19166-19169	not	_	
101-25	19170-19180	correlated	_	
101-26	19181-19185	with	_	
101-27	19186-19199	antipsychotic	_	
101-28	19200-19210	medication	_	
101-29	19211-19217	dosage	_	
101-30	19217-19218	,	_	
101-31	19219-19222	i.e	_	
101-32	19222-19223	.	_	
101-33	19224-19238	chlorpromazine	_	
101-34	19239-19250	equivalents	_	
101-35	19250-19251	.	_	

#Text=Associations with clinical ratings were modest, consistent with the prior literature.
102-1	19252-19264	Associations	_	
102-2	19265-19269	with	_	
102-3	19270-19278	clinical	_	
102-4	19279-19286	ratings	_	
102-5	19287-19291	were	_	
102-6	19292-19298	modest	_	
102-7	19298-19299	,	_	
102-8	19300-19310	consistent	_	
102-9	19311-19315	with	_	
102-10	19316-19319	the	_	
102-11	19320-19325	prior	_	
102-12	19326-19336	literature	_	
102-13	19336-19337	.	_	

#Text=PANSS scores only correlated with FC between SEF and bilateral thalamus (PANSSTotal r=0.39, p<0.001, PANSSPositive r=0.36, p=0.001 PANSSNegative r=0.26, p=0.02) but not with any other clinical rating or ALFF measures.
103-1	19338-19343	PANSS	_	
103-2	19344-19350	scores	_	
103-3	19351-19355	only	_	
103-4	19356-19366	correlated	_	
103-5	19367-19371	with	_	
103-6	19372-19374	FC	_	
103-7	19375-19382	between	_	
103-8	19383-19386	SEF	_	
103-9	19387-19390	and	_	
103-10	19391-19400	bilateral	_	
103-11	19401-19409	thalamus	_	
103-12	19410-19411	(	_	
103-13	19411-19421	PANSSTotal	_	
103-14	19422-19423	r	_	
103-15	19423-19424	=	_	
103-16	19424-19428	0.39	_	
103-17	19428-19429	,	_	
103-18	19430-19431	p	_	
103-19	19431-19432	<	_	
103-20	19432-19437	0.001	_	
103-21	19437-19438	,	_	
103-22	19439-19452	PANSSPositive	_	
103-23	19453-19454	r	_	
103-24	19454-19455	=	_	
103-25	19455-19459	0.36	_	
103-26	19459-19460	,	_	
103-27	19461-19462	p	_	
103-28	19462-19463	=	_	
103-29	19463-19468	0.001	_	
103-30	19469-19482	PANSSNegative	_	
103-31	19483-19484	r	_	
103-32	19484-19485	=	_	
103-33	19485-19489	0.26	_	
103-34	19489-19490	,	_	
103-35	19491-19492	p	_	
103-36	19492-19493	=	_	
103-37	19493-19497	0.02	_	
103-38	19497-19498	)	_	
103-39	19499-19502	but	_	
103-40	19503-19506	not	_	
103-41	19507-19511	with	_	
103-42	19512-19515	any	_	
103-43	19516-19521	other	_	
103-44	19522-19530	clinical	_	
103-45	19531-19537	rating	_	
103-46	19538-19540	or	_	
103-47	19541-19545	ALFF	_	
103-48	19546-19554	measures	_	
103-49	19554-19555	.	_	

#Text=Discussion
#Text=There are two important aspects to our findings from this first study to investigate associations of alterations of resting state brain physiology in fronto-thalamo-parietal networks with the well-established biomarker of increased antisaccade error rates in patients with psychosis.
104-1	19556-19566	Discussion	_	
104-2	19567-19572	There	_	
104-3	19573-19576	are	_	
104-4	19577-19580	two	_	
104-5	19581-19590	important	_	
104-6	19591-19598	aspects	_	
104-7	19599-19601	to	_	
104-8	19602-19605	our	_	
104-9	19606-19614	findings	_	
104-10	19615-19619	from	_	
104-11	19620-19624	this	_	
104-12	19625-19630	first	_	
104-13	19631-19636	study	_	
104-14	19637-19639	to	_	
104-15	19640-19651	investigate	_	
104-16	19652-19664	associations	_	
104-17	19665-19667	of	_	
104-18	19668-19679	alterations	_	
104-19	19680-19682	of	_	
104-20	19683-19690	resting	_	
104-21	19691-19696	state	_	
104-22	19697-19702	brain	_	
104-23	19703-19713	physiology	_	
104-24	19714-19716	in	_	
104-25	19717-19740	fronto-thalamo-parietal	_	
104-26	19741-19749	networks	_	
104-27	19750-19754	with	_	
104-28	19755-19758	the	_	
104-29	19759-19775	well-established	_	
104-30	19776-19785	biomarker	_	
104-31	19786-19788	of	_	
104-32	19789-19798	increased	_	
104-33	19799-19810	antisaccade	_	
104-34	19811-19816	error	_	
104-35	19817-19822	rates	_	
104-36	19823-19825	in	_	
104-37	19826-19834	patients	_	
104-38	19835-19839	with	_	
104-39	19840-19849	psychosis	_	
104-40	19849-19850	.	_	

#Text=First, our results indicate a behavioural relevance of altered resting state brain function in psychotic disorders, specifically to deficits in cognitive control.
105-1	19851-19856	First	_	
105-2	19856-19857	,	_	
105-3	19858-19861	our	_	
105-4	19862-19869	results	_	
105-5	19870-19878	indicate	_	
105-6	19879-19880	a	_	
105-7	19881-19892	behavioural	_	
105-8	19893-19902	relevance	_	
105-9	19903-19905	of	_	
105-10	19906-19913	altered	_	
105-11	19914-19921	resting	_	
105-12	19922-19927	state	_	
105-13	19928-19933	brain	_	
105-14	19934-19942	function	_	
105-15	19943-19945	in	_	
105-16	19946-19955	psychotic	_	
105-17	19956-19965	disorders	_	
105-18	19965-19966	,	_	
105-19	19967-19979	specifically	_	
105-20	19980-19982	to	_	
105-21	19983-19991	deficits	_	
105-22	19992-19994	in	_	
105-23	19995-20004	cognitive	_	
105-24	20005-20012	control	_	
105-25	20012-20013	.	_	

#Text=Second, our findings demonstrate that increased inhibition error rates in patients with psychotic disorders are related to predominantly weaker functional connectivity in intrinsic fronto-thalamo-parietal brain systems rather than to altered local activity in oculomotor areas such as FEF, SEF or thalamus.
106-1	20014-20020	Second	_	
106-2	20020-20021	,	_	
106-3	20022-20025	our	_	
106-4	20026-20034	findings	_	
106-5	20035-20046	demonstrate	_	
106-6	20047-20051	that	_	
106-7	20052-20061	increased	_	
106-8	20062-20072	inhibition	_	
106-9	20073-20078	error	_	
106-10	20079-20084	rates	_	
106-11	20085-20087	in	_	
106-12	20088-20096	patients	_	
106-13	20097-20101	with	_	
106-14	20102-20111	psychotic	_	
106-15	20112-20121	disorders	_	
106-16	20122-20125	are	_	
106-17	20126-20133	related	_	
106-18	20134-20136	to	_	
106-19	20137-20150	predominantly	_	
106-20	20151-20157	weaker	_	
106-21	20158-20168	functional	_	
106-22	20169-20181	connectivity	_	
106-23	20182-20184	in	_	
106-24	20185-20194	intrinsic	_	
106-25	20195-20218	fronto-thalamo-parietal	_	
106-26	20219-20224	brain	_	
106-27	20225-20232	systems	_	
106-28	20233-20239	rather	_	
106-29	20240-20244	than	_	
106-30	20245-20247	to	_	
106-31	20248-20255	altered	_	
106-32	20256-20261	local	_	
106-33	20262-20270	activity	_	
106-34	20271-20273	in	_	
106-35	20274-20284	oculomotor	_	
106-36	20285-20290	areas	_	
106-37	20291-20295	such	_	
106-38	20296-20298	as	_	
106-39	20299-20302	FEF	_	
106-40	20302-20303	,	_	
106-41	20304-20307	SEF	_	
106-42	20308-20310	or	_	
106-43	20311-20319	thalamus	_	
106-44	20319-20320	.	_	

#Text=In secondary analyses, we studied the relation between intrinsic brain activity and processing speed required to generate correct antisaccade responses.
107-1	20321-20323	In	_	
107-2	20324-20333	secondary	_	
107-3	20334-20342	analyses	_	
107-4	20342-20343	,	_	
107-5	20344-20346	we	_	
107-6	20347-20354	studied	_	
107-7	20355-20358	the	_	
107-8	20359-20367	relation	_	
107-9	20368-20375	between	_	
107-10	20376-20385	intrinsic	_	
107-11	20386-20391	brain	_	
107-12	20392-20400	activity	_	
107-13	20401-20404	and	_	
107-14	20405-20415	processing	_	
107-15	20416-20421	speed	_	
107-16	20422-20430	required	_	
107-17	20431-20433	to	_	
107-18	20434-20442	generate	_	
107-19	20443-20450	correct	_	
107-20	20451-20462	antisaccade	_	
107-21	20463-20472	responses	_	
107-22	20472-20473	.	_	

#Text=Consistent with studies in nonhuman primates, volitional saccadic behavior in controls was supported by a widely distributed fronto-thalamo-parietal network that includes the anterior cingulate.
108-1	20474-20484	Consistent	_	
108-2	20485-20489	with	_	
108-3	20490-20497	studies	_	
108-4	20498-20500	in	_	
108-5	20501-20509	nonhuman	_	
108-6	20510-20518	primates	_	
108-7	20518-20519	,	_	
108-8	20520-20530	volitional	_	
108-9	20531-20539	saccadic	_	
108-10	20540-20548	behavior	_	
108-11	20549-20551	in	_	
108-12	20552-20560	controls	_	
108-13	20561-20564	was	_	
108-14	20565-20574	supported	_	
108-15	20575-20577	by	_	
108-16	20578-20579	a	_	
108-17	20580-20586	widely	_	
108-18	20587-20598	distributed	_	
108-19	20599-20622	fronto-thalamo-parietal	_	
108-20	20623-20630	network	_	
108-21	20631-20635	that	_	
108-22	20636-20644	includes	_	
108-23	20645-20648	the	_	
108-24	20649-20657	anterior	_	
108-25	20658-20667	cingulate	_	
108-26	20667-20668	.	_	

#Text=In patients, processing speed was associated with fewer significant functional connections in this circuitry.
109-1	20669-20671	In	_	
109-2	20672-20680	patients	_	
109-3	20680-20681	,	_	
109-4	20682-20692	processing	_	
109-5	20693-20698	speed	_	
109-6	20699-20702	was	_	
109-7	20703-20713	associated	_	
109-8	20714-20718	with	_	
109-9	20719-20724	fewer	_	
109-10	20725-20736	significant	_	
109-11	20737-20747	functional	_	
109-12	20748-20759	connections	_	
109-13	20760-20762	in	_	
109-14	20763-20767	this	_	
109-15	20768-20777	circuitry	_	
109-16	20777-20778	.	_	

#Text=Together, our findings extend previous reports from patients with psychosis showing alterations in a fronto-thalamo-parietal network during active antisaccade performance in task-based fMRI studies.
110-1	20779-20787	Together	_	
110-2	20787-20788	,	_	
110-3	20789-20792	our	_	
110-4	20793-20801	findings	_	
110-5	20802-20808	extend	_	
110-6	20809-20817	previous	_	
110-7	20818-20825	reports	_	
110-8	20826-20830	from	_	
110-9	20831-20839	patients	_	
110-10	20840-20844	with	_	
110-11	20845-20854	psychosis	_	
110-12	20855-20862	showing	_	
110-13	20863-20874	alterations	_	
110-14	20875-20877	in	_	
110-15	20878-20879	a	_	
110-16	20880-20903	fronto-thalamo-parietal	_	
110-17	20904-20911	network	_	
110-18	20912-20918	during	_	
110-19	20919-20925	active	_	
110-20	20926-20937	antisaccade	_	
110-21	20938-20949	performance	_	
110-22	20950-20952	in	_	
110-23	20953-20963	task-based	_	
110-24	20964-20968	fMRI	_	
110-25	20969-20976	studies	_	
110-26	20976-20977	.	_	

#Text=Thus, our findings provide new understanding of the brain substrate of this familial abnormality associated with psychotic disorders by providing novel evidence that similar network alterations are seen in resting-state studies and that connectivity alterations rather than altered regional activity are more related to this domain of behavioural deficit on a task where resting physiology prior to trial onset is known to be an important factor relevant to task performance.
111-1	20978-20982	Thus	_	
111-2	20982-20983	,	_	
111-3	20984-20987	our	_	
111-4	20988-20996	findings	_	
111-5	20997-21004	provide	_	
111-6	21005-21008	new	_	
111-7	21009-21022	understanding	_	
111-8	21023-21025	of	_	
111-9	21026-21029	the	_	
111-10	21030-21035	brain	_	
111-11	21036-21045	substrate	_	
111-12	21046-21048	of	_	
111-13	21049-21053	this	_	
111-14	21054-21062	familial	_	
111-15	21063-21074	abnormality	_	
111-16	21075-21085	associated	_	
111-17	21086-21090	with	_	
111-18	21091-21100	psychotic	_	
111-19	21101-21110	disorders	_	
111-20	21111-21113	by	_	
111-21	21114-21123	providing	_	
111-22	21124-21129	novel	_	
111-23	21130-21138	evidence	_	
111-24	21139-21143	that	_	
111-25	21144-21151	similar	_	
111-26	21152-21159	network	_	
111-27	21160-21171	alterations	_	
111-28	21172-21175	are	_	
111-29	21176-21180	seen	_	
111-30	21181-21183	in	_	
111-31	21184-21197	resting-state	_	
111-32	21198-21205	studies	_	
111-33	21206-21209	and	_	
111-34	21210-21214	that	_	
111-35	21215-21227	connectivity	_	
111-36	21228-21239	alterations	_	
111-37	21240-21246	rather	_	
111-38	21247-21251	than	_	
111-39	21252-21259	altered	_	
111-40	21260-21268	regional	_	
111-41	21269-21277	activity	_	
111-42	21278-21281	are	_	
111-43	21282-21286	more	_	
111-44	21287-21294	related	_	
111-45	21295-21297	to	_	
111-46	21298-21302	this	_	
111-47	21303-21309	domain	_	
111-48	21310-21312	of	_	
111-49	21313-21324	behavioural	_	
111-50	21325-21332	deficit	_	
111-51	21333-21335	on	_	
111-52	21336-21337	a	_	
111-53	21338-21342	task	_	
111-54	21343-21348	where	_	
111-55	21349-21356	resting	_	
111-56	21357-21367	physiology	_	
111-57	21368-21373	prior	_	
111-58	21374-21376	to	_	
111-59	21377-21382	trial	_	
111-60	21383-21388	onset	_	
111-61	21389-21391	is	_	
111-62	21392-21397	known	_	
111-63	21398-21400	to	_	
111-64	21401-21403	be	_	
111-65	21404-21406	an	_	
111-66	21407-21416	important	_	
111-67	21417-21423	factor	_	
111-68	21424-21432	relevant	_	
111-69	21433-21435	to	_	
111-70	21436-21440	task	_	
111-71	21441-21452	performance	_	
111-72	21452-21453	.	_	

#Text=Previous rs-MRI studies from patients with schizophrenia, schizoaffective disorder and psychotic bipolar disorder demonstrated disruptions of intrinsic cortical network organization and integration including the sensorimotor network guiding attention and action towards external sensory stimuli, the fronto-parietal network subserving executive control, and the default mode network.
112-1	21454-21462	Previous	_	
112-2	21463-21469	rs-MRI	_	
112-3	21470-21477	studies	_	
112-4	21478-21482	from	_	
112-5	21483-21491	patients	_	
112-6	21492-21496	with	_	
112-7	21497-21510	schizophrenia	_	
112-8	21510-21511	,	_	
112-9	21512-21527	schizoaffective	_	
112-10	21528-21536	disorder	_	
112-11	21537-21540	and	_	
112-12	21541-21550	psychotic	_	
112-13	21551-21558	bipolar	_	
112-14	21559-21567	disorder	_	
112-15	21568-21580	demonstrated	_	
112-16	21581-21592	disruptions	_	
112-17	21593-21595	of	_	
112-18	21596-21605	intrinsic	_	
112-19	21606-21614	cortical	_	
112-20	21615-21622	network	_	
112-21	21623-21635	organization	_	
112-22	21636-21639	and	_	
112-23	21640-21651	integration	_	
112-24	21652-21661	including	_	
112-25	21662-21665	the	_	
112-26	21666-21678	sensorimotor	_	
112-27	21679-21686	network	_	
112-28	21687-21694	guiding	_	
112-29	21695-21704	attention	_	
112-30	21705-21708	and	_	
112-31	21709-21715	action	_	
112-32	21716-21723	towards	_	
112-33	21724-21732	external	_	
112-34	21733-21740	sensory	_	
112-35	21741-21748	stimuli	_	
112-36	21748-21749	,	_	
112-37	21750-21753	the	_	
112-38	21754-21769	fronto-parietal	_	
112-39	21770-21777	network	_	
112-40	21778-21788	subserving	_	
112-41	21789-21798	executive	_	
112-42	21799-21806	control	_	
112-43	21806-21807	,	_	
112-44	21808-21811	and	_	
112-45	21812-21815	the	_	
112-46	21816-21823	default	_	
112-47	21824-21828	mode	_	
112-48	21829-21836	network	_	
112-49	21836-21837	.	_	

#Text=The areas with reduced ALFF in patients that we used as seed areas form part of the fronto-striatal sensorimotor network including FEF and SEF regions, and thalamus.
113-1	21838-21841	The	_	
113-2	21842-21847	areas	_	
113-3	21848-21852	with	_	
113-4	21853-21860	reduced	_	
113-5	21861-21865	ALFF	_	
113-6	21866-21868	in	_	
113-7	21869-21877	patients	_	
113-8	21878-21882	that	_	
113-9	21883-21885	we	_	
113-10	21886-21890	used	_	
113-11	21891-21893	as	_	
113-12	21894-21898	seed	_	
113-13	21899-21904	areas	_	
113-14	21905-21909	form	_	
113-15	21910-21914	part	_	
113-16	21915-21917	of	_	
113-17	21918-21921	the	_	
113-18	21922-21937	fronto-striatal	_	
113-19	21938-21950	sensorimotor	_	
113-20	21951-21958	network	_	
113-21	21959-21968	including	_	
113-22	21969-21972	FEF	_	
113-23	21973-21976	and	_	
113-24	21977-21980	SEF	_	
113-25	21981-21988	regions	_	
113-26	21988-21989	,	_	
113-27	21990-21993	and	_	
113-28	21994-22002	thalamus	_	
113-29	22002-22003	.	_	

#Text=As expected, we found that ALFF in FEF and thalamus was directly related to antisaccade error rates in controls, a finding that is in line with results from a large meta-analyses that included the few rs-MRI studies in addition to fMRI studies with active antisaccade performance.
114-1	22004-22006	As	_	
114-2	22007-22015	expected	_	
114-3	22015-22016	,	_	
114-4	22017-22019	we	_	
114-5	22020-22025	found	_	
114-6	22026-22030	that	_	
114-7	22031-22035	ALFF	_	
114-8	22036-22038	in	_	
114-9	22039-22042	FEF	_	
114-10	22043-22046	and	_	
114-11	22047-22055	thalamus	_	
114-12	22056-22059	was	_	
114-13	22060-22068	directly	_	
114-14	22069-22076	related	_	
114-15	22077-22079	to	_	
114-16	22080-22091	antisaccade	_	
114-17	22092-22097	error	_	
114-18	22098-22103	rates	_	
114-19	22104-22106	in	_	
114-20	22107-22115	controls	_	
114-21	22115-22116	,	_	
114-22	22117-22118	a	_	
114-23	22119-22126	finding	_	
114-24	22127-22131	that	_	
114-25	22132-22134	is	_	
114-26	22135-22137	in	_	
114-27	22138-22142	line	_	
114-28	22143-22147	with	_	
114-29	22148-22155	results	_	
114-30	22156-22160	from	_	
114-31	22161-22162	a	_	
114-32	22163-22168	large	_	
114-33	22169-22182	meta-analyses	_	
114-34	22183-22187	that	_	
114-35	22188-22196	included	_	
114-36	22197-22200	the	_	
114-37	22201-22204	few	_	
114-38	22205-22211	rs-MRI	_	
114-39	22212-22219	studies	_	
114-40	22220-22222	in	_	
114-41	22223-22231	addition	_	
114-42	22232-22234	to	_	
114-43	22235-22239	fMRI	_	
114-44	22240-22247	studies	_	
114-45	22248-22252	with	_	
114-46	22253-22259	active	_	
114-47	22260-22271	antisaccade	_	
114-48	22272-22283	performance	_	
114-49	22283-22284	.	_	

#Text=It suggests that high intrinsic activity in FEF and low activity in thalamus contribute to keeping saccade inhibition error rates low.
115-1	22285-22287	It	_	
115-2	22288-22296	suggests	_	
115-3	22297-22301	that	_	
115-4	22302-22306	high	_	
115-5	22307-22316	intrinsic	_	
115-6	22317-22325	activity	_	
115-7	22326-22328	in	_	
115-8	22329-22332	FEF	_	
115-9	22333-22336	and	_	
115-10	22337-22340	low	_	
115-11	22341-22349	activity	_	
115-12	22350-22352	in	_	
115-13	22353-22361	thalamus	_	
115-14	22362-22372	contribute	_	
115-15	22373-22375	to	_	
115-16	22376-22383	keeping	_	
115-17	22384-22391	saccade	_	
115-18	22392-22402	inhibition	_	
115-19	22403-22408	error	_	
115-20	22409-22414	rates	_	
115-21	22415-22418	low	_	
115-22	22418-22419	.	_	

#Text=These associations were not significant in patients.
116-1	22420-22425	These	_	
116-2	22426-22438	associations	_	
116-3	22439-22443	were	_	
116-4	22444-22447	not	_	
116-5	22448-22459	significant	_	
116-6	22460-22462	in	_	
116-7	22463-22471	patients	_	
116-8	22471-22472	.	_	

#Text=Instead, error rates were associated with several measures of functional connectivity, including connectivity from FEF to nodes in the default mode network comprising inferior parietal gyrus, the angular gyrus, precuneus and middle temporal gyrus.
117-1	22473-22480	Instead	_	
117-2	22480-22481	,	_	
117-3	22482-22487	error	_	
117-4	22488-22493	rates	_	
117-5	22494-22498	were	_	
117-6	22499-22509	associated	_	
117-7	22510-22514	with	_	
117-8	22515-22522	several	_	
117-9	22523-22531	measures	_	
117-10	22532-22534	of	_	
117-11	22535-22545	functional	_	
117-12	22546-22558	connectivity	_	
117-13	22558-22559	,	_	
117-14	22560-22569	including	_	
117-15	22570-22582	connectivity	_	
117-16	22583-22587	from	_	
117-17	22588-22591	FEF	_	
117-18	22592-22594	to	_	
117-19	22595-22600	nodes	_	
117-20	22601-22603	in	_	
117-21	22604-22607	the	_	
117-22	22608-22615	default	_	
117-23	22616-22620	mode	_	
117-24	22621-22628	network	_	
117-25	22629-22639	comprising	_	
117-26	22640-22648	inferior	_	
117-27	22649-22657	parietal	_	
117-28	22658-22663	gyrus	_	
117-29	22663-22664	,	_	
117-30	22665-22668	the	_	
117-31	22669-22676	angular	_	
117-32	22677-22682	gyrus	_	
117-33	22682-22683	,	_	
117-34	22684-22693	precuneus	_	
117-35	22694-22697	and	_	
117-36	22698-22704	middle	_	
117-37	22705-22713	temporal	_	
117-38	22714-22719	gyrus	_	
117-39	22719-22720	.	_	

#Text=Other inhibition error related connectivity alterations in patients involved connections between thalamus and both SEF and parahippocampus, as well as the fronto-parietal connections including the DLPFC as part of the middle frontal gyrus (MFG).
118-1	22721-22726	Other	_	
118-2	22727-22737	inhibition	_	
118-3	22738-22743	error	_	
118-4	22744-22751	related	_	
118-5	22752-22764	connectivity	_	
118-6	22765-22776	alterations	_	
118-7	22777-22779	in	_	
118-8	22780-22788	patients	_	
118-9	22789-22797	involved	_	
118-10	22798-22809	connections	_	
118-11	22810-22817	between	_	
118-12	22818-22826	thalamus	_	
118-13	22827-22830	and	_	
118-14	22831-22835	both	_	
118-15	22836-22839	SEF	_	
118-16	22840-22843	and	_	
118-17	22844-22859	parahippocampus	_	
118-18	22859-22860	,	_	
118-19	22861-22863	as	_	
118-20	22864-22868	well	_	
118-21	22869-22871	as	_	
118-22	22872-22875	the	_	
118-23	22876-22891	fronto-parietal	_	
118-24	22892-22903	connections	_	
118-25	22904-22913	including	_	
118-26	22914-22917	the	_	
118-27	22918-22923	DLPFC	_	
118-28	22924-22926	as	_	
118-29	22927-22931	part	_	
118-30	22932-22934	of	_	
118-31	22935-22938	the	_	
118-32	22939-22945	middle	_	
118-33	22946-22953	frontal	_	
118-34	22954-22959	gyrus	_	
118-35	22960-22961	(	_	
118-36	22961-22964	MFG	_	
118-37	22964-22965	)	_	
118-38	22965-22966	.	_	

#Text=To understand the relation between altered functional connectivity within these brain systems and disturbances of inhibitory reflexive control, it is important to consider the specific oculomotor functions of the relevant brain regions.
119-1	22967-22969	To	_	
119-2	22970-22980	understand	_	
119-3	22981-22984	the	_	
119-4	22985-22993	relation	_	
119-5	22994-23001	between	_	
119-6	23002-23009	altered	_	
119-7	23010-23020	functional	_	
119-8	23021-23033	connectivity	_	
119-9	23034-23040	within	_	
119-10	23041-23046	these	_	
119-11	23047-23052	brain	_	
119-12	23053-23060	systems	_	
119-13	23061-23064	and	_	
119-14	23065-23077	disturbances	_	
119-15	23078-23080	of	_	
119-16	23081-23091	inhibitory	_	
119-17	23092-23101	reflexive	_	
119-18	23102-23109	control	_	
119-19	23109-23110	,	_	
119-20	23111-23113	it	_	
119-21	23114-23116	is	_	
119-22	23117-23126	important	_	
119-23	23127-23129	to	_	
119-24	23130-23138	consider	_	
119-25	23139-23142	the	_	
119-26	23143-23151	specific	_	
119-27	23152-23162	oculomotor	_	
119-28	23163-23172	functions	_	
119-29	23173-23175	of	_	
119-30	23176-23179	the	_	
119-31	23180-23188	relevant	_	
119-32	23189-23194	brain	_	
119-33	23195-23202	regions	_	
119-34	23202-23203	.	_	

#Text=Connectivity alterations between regions of specific oculomotor function
#Text=The FEF represents the core cortical hub related to saccade generation.
120-1	23204-23216	Connectivity	_	
120-2	23217-23228	alterations	_	
120-3	23229-23236	between	_	
120-4	23237-23244	regions	_	
120-5	23245-23247	of	_	
120-6	23248-23256	specific	_	
120-7	23257-23267	oculomotor	_	
120-8	23268-23276	function	_	
120-9	23277-23280	The	_	
120-10	23281-23284	FEF	_	
120-11	23285-23295	represents	_	
120-12	23296-23299	the	_	
120-13	23300-23304	core	_	
120-14	23305-23313	cortical	_	
120-15	23314-23317	hub	_	
120-16	23318-23325	related	_	
120-17	23326-23328	to	_	
120-18	23329-23336	saccade	_	
120-19	23337-23347	generation	_	
120-20	23347-23348	.	_	

#Text=It has connections throughout the brain where cortical saccade planning and generation of oculomotor commands are coded.
121-1	23349-23351	It	_	
121-2	23352-23355	has	_	
121-3	23356-23367	connections	_	
121-4	23368-23378	throughout	_	
121-5	23379-23382	the	_	
121-6	23383-23388	brain	_	
121-7	23389-23394	where	_	
121-8	23395-23403	cortical	_	
121-9	23404-23411	saccade	_	
121-10	23412-23420	planning	_	
121-11	23421-23424	and	_	
121-12	23425-23435	generation	_	
121-13	23436-23438	of	_	
121-14	23439-23449	oculomotor	_	
121-15	23450-23458	commands	_	
121-16	23459-23462	are	_	
121-17	23463-23468	coded	_	
121-18	23468-23469	.	_	

#Text=Functional FEF alterations have previously been suggested in psychotic disorders by eye movement laboratory studies and task-based saccade fMRI studies.
122-1	23470-23480	Functional	_	
122-2	23481-23484	FEF	_	
122-3	23485-23496	alterations	_	
122-4	23497-23501	have	_	
122-5	23502-23512	previously	_	
122-6	23513-23517	been	_	
122-7	23518-23527	suggested	_	
122-8	23528-23530	in	_	
122-9	23531-23540	psychotic	_	
122-10	23541-23550	disorders	_	
122-11	23551-23553	by	_	
122-12	23554-23557	eye	_	
122-13	23558-23566	movement	_	
122-14	23567-23577	laboratory	_	
122-15	23578-23585	studies	_	
122-16	23586-23589	and	_	
122-17	23590-23600	task-based	_	
122-18	23601-23608	saccade	_	
122-19	23609-23613	fMRI	_	
122-20	23614-23621	studies	_	
122-21	23621-23622	.	_	

#Text=Second, the SEF is known to be important in higher order saccade control such as in visuomotor sequence learning and prediction.
123-1	23623-23629	Second	_	
123-2	23629-23630	,	_	
123-3	23631-23634	the	_	
123-4	23635-23638	SEF	_	
123-5	23639-23641	is	_	
123-6	23642-23647	known	_	
123-7	23648-23650	to	_	
123-8	23651-23653	be	_	
123-9	23654-23663	important	_	
123-10	23664-23666	in	_	
123-11	23667-23673	higher	_	
123-12	23674-23679	order	_	
123-13	23680-23687	saccade	_	
123-14	23688-23695	control	_	
123-15	23696-23700	such	_	
123-16	23701-23703	as	_	
123-17	23704-23706	in	_	
123-18	23707-23717	visuomotor	_	
123-19	23718-23726	sequence	_	
123-20	23727-23735	learning	_	
123-21	23736-23739	and	_	
123-22	23740-23750	prediction	_	
123-23	23750-23751	.	_	

#Text=Third, the thalamus is known to play important roles in cortical connectivity generally, and fronto-striatal systems in particular, and to be involved in visual information processing.
124-1	23752-23757	Third	_	
124-2	23757-23758	,	_	
124-3	23759-23762	the	_	
124-4	23763-23771	thalamus	_	
124-5	23772-23774	is	_	
124-6	23775-23780	known	_	
124-7	23781-23783	to	_	
124-8	23784-23788	play	_	
124-9	23789-23798	important	_	
124-10	23799-23804	roles	_	
124-11	23805-23807	in	_	
124-12	23808-23816	cortical	_	
124-13	23817-23829	connectivity	_	
124-14	23830-23839	generally	_	
124-15	23839-23840	,	_	
124-16	23841-23844	and	_	
124-17	23845-23860	fronto-striatal	_	
124-18	23861-23868	systems	_	
124-19	23869-23871	in	_	
124-20	23872-23882	particular	_	
124-21	23882-23883	,	_	
124-22	23884-23887	and	_	
124-23	23888-23890	to	_	
124-24	23891-23893	be	_	
124-25	23894-23902	involved	_	
124-26	23903-23905	in	_	
124-27	23906-23912	visual	_	
124-28	23913-23924	information	_	
124-29	23925-23935	processing	_	
124-30	23935-23936	.	_	

#Text=Together, the FEF, the SEF and the thalamus represent core areas of the oculomotor cortico-striato-thalamo-cortical loop that is integrated with wider networks including the PPC, precuneus, cuneus and angular gyrus, all of which are important for the spatial inversion of the visual target to its mirror position required for antisaccade generation.
125-1	23937-23945	Together	_	
125-2	23945-23946	,	_	
125-3	23947-23950	the	_	
125-4	23951-23954	FEF	_	
125-5	23954-23955	,	_	
125-6	23956-23959	the	_	
125-7	23960-23963	SEF	_	
125-8	23964-23967	and	_	
125-9	23968-23971	the	_	
125-10	23972-23980	thalamus	_	
125-11	23981-23990	represent	_	
125-12	23991-23995	core	_	
125-13	23996-24001	areas	_	
125-14	24002-24004	of	_	
125-15	24005-24008	the	_	
125-16	24009-24019	oculomotor	_	
125-17	24020-24052	cortico-striato-thalamo-cortical	_	
125-18	24053-24057	loop	_	
125-19	24058-24062	that	_	
125-20	24063-24065	is	_	
125-21	24066-24076	integrated	_	
125-22	24077-24081	with	_	
125-23	24082-24087	wider	_	
125-24	24088-24096	networks	_	
125-25	24097-24106	including	_	
125-26	24107-24110	the	_	
125-27	24111-24114	PPC	_	
125-28	24114-24115	,	_	
125-29	24116-24125	precuneus	_	
125-30	24125-24126	,	_	
125-31	24127-24133	cuneus	_	
125-32	24134-24137	and	_	
125-33	24138-24145	angular	_	
125-34	24146-24151	gyrus	_	
125-35	24151-24152	,	_	
125-36	24153-24156	all	_	
125-37	24157-24159	of	_	
125-38	24160-24165	which	_	
125-39	24166-24169	are	_	
125-40	24170-24179	important	_	
125-41	24180-24183	for	_	
125-42	24184-24187	the	_	
125-43	24188-24195	spatial	_	
125-44	24196-24205	inversion	_	
125-45	24206-24208	of	_	
125-46	24209-24212	the	_	
125-47	24213-24219	visual	_	
125-48	24220-24226	target	_	
125-49	24227-24229	to	_	
125-50	24230-24233	its	_	
125-51	24234-24240	mirror	_	
125-52	24241-24249	position	_	
125-53	24250-24258	required	_	
125-54	24259-24262	for	_	
125-55	24263-24274	antisaccade	_	
125-56	24275-24285	generation	_	
125-57	24285-24286	.	_	

#Text=The DLPFC has been frequently implicated in antisaccade execution although its specific role is still not fully understood.
126-1	24287-24290	The	_	
126-2	24291-24296	DLPFC	_	
126-3	24297-24300	has	_	
126-4	24301-24305	been	_	
126-5	24306-24316	frequently	_	
126-6	24317-24327	implicated	_	
126-7	24328-24330	in	_	
126-8	24331-24342	antisaccade	_	
126-9	24343-24352	execution	_	
126-10	24353-24361	although	_	
126-11	24362-24365	its	_	
126-12	24366-24374	specific	_	
126-13	24375-24379	role	_	
126-14	24380-24382	is	_	
126-15	24383-24388	still	_	
126-16	24389-24392	not	_	
126-17	24393-24398	fully	_	
126-18	24399-24409	understood	_	
126-19	24409-24410	.	_	

#Text=It shows strong functional connectivity within the fronto-parietal network in resting state studies projecting directly and indirectly to SC to mediate top-down resting and excitatory control over SC neurons.
127-1	24411-24413	It	_	
127-2	24414-24419	shows	_	
127-3	24420-24426	strong	_	
127-4	24427-24437	functional	_	
127-5	24438-24450	connectivity	_	
127-6	24451-24457	within	_	
127-7	24458-24461	the	_	
127-8	24462-24477	fronto-parietal	_	
127-9	24478-24485	network	_	
127-10	24486-24488	in	_	
127-11	24489-24496	resting	_	
127-12	24497-24502	state	_	
127-13	24503-24510	studies	_	
127-14	24511-24521	projecting	_	
127-15	24522-24530	directly	_	
127-16	24531-24534	and	_	
127-17	24535-24545	indirectly	_	
127-18	24546-24548	to	_	
127-19	24549-24551	SC	_	
127-20	24552-24554	to	_	
127-21	24555-24562	mediate	_	
127-22	24563-24571	top-down	_	
127-23	24572-24579	resting	_	
127-24	24580-24583	and	_	
127-25	24584-24594	excitatory	_	
127-26	24595-24602	control	_	
127-27	24603-24607	over	_	
127-28	24608-24610	SC	_	
127-29	24611-24618	neurons	_	
127-30	24618-24619	.	_	

#Text=Others have shown that components of the default mode network including the middle temporal gyrus and the inferior parietal cortex, as well as the parahippocampus, are also involved in active antisaccade generation.
128-1	24620-24626	Others	_	
128-2	24627-24631	have	_	
128-3	24632-24637	shown	_	
128-4	24638-24642	that	_	
128-5	24643-24653	components	_	
128-6	24654-24656	of	_	
128-7	24657-24660	the	_	
128-8	24661-24668	default	_	
128-9	24669-24673	mode	_	
128-10	24674-24681	network	_	
128-11	24682-24691	including	_	
128-12	24692-24695	the	_	
128-13	24696-24702	middle	_	
128-14	24703-24711	temporal	_	
128-15	24712-24717	gyrus	_	
128-16	24718-24721	and	_	
128-17	24722-24725	the	_	
128-18	24726-24734	inferior	_	
128-19	24735-24743	parietal	_	
128-20	24744-24750	cortex	_	
128-21	24750-24751	,	_	
128-22	24752-24754	as	_	
128-23	24755-24759	well	_	
128-24	24760-24762	as	_	
128-25	24763-24766	the	_	
128-26	24767-24782	parahippocampus	_	
128-27	24782-24783	,	_	
128-28	24784-24787	are	_	
128-29	24788-24792	also	_	
128-30	24793-24801	involved	_	
128-31	24802-24804	in	_	
128-32	24805-24811	active	_	
128-33	24812-24823	antisaccade	_	
128-34	24824-24834	generation	_	
128-35	24834-24835	.	_	

#Text=Alterations in FEF connectivity related to inhibition error rate
#Text=Our findings of weaker intrinsic connectivity strength from FEF to inferior parietal gyrus, precuneus and middle temporal gyrus predicting higher rates of antisaccade errors in patients suggest that increased inhibition errors are at least partly driven by alterations in intrinsic brain systems supporting visuospatial attention and their relation to sensorimotor transformation and volitional behavioral control.
129-1	24836-24847	Alterations	_	
129-2	24848-24850	in	_	
129-3	24851-24854	FEF	_	
129-4	24855-24867	connectivity	_	
129-5	24868-24875	related	_	
129-6	24876-24878	to	_	
129-7	24879-24889	inhibition	_	
129-8	24890-24895	error	_	
129-9	24896-24900	rate	_	
129-10	24901-24904	Our	_	
129-11	24905-24913	findings	_	
129-12	24914-24916	of	_	
129-13	24917-24923	weaker	_	
129-14	24924-24933	intrinsic	_	
129-15	24934-24946	connectivity	_	
129-16	24947-24955	strength	_	
129-17	24956-24960	from	_	
129-18	24961-24964	FEF	_	
129-19	24965-24967	to	_	
129-20	24968-24976	inferior	_	
129-21	24977-24985	parietal	_	
129-22	24986-24991	gyrus	_	
129-23	24991-24992	,	_	
129-24	24993-25002	precuneus	_	
129-25	25003-25006	and	_	
129-26	25007-25013	middle	_	
129-27	25014-25022	temporal	_	
129-28	25023-25028	gyrus	_	
129-29	25029-25039	predicting	_	
129-30	25040-25046	higher	_	
129-31	25047-25052	rates	_	
129-32	25053-25055	of	_	
129-33	25056-25067	antisaccade	_	
129-34	25068-25074	errors	_	
129-35	25075-25077	in	_	
129-36	25078-25086	patients	_	
129-37	25087-25094	suggest	_	
129-38	25095-25099	that	_	
129-39	25100-25109	increased	_	
129-40	25110-25120	inhibition	_	
129-41	25121-25127	errors	_	
129-42	25128-25131	are	_	
129-43	25132-25134	at	_	
129-44	25135-25140	least	_	
129-45	25141-25147	partly	_	
129-46	25148-25154	driven	_	
129-47	25155-25157	by	_	
129-48	25158-25169	alterations	_	
129-49	25170-25172	in	_	
129-50	25173-25182	intrinsic	_	
129-51	25183-25188	brain	_	
129-52	25189-25196	systems	_	
129-53	25197-25207	supporting	_	
129-54	25208-25220	visuospatial	_	
129-55	25221-25230	attention	_	
129-56	25231-25234	and	_	
129-57	25235-25240	their	_	
129-58	25241-25249	relation	_	
129-59	25250-25252	to	_	
129-60	25253-25265	sensorimotor	_	
129-61	25266-25280	transformation	_	
129-62	25281-25284	and	_	
129-63	25285-25295	volitional	_	
129-64	25296-25306	behavioral	_	
129-65	25307-25314	control	_	
129-66	25314-25315	.	_	

#Text=Notably, higher functional connectivity between FEF and angular gyrus predicted higher inhibition errors in patients, implying a higher tone of sensorimotor integration that might reduce the ability to suppress saccade responses to visual target presentation.
130-1	25316-25323	Notably	_	
130-2	25323-25324	,	_	
130-3	25325-25331	higher	_	
130-4	25332-25342	functional	_	
130-5	25343-25355	connectivity	_	
130-6	25356-25363	between	_	
130-7	25364-25367	FEF	_	
130-8	25368-25371	and	_	
130-9	25372-25379	angular	_	
130-10	25380-25385	gyrus	_	
130-11	25386-25395	predicted	_	
130-12	25396-25402	higher	_	
130-13	25403-25413	inhibition	_	
130-14	25414-25420	errors	_	
130-15	25421-25423	in	_	
130-16	25424-25432	patients	_	
130-17	25432-25433	,	_	
130-18	25434-25442	implying	_	
130-19	25443-25444	a	_	
130-20	25445-25451	higher	_	
130-21	25452-25456	tone	_	
130-22	25457-25459	of	_	
130-23	25460-25472	sensorimotor	_	
130-24	25473-25484	integration	_	
130-25	25485-25489	that	_	
130-26	25490-25495	might	_	
130-27	25496-25502	reduce	_	
130-28	25503-25506	the	_	
130-29	25507-25514	ability	_	
130-30	25515-25517	to	_	
130-31	25518-25526	suppress	_	
130-32	25527-25534	saccade	_	
130-33	25535-25544	responses	_	
130-34	25545-25547	to	_	
130-35	25548-25554	visual	_	
130-36	25555-25561	target	_	
130-37	25562-25574	presentation	_	
130-38	25574-25575	.	_	

#Text=Angular gyrus dysfunction has been shown to result in laterality discrimination difficulties that may impact generation of an antisaccade to the mirror position.
131-1	25576-25583	Angular	_	
131-2	25584-25589	gyrus	_	
131-3	25590-25601	dysfunction	_	
131-4	25602-25605	has	_	
131-5	25606-25610	been	_	
131-6	25611-25616	shown	_	
131-7	25617-25619	to	_	
131-8	25620-25626	result	_	
131-9	25627-25629	in	_	
131-10	25630-25640	laterality	_	
131-11	25641-25655	discrimination	_	
131-12	25656-25668	difficulties	_	
131-13	25669-25673	that	_	
131-14	25674-25677	may	_	
131-15	25678-25684	impact	_	
131-16	25685-25695	generation	_	
131-17	25696-25698	of	_	
131-18	25699-25701	an	_	
131-19	25702-25713	antisaccade	_	
131-20	25714-25716	to	_	
131-21	25717-25720	the	_	
131-22	25721-25727	mirror	_	
131-23	25728-25736	position	_	
131-24	25736-25737	.	_	

#Text=Alterations in thalamus connectivity related to inhibition error rate
#Text=We also observed stronger connectivity between thalamus and SEF, and weaker connectivity between thalamus and DLPFC in MFG at rest that predicted higher error rates in patients, Figure 1.
132-1	25738-25749	Alterations	_	
132-2	25750-25752	in	_	
132-3	25753-25761	thalamus	_	
132-4	25762-25774	connectivity	_	
132-5	25775-25782	related	_	
132-6	25783-25785	to	_	
132-7	25786-25796	inhibition	_	
132-8	25797-25802	error	_	
132-9	25803-25807	rate	_	
132-10	25808-25810	We	_	
132-11	25811-25815	also	_	
132-12	25816-25824	observed	_	
132-13	25825-25833	stronger	_	
132-14	25834-25846	connectivity	_	
132-15	25847-25854	between	_	
132-16	25855-25863	thalamus	_	
132-17	25864-25867	and	_	
132-18	25868-25871	SEF	_	
132-19	25871-25872	,	_	
132-20	25873-25876	and	_	
132-21	25877-25883	weaker	_	
132-22	25884-25896	connectivity	_	
132-23	25897-25904	between	_	
132-24	25905-25913	thalamus	_	
132-25	25914-25917	and	_	
132-26	25918-25923	DLPFC	_	
132-27	25924-25926	in	_	
132-28	25927-25930	MFG	_	
132-29	25931-25933	at	_	
132-30	25934-25938	rest	_	
132-31	25939-25943	that	_	
132-32	25944-25953	predicted	_	
132-33	25954-25960	higher	_	
132-34	25961-25966	error	_	
132-35	25967-25972	rates	_	
132-36	25973-25975	in	_	
132-37	25976-25984	patients	_	
132-38	25984-25985	,	_	
132-39	25986-25992	Figure	_	
132-40	25993-25994	1	_	
132-41	25994-25995	.	_	

#Text=This finding reflects an imbalance in the higher order control of sensorimotor systems, with more input from premotor cortex and less from prefrontal cortex.
133-1	25996-26000	This	_	
133-2	26001-26008	finding	_	
133-3	26009-26017	reflects	_	
133-4	26018-26020	an	_	
133-5	26021-26030	imbalance	_	
133-6	26031-26033	in	_	
133-7	26034-26037	the	_	
133-8	26038-26044	higher	_	
133-9	26045-26050	order	_	
133-10	26051-26058	control	_	
133-11	26059-26061	of	_	
133-12	26062-26074	sensorimotor	_	
133-13	26075-26082	systems	_	
133-14	26082-26083	,	_	
133-15	26084-26088	with	_	
133-16	26089-26093	more	_	
133-17	26094-26099	input	_	
133-18	26100-26104	from	_	
133-19	26105-26113	premotor	_	
133-20	26114-26120	cortex	_	
133-21	26121-26124	and	_	
133-22	26125-26129	less	_	
133-23	26130-26134	from	_	
133-24	26135-26145	prefrontal	_	
133-25	26146-26152	cortex	_	
133-26	26152-26153	.	_	

#Text=It is in line with a very recent study using rs-MRI showing a pattern of increased connectivity between sensorimotor cortex, i.e.
134-1	26154-26156	It	_	
134-2	26157-26159	is	_	
134-3	26160-26162	in	_	
134-4	26163-26167	line	_	
134-5	26168-26172	with	_	
134-6	26173-26174	a	_	
134-7	26175-26179	very	_	
134-8	26180-26186	recent	_	
134-9	26187-26192	study	_	
134-10	26193-26198	using	_	
134-11	26199-26205	rs-MRI	_	
134-12	26206-26213	showing	_	
134-13	26214-26215	a	_	
134-14	26216-26223	pattern	_	
134-15	26224-26226	of	_	
134-16	26227-26236	increased	_	
134-17	26237-26249	connectivity	_	
134-18	26250-26257	between	_	
134-19	26258-26270	sensorimotor	_	
134-20	26271-26277	cortex	_	
134-21	26277-26278	,	_	
134-22	26279-26282	i.e	_	
134-23	26282-26283	.	_	

#Text=SEF, and thalamus on the one hand and decreased connectivity between thalamus and prefrontal areas being related to proactive response inhibition.
135-1	26284-26287	SEF	_	
135-2	26287-26288	,	_	
135-3	26289-26292	and	_	
135-4	26293-26301	thalamus	_	
135-5	26302-26304	on	_	
135-6	26305-26308	the	_	
135-7	26309-26312	one	_	
135-8	26313-26317	hand	_	
135-9	26318-26321	and	_	
135-10	26322-26331	decreased	_	
135-11	26332-26344	connectivity	_	
135-12	26345-26352	between	_	
135-13	26353-26361	thalamus	_	
135-14	26362-26365	and	_	
135-15	26366-26376	prefrontal	_	
135-16	26377-26382	areas	_	
135-17	26383-26388	being	_	
135-18	26389-26396	related	_	
135-19	26397-26399	to	_	
135-20	26400-26409	proactive	_	
135-21	26410-26418	response	_	
135-22	26419-26429	inhibition	_	
135-23	26429-26430	.	_	

#Text=Heightened thalamic interaction with SEF might also serve to increase resting tone in saccade generation systems, which would have the effect of reducing the ability to inhibit responses to sensory input.
136-1	26431-26441	Heightened	_	
136-2	26442-26450	thalamic	_	
136-3	26451-26462	interaction	_	
136-4	26463-26467	with	_	
136-5	26468-26471	SEF	_	
136-6	26472-26477	might	_	
136-7	26478-26482	also	_	
136-8	26483-26488	serve	_	
136-9	26489-26491	to	_	
136-10	26492-26500	increase	_	
136-11	26501-26508	resting	_	
136-12	26509-26513	tone	_	
136-13	26514-26516	in	_	
136-14	26517-26524	saccade	_	
136-15	26525-26535	generation	_	
136-16	26536-26543	systems	_	
136-17	26543-26544	,	_	
136-18	26545-26550	which	_	
136-19	26551-26556	would	_	
136-20	26557-26561	have	_	
136-21	26562-26565	the	_	
136-22	26566-26572	effect	_	
136-23	26573-26575	of	_	
136-24	26576-26584	reducing	_	
136-25	26585-26588	the	_	
136-26	26589-26596	ability	_	
136-27	26597-26599	to	_	
136-28	26600-26607	inhibit	_	
136-29	26608-26617	responses	_	
136-30	26618-26620	to	_	
136-31	26621-26628	sensory	_	
136-32	26629-26634	input	_	
136-33	26634-26635	.	_	

#Text=In the language of stop signal models, this could bias the system to respond to input which would reduce the ability of top down control to inhibit prosaccade responses, which might already be reduced by lowered DLPFC connectivity.
137-1	26636-26638	In	_	
137-2	26639-26642	the	_	
137-3	26643-26651	language	_	
137-4	26652-26654	of	_	
137-5	26655-26659	stop	_	
137-6	26660-26666	signal	_	
137-7	26667-26673	models	_	
137-8	26673-26674	,	_	
137-9	26675-26679	this	_	
137-10	26680-26685	could	_	
137-11	26686-26690	bias	_	
137-12	26691-26694	the	_	
137-13	26695-26701	system	_	
137-14	26702-26704	to	_	
137-15	26705-26712	respond	_	
137-16	26713-26715	to	_	
137-17	26716-26721	input	_	
137-18	26722-26727	which	_	
137-19	26728-26733	would	_	
137-20	26734-26740	reduce	_	
137-21	26741-26744	the	_	
137-22	26745-26752	ability	_	
137-23	26753-26755	of	_	
137-24	26756-26759	top	_	
137-25	26760-26764	down	_	
137-26	26765-26772	control	_	
137-27	26773-26775	to	_	
137-28	26776-26783	inhibit	_	
137-29	26784-26794	prosaccade	_	
137-30	26795-26804	responses	_	
137-31	26804-26805	,	_	
137-32	26806-26811	which	_	
137-33	26812-26817	might	_	
137-34	26818-26825	already	_	
137-35	26826-26828	be	_	
137-36	26829-26836	reduced	_	
137-37	26837-26839	by	_	
137-38	26840-26847	lowered	_	
137-39	26848-26853	DLPFC	_	
137-40	26854-26866	connectivity	_	
137-41	26866-26867	.	_	

#Text=Of note, the higher connectivity between SEF and thalamus was the only connection that correlated with higher symptom expression on PANSS scores indicating a possible association with illness severity, which itself has previously been linked to antisaccade performance.
138-1	26868-26870	Of	_	
138-2	26871-26875	note	_	
138-3	26875-26876	,	_	
138-4	26877-26880	the	_	
138-5	26881-26887	higher	_	
138-6	26888-26900	connectivity	_	
138-7	26901-26908	between	_	
138-8	26909-26912	SEF	_	
138-9	26913-26916	and	_	
138-10	26917-26925	thalamus	_	
138-11	26926-26929	was	_	
138-12	26930-26933	the	_	
138-13	26934-26938	only	_	
138-14	26939-26949	connection	_	
138-15	26950-26954	that	_	
138-16	26955-26965	correlated	_	
138-17	26966-26970	with	_	
138-18	26971-26977	higher	_	
138-19	26978-26985	symptom	_	
138-20	26986-26996	expression	_	
138-21	26997-26999	on	_	
138-22	27000-27005	PANSS	_	
138-23	27006-27012	scores	_	
138-24	27013-27023	indicating	_	
138-25	27024-27025	a	_	
138-26	27026-27034	possible	_	
138-27	27035-27046	association	_	
138-28	27047-27051	with	_	
138-29	27052-27059	illness	_	
138-30	27060-27068	severity	_	
138-31	27068-27069	,	_	
138-32	27070-27075	which	_	
138-33	27076-27082	itself	_	
138-34	27083-27086	has	_	
138-35	27087-27097	previously	_	
138-36	27098-27102	been	_	
138-37	27103-27109	linked	_	
138-38	27110-27112	to	_	
138-39	27113-27124	antisaccade	_	
138-40	27125-27136	performance	_	
138-41	27136-27137	.	_	

#Text=Intrinsic brain systems for processing speed of correct antisaccades
#Text=Processing speed in controls was influenced by connectivity from FEF and SEF to cognitively-relevant frontal regions including DLPFC in MFG and ACC, two regions highly implicated in antisaccade control and cognitive control generally.
139-1	27138-27147	Intrinsic	_	
139-2	27148-27153	brain	_	
139-3	27154-27161	systems	_	
139-4	27162-27165	for	_	
139-5	27166-27176	processing	_	
139-6	27177-27182	speed	_	
139-7	27183-27185	of	_	
139-8	27186-27193	correct	_	
139-9	27194-27206	antisaccades	_	
139-10	27207-27217	Processing	_	
139-11	27218-27223	speed	_	
139-12	27224-27226	in	_	
139-13	27227-27235	controls	_	
139-14	27236-27239	was	_	
139-15	27240-27250	influenced	_	
139-16	27251-27253	by	_	
139-17	27254-27266	connectivity	_	
139-18	27267-27271	from	_	
139-19	27272-27275	FEF	_	
139-20	27276-27279	and	_	
139-21	27280-27283	SEF	_	
139-22	27284-27286	to	_	
139-23	27287-27307	cognitively-relevant	_	
139-24	27308-27315	frontal	_	
139-25	27316-27323	regions	_	
139-26	27324-27333	including	_	
139-27	27334-27339	DLPFC	_	
139-28	27340-27342	in	_	
139-29	27343-27346	MFG	_	
139-30	27347-27350	and	_	
139-31	27351-27354	ACC	_	
139-32	27354-27355	,	_	
139-33	27356-27359	two	_	
139-34	27360-27367	regions	_	
139-35	27368-27374	highly	_	
139-36	27375-27385	implicated	_	
139-37	27386-27388	in	_	
139-38	27389-27400	antisaccade	_	
139-39	27401-27408	control	_	
139-40	27409-27412	and	_	
139-41	27413-27422	cognitive	_	
139-42	27423-27430	control	_	
139-43	27431-27440	generally	_	
139-44	27440-27441	.	_	

#Text=Stronger connectivity being related to longer processing time could reflect task specific involvement of the DLPFC for contextual processing and evaluation of error responses for performance optimization in ACC.
140-1	27442-27450	Stronger	_	
140-2	27451-27463	connectivity	_	
140-3	27464-27469	being	_	
140-4	27470-27477	related	_	
140-5	27478-27480	to	_	
140-6	27481-27487	longer	_	
140-7	27488-27498	processing	_	
140-8	27499-27503	time	_	
140-9	27504-27509	could	_	
140-10	27510-27517	reflect	_	
140-11	27518-27522	task	_	
140-12	27523-27531	specific	_	
140-13	27532-27543	involvement	_	
140-14	27544-27546	of	_	
140-15	27547-27550	the	_	
140-16	27551-27556	DLPFC	_	
140-17	27557-27560	for	_	
140-18	27561-27571	contextual	_	
140-19	27572-27582	processing	_	
140-20	27583-27586	and	_	
140-21	27587-27597	evaluation	_	
140-22	27598-27600	of	_	
140-23	27601-27606	error	_	
140-24	27607-27616	responses	_	
140-25	27617-27620	for	_	
140-26	27621-27632	performance	_	
140-27	27633-27645	optimization	_	
140-28	27646-27648	in	_	
140-29	27649-27652	ACC	_	
140-30	27652-27653	.	_	

#Text=On the other hand, faster processing speed was related to stronger connectivity from FEF and SEF to thalamus and the precuneus which mediate visuospatial attention and remapping required for antisaccade performance.
141-1	27654-27656	On	_	
141-2	27657-27660	the	_	
141-3	27661-27666	other	_	
141-4	27667-27671	hand	_	
141-5	27671-27672	,	_	
141-6	27673-27679	faster	_	
141-7	27680-27690	processing	_	
141-8	27691-27696	speed	_	
141-9	27697-27700	was	_	
141-10	27701-27708	related	_	
141-11	27709-27711	to	_	
141-12	27712-27720	stronger	_	
141-13	27721-27733	connectivity	_	
141-14	27734-27738	from	_	
141-15	27739-27742	FEF	_	
141-16	27743-27746	and	_	
141-17	27747-27750	SEF	_	
141-18	27751-27753	to	_	
141-19	27754-27762	thalamus	_	
141-20	27763-27766	and	_	
141-21	27767-27770	the	_	
141-22	27771-27780	precuneus	_	
141-23	27781-27786	which	_	
141-24	27787-27794	mediate	_	
141-25	27795-27807	visuospatial	_	
141-26	27808-27817	attention	_	
141-27	27818-27821	and	_	
141-28	27822-27831	remapping	_	
141-29	27832-27840	required	_	
141-30	27841-27844	for	_	
141-31	27845-27856	antisaccade	_	
141-32	27857-27868	performance	_	
141-33	27868-27869	.	_	

#Text=Limitations
#Text=First, combining patients with psychotic disorders as implemented in the B-SNIP study was planned based on previous laboratory antisaccade studies and resting state studies across disorders to increase the power of analyses.
142-1	27870-27881	Limitations	_	
142-2	27882-27887	First	_	
142-3	27887-27888	,	_	
142-4	27889-27898	combining	_	
142-5	27899-27907	patients	_	
142-6	27908-27912	with	_	
142-7	27913-27922	psychotic	_	
142-8	27923-27932	disorders	_	
142-9	27933-27935	as	_	
142-10	27936-27947	implemented	_	
142-11	27948-27950	in	_	
142-12	27951-27954	the	_	
142-13	27955-27961	B-SNIP	_	
142-14	27962-27967	study	_	
142-15	27968-27971	was	_	
142-16	27972-27979	planned	_	
142-17	27980-27985	based	_	
142-18	27986-27988	on	_	
142-19	27989-27997	previous	_	
142-20	27998-28008	laboratory	_	
142-21	28009-28020	antisaccade	_	
142-22	28021-28028	studies	_	
142-23	28029-28032	and	_	
142-24	28033-28040	resting	_	
142-25	28041-28046	state	_	
142-26	28047-28054	studies	_	
142-27	28055-28061	across	_	
142-28	28062-28071	disorders	_	
142-29	28072-28074	to	_	
142-30	28075-28083	increase	_	
142-31	28084-28087	the	_	
142-32	28088-28093	power	_	
142-33	28094-28096	of	_	
142-34	28097-28105	analyses	_	
142-35	28105-28106	.	_	

#Text=In the present sample, there was no difference between groups regarding antisaccade error rates supporting the hypothesis that increased error rates represent a more general biomarker across psychotic disorders.
143-1	28107-28109	In	_	
143-2	28110-28113	the	_	
143-3	28114-28121	present	_	
143-4	28122-28128	sample	_	
143-5	28128-28129	,	_	
143-6	28130-28135	there	_	
143-7	28136-28139	was	_	
143-8	28140-28142	no	_	
143-9	28143-28153	difference	_	
143-10	28154-28161	between	_	
143-11	28162-28168	groups	_	
143-12	28169-28178	regarding	_	
143-13	28179-28190	antisaccade	_	
143-14	28191-28196	error	_	
143-15	28197-28202	rates	_	
143-16	28203-28213	supporting	_	
143-17	28214-28217	the	_	
143-18	28218-28228	hypothesis	_	
143-19	28229-28233	that	_	
143-20	28234-28243	increased	_	
143-21	28244-28249	error	_	
143-22	28250-28255	rates	_	
143-23	28256-28265	represent	_	
143-24	28266-28267	a	_	
143-25	28268-28272	more	_	
143-26	28273-28280	general	_	
143-27	28281-28290	biomarker	_	
143-28	28291-28297	across	_	
143-29	28298-28307	psychotic	_	
143-30	28308-28317	disorders	_	
143-31	28317-28318	.	_	

#Text=However, future studies with larger samples are needed to reveal specific differences of alterations in fronto-thalamo-parietal networks associated with antisaccade error rate between psychotic disorders.
144-1	28319-28326	However	_	
144-2	28326-28327	,	_	
144-3	28328-28334	future	_	
144-4	28335-28342	studies	_	
144-5	28343-28347	with	_	
144-6	28348-28354	larger	_	
144-7	28355-28362	samples	_	
144-8	28363-28366	are	_	
144-9	28367-28373	needed	_	
144-10	28374-28376	to	_	
144-11	28377-28383	reveal	_	
144-12	28384-28392	specific	_	
144-13	28393-28404	differences	_	
144-14	28405-28407	of	_	
144-15	28408-28419	alterations	_	
144-16	28420-28422	in	_	
144-17	28423-28446	fronto-thalamo-parietal	_	
144-18	28447-28455	networks	_	
144-19	28456-28466	associated	_	
144-20	28467-28471	with	_	
144-21	28472-28483	antisaccade	_	
144-22	28484-28489	error	_	
144-23	28490-28494	rate	_	
144-24	28495-28502	between	_	
144-25	28503-28512	psychotic	_	
144-26	28513-28522	disorders	_	
144-27	28522-28523	.	_	

#Text=Second, we found a relative independence of intrinsic brain activity from current medications and symptom expression.
145-1	28524-28530	Second	_	
145-2	28530-28531	,	_	
145-3	28532-28534	we	_	
145-4	28535-28540	found	_	
145-5	28541-28542	a	_	
145-6	28543-28551	relative	_	
145-7	28552-28564	independence	_	
145-8	28565-28567	of	_	
145-9	28568-28577	intrinsic	_	
145-10	28578-28583	brain	_	
145-11	28584-28592	activity	_	
145-12	28593-28597	from	_	
145-13	28598-28605	current	_	
145-14	28606-28617	medications	_	
145-15	28618-28621	and	_	
145-16	28622-28629	symptom	_	
145-17	28630-28640	expression	_	
145-18	28640-28641	.	_	

#Text=This may in part be due to the fact that by design, our patients were relatively clinically stable and on stable pharmacological treatment.
146-1	28642-28646	This	_	
146-2	28647-28650	may	_	
146-3	28651-28653	in	_	
146-4	28654-28658	part	_	
146-5	28659-28661	be	_	
146-6	28662-28665	due	_	
146-7	28666-28668	to	_	
146-8	28669-28672	the	_	
146-9	28673-28677	fact	_	
146-10	28678-28682	that	_	
146-11	28683-28685	by	_	
146-12	28686-28692	design	_	
146-13	28692-28693	,	_	
146-14	28694-28697	our	_	
146-15	28698-28706	patients	_	
146-16	28707-28711	were	_	
146-17	28712-28722	relatively	_	
146-18	28723-28733	clinically	_	
146-19	28734-28740	stable	_	
146-20	28741-28744	and	_	
146-21	28745-28747	on	_	
146-22	28748-28754	stable	_	
146-23	28755-28770	pharmacological	_	
146-24	28771-28780	treatment	_	
146-25	28780-28781	.	_	

#Text=Third, to control for possible confounds by head motion participants with head translation >1.5mm and rotation >1.5° during fMRI scanning were excluded and head motion parameters were additionally used as covariates.
147-1	28782-28787	Third	_	
147-2	28787-28788	,	_	
147-3	28789-28791	to	_	
147-4	28792-28799	control	_	
147-5	28800-28803	for	_	
147-6	28804-28812	possible	_	
147-7	28813-28822	confounds	_	
147-8	28823-28825	by	_	
147-9	28826-28830	head	_	
147-10	28831-28837	motion	_	
147-11	28838-28850	participants	_	
147-12	28851-28855	with	_	
147-13	28856-28860	head	_	
147-14	28861-28872	translation	_	
147-15	28873-28874	>	_	
147-16	28874-28879	1.5mm	_	
147-17	28880-28883	and	_	
147-18	28884-28892	rotation	_	
147-19	28893-28894	>	_	
147-20	28894-28897	1.5	_	
147-21	28897-28898	°	_	
147-22	28899-28905	during	_	
147-23	28906-28910	fMRI	_	
147-24	28911-28919	scanning	_	
147-25	28920-28924	were	_	
147-26	28925-28933	excluded	_	
147-27	28934-28937	and	_	
147-28	28938-28942	head	_	
147-29	28943-28949	motion	_	
147-30	28950-28960	parameters	_	
147-31	28961-28965	were	_	
147-32	28966-28978	additionally	_	
147-33	28979-28983	used	_	
147-34	28984-28986	as	_	
147-35	28987-28997	covariates	_	
147-36	28997-28998	.	_	

#Text=However, possible effects of this confound cannot be fully excluded.
148-1	28999-29006	However	_	
148-2	29006-29007	,	_	
148-3	29008-29016	possible	_	
148-4	29017-29024	effects	_	
148-5	29025-29027	of	_	
148-6	29028-29032	this	_	
148-7	29033-29041	confound	_	
148-8	29042-29048	cannot	_	
148-9	29049-29051	be	_	
148-10	29052-29057	fully	_	
148-11	29058-29066	excluded	_	
148-12	29066-29067	.	_	

#Text=The findings from this study support a linkage between a well-established biomarker for psychotic disorders and alterations in intrinsic brain systems subserving this behavior.
149-1	29068-29071	The	_	
149-2	29072-29080	findings	_	
149-3	29081-29085	from	_	
149-4	29086-29090	this	_	
149-5	29091-29096	study	_	
149-6	29097-29104	support	_	
149-7	29105-29106	a	_	
149-8	29107-29114	linkage	_	
149-9	29115-29122	between	_	
149-10	29123-29124	a	_	
149-11	29125-29141	well-established	_	
149-12	29142-29151	biomarker	_	
149-13	29152-29155	for	_	
149-14	29156-29165	psychotic	_	
149-15	29166-29175	disorders	_	
149-16	29176-29179	and	_	
149-17	29180-29191	alterations	_	
149-18	29192-29194	in	_	
149-19	29195-29204	intrinsic	_	
149-20	29205-29210	brain	_	
149-21	29211-29218	systems	_	
149-22	29219-29229	subserving	_	
149-23	29230-29234	this	_	
149-24	29235-29243	behavior	_	
149-25	29243-29244	.	_	

#Text=Our findings provide novel evidence that disturbances in these brain systems at rest contribute to impaired antisaccade task performance.
150-1	29245-29248	Our	_	
150-2	29249-29257	findings	_	
150-3	29258-29265	provide	_	
150-4	29266-29271	novel	_	
150-5	29272-29280	evidence	_	
150-6	29281-29285	that	_	
150-7	29286-29298	disturbances	_	
150-8	29299-29301	in	_	
150-9	29302-29307	these	_	
150-10	29308-29313	brain	_	
150-11	29314-29321	systems	_	
150-12	29322-29324	at	_	
150-13	29325-29329	rest	_	
150-14	29330-29340	contribute	_	
150-15	29341-29343	to	_	
150-16	29344-29352	impaired	_	
150-17	29353-29364	antisaccade	_	
150-18	29365-29369	task	_	
150-19	29370-29381	performance	_	
150-20	29381-29382	.	_	

#Text=Future studies are needed to unravel how alterations in resting state activity contribute to other cognitive control deficits in psychotic disorders, and whether there are informative genetic associations with these alterations.
151-1	29383-29389	Future	_	
151-2	29390-29397	studies	_	
151-3	29398-29401	are	_	
151-4	29402-29408	needed	_	
151-5	29409-29411	to	_	
151-6	29412-29419	unravel	_	
151-7	29420-29423	how	_	
151-8	29424-29435	alterations	_	
151-9	29436-29438	in	_	
151-10	29439-29446	resting	_	
151-11	29447-29452	state	_	
151-12	29453-29461	activity	_	
151-13	29462-29472	contribute	_	
151-14	29473-29475	to	_	
151-15	29476-29481	other	_	
151-16	29482-29491	cognitive	_	
151-17	29492-29499	control	_	
151-18	29500-29508	deficits	_	
151-19	29509-29511	in	_	
151-20	29512-29521	psychotic	_	
151-21	29522-29531	disorders	_	
151-22	29531-29532	,	_	
151-23	29533-29536	and	_	
151-24	29537-29544	whether	_	
151-25	29545-29550	there	_	
151-26	29551-29554	are	_	
151-27	29555-29566	informative	_	
151-28	29567-29574	genetic	_	
151-29	29575-29587	associations	_	
151-30	29588-29592	with	_	
151-31	29593-29598	these	_	
151-32	29599-29610	alterations	_	
151-33	29610-29611	.	_	

#Text=Supplementary Material
#Text=           Conflict of interests         
#Text=All authors have declared no conflicts of interest in relation to the subject of this study.
152-1	29612-29625	Supplementary	_	
152-2	29626-29634	Material	_	
152-3	29646-29654	Conflict	_	
152-4	29655-29657	of	_	
152-5	29658-29667	interests	_	
152-6	29677-29680	All	_	
152-7	29681-29688	authors	_	
152-8	29689-29693	have	_	
152-9	29694-29702	declared	_	
152-10	29703-29705	no	_	
152-11	29706-29715	conflicts	_	
152-12	29716-29718	of	_	
152-13	29719-29727	interest	_	
152-14	29728-29730	in	_	
152-15	29731-29739	relation	_	
152-16	29740-29742	to	_	
152-17	29743-29746	the	_	
152-18	29747-29754	subject	_	
152-19	29755-29757	of	_	
152-20	29758-29762	this	_	
152-21	29763-29768	study	_	
152-22	29768-29769	.	_	

#Text=Carol A.
153-1	29770-29775	Carol	_	
153-2	29776-29777	A	_	
153-3	29777-29778	.	_	

#Text=Tamminga reports the following financial disclosures:
#Text=American Psychiatric Association – Deputy Editor; Astellas – Ad Hoc Consultant; Autifony – Ad Hoc Consultant; The Brain and Behavior Foundation – Council Member; Eli Lilly Pharmaceuticals – Ad Hoc Consultant; Intra-cellular Therapies (ITI, Inc.) – Advisory Board, drug development; Institute of Medicine – Council Member; National Academy of Medicine – Council Member; Pfizer – Ad Hoc Consultant; Sunovion -- Investigator Initiated grant funding.
154-1	29779-29787	Tamminga	_	
154-2	29788-29795	reports	_	
154-3	29796-29799	the	_	
154-4	29800-29809	following	_	
154-5	29810-29819	financial	_	
154-6	29820-29831	disclosures	_	
154-7	29831-29832	:	_	
154-8	29833-29841	American	_	
154-9	29842-29853	Psychiatric	_	
154-10	29854-29865	Association	_	
154-11	29866-29867	–	_	
154-12	29868-29874	Deputy	_	
154-13	29875-29881	Editor	_	
154-14	29881-29882	;	_	
154-15	29883-29891	Astellas	_	
154-16	29892-29893	–	_	
154-17	29894-29896	Ad	_	
154-18	29897-29900	Hoc	_	
154-19	29901-29911	Consultant	_	
154-20	29911-29912	;	_	
154-21	29913-29921	Autifony	_	
154-22	29922-29923	–	_	
154-23	29924-29926	Ad	_	
154-24	29927-29930	Hoc	_	
154-25	29931-29941	Consultant	_	
154-26	29941-29942	;	_	
154-27	29943-29946	The	_	
154-28	29947-29952	Brain	_	
154-29	29953-29956	and	_	
154-30	29957-29965	Behavior	_	
154-31	29966-29976	Foundation	_	
154-32	29977-29978	–	_	
154-33	29979-29986	Council	_	
154-34	29987-29993	Member	_	
154-35	29993-29994	;	_	
154-36	29995-29998	Eli	_	
154-37	29999-30004	Lilly	_	
154-38	30005-30020	Pharmaceuticals	_	
154-39	30021-30022	–	_	
154-40	30023-30025	Ad	_	
154-41	30026-30029	Hoc	_	
154-42	30030-30040	Consultant	_	
154-43	30040-30041	;	_	
154-44	30042-30056	Intra-cellular	_	
154-45	30057-30066	Therapies	_	
154-46	30067-30068	(	_	
154-47	30068-30071	ITI	_	
154-48	30071-30072	,	_	
154-49	30073-30076	Inc	_	
154-50	30076-30077	.	_	
154-51	30077-30078	)	_	
154-52	30079-30080	–	_	
154-53	30081-30089	Advisory	_	
154-54	30090-30095	Board	_	
154-55	30095-30096	,	_	
154-56	30097-30101	drug	_	
154-57	30102-30113	development	_	
154-58	30113-30114	;	_	
154-59	30115-30124	Institute	_	
154-60	30125-30127	of	_	
154-61	30128-30136	Medicine	_	
154-62	30137-30138	–	_	
154-63	30139-30146	Council	_	
154-64	30147-30153	Member	_	
154-65	30153-30154	;	_	
154-66	30155-30163	National	_	
154-67	30164-30171	Academy	_	
154-68	30172-30174	of	_	
154-69	30175-30183	Medicine	_	
154-70	30184-30185	–	_	
154-71	30186-30193	Council	_	
154-72	30194-30200	Member	_	
154-73	30200-30201	;	_	
154-74	30202-30208	Pfizer	_	
154-75	30209-30210	–	_	
154-76	30211-30213	Ad	_	
154-77	30214-30217	Hoc	_	
154-78	30218-30228	Consultant	_	
154-79	30228-30229	;	_	
154-80	30230-30238	Sunovion	_	
154-81	30239-30240	-	_	
154-82	30240-30241	-	_	
154-83	30242-30254	Investigator	_	
154-84	30255-30264	Initiated	_	
154-85	30265-30270	grant	_	
154-86	30271-30278	funding	_	
154-87	30278-30279	.	_	

#Text=References
#Text=Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, “prefrontal” and “limbic” functions
#Text=Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs
#Text=Disruption of cortical association networks in schizophrenia and psychotic bipolar disorder
#Text=Frontoparietal activation with preparation for antisaccades
#Text=Isolation of saccade inhibition processes: rapid event-related fMRI of saccades and nogo trials
#Text=The brain’s default network: origins and implications for the study of psychosis
#Text=Different involvement of subregions within dorsal premotor and medial frontal cortex for pro- and antisaccades
#Text=Frequencies contributing to functional connectivity in the cerebral cortex in “resting-state” data
#Text=Neural networks related to pro-saccades and anti-saccades revealed by independent component analysis
#Text=Volumetric neural correlates of antisaccade eye movements in first-episode psychosis
#Text=Smooth pursuit and antisaccade eye movements in siblings discordant for schizophrenia
#Text=
#Text=Movement-related effects in fMRI time-series
#Text=Hyperfrontality in patients with schizophrenia during saccade and antisaccade tasks: a study with fMRI
#Text=Review of thalamocortical resting-state fMRI studies in schizophrenia
#Text=Longitudinal studies of antisaccades in antipsychotic-naive first-episode schizophrenia
#Text=Response suppression deficits in treatment-naive first-episode patients with schizophrenia, psychotic bipolar disorder and psychotic major depression
#Text=Activation of frontoparietal cortices during memorized triple-step sequences of saccadic eye movements: an fMRI study
#Text=Functional magnetic resonance imaging of sensorimotor transformations in saccades and antisaccades
#Text=TMS over the left angular gyrus impairs the ability to discriminate left from right
#Text=Functional specialization within macaque dorsolateral prefrontal cortex for the maintenance of task rules and cognitive control
#Text=The antisaccade task as a research tool in psychopathology: a critical review
#Text=Intrinsic Connectivity Provides the Baseline Framework for Variability in Motor Performance: A Multivariate Fusion Analysis of Low- and High-Frequency Resting-State Oscillations and Antisaccade Performance
#Text=Quantitative meta-analysis of fMRI and PET studies reveals consistent activation in fronto-striatal-parietal regions and cerebellum during antisaccades and prosaccades
#Text=Behavioral and Neural Plasticity of Ocular Motor Control: Changes in Performance and fMRI Activity Following Antisaccade Training
#Text=Macaque dorsolateral prefrontal cortex does not suppress saccade-related activity in the superior colliculus
#Text=Poor performance in smooth pursuit and antisaccadic eye-movement tasks in healthy siblings of patients with schizophrenia
#Text=The positive and negative syndrome scale (PANSS) for schizophrenia
#Text=Disease and drug effects on internally-generated and externally-elicited responses in first episode schizophrenia and psychotic bipolar disorder
#Text=Functional magnetic resonance imaging studies of eye movements in first episode schizophrenia: smooth pursuit, visually guided saccades and the oculomotor delayed response task
#Text=Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS)
#Text=Effects of unilateral deactivations of dorsolateral prefrontal cortex and anterior cingulate cortex on saccadic eye movements
#Text=Prefrontal cortex deactivation in macaques alters activity in the superior colliculus and impairs voluntary control of saccades
#Text=Longitudinal Changes in Resting-State Cerebral Activity in Patients with First-Episode Schizophrenia: A 1-Year Follow-up Functional MR Imaging Study
#Text=Psychoradiology: the frontier of neuroimaging in psychiatry
#Text=Resting-state brain function in schizophrenia and psychotic bipolar probands and their first-degree relatives
#Text=The Contribution of Network Organization and Integration to the Development of Cognitive Control
#Text=Neural correlates of refixation saccades and antisaccades in normal and schizophrenia subjects
#Text=Measuring liability for schizophrenia using optimized antisaccade stimulus parameters
#Text=A new depression scale designed to be sensitive to change
#Text=Consistency of network modules in resting-state FMRI connectome data
#Text=Functional neuroanatomy of antisaccade eye movements investigated with positron emission tomography
#Text=Rostral and dorsal anterior cingulate cortex make dissociable contributions during antisaccade error commission
#Text=Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion
#Text=Antisaccade performance in schizophrenia patients, their first-degree biological relatives, and community comparison subjects: data from the COGS study
#Text=Neuronal substrate of the saccadic inhibition deficit in schizophrenia investigated with 3-dimensional event-related functional magnetic resonance imaging
#Text=Elevated antisaccade error rate as an intermediate phenotype for psychosis across diagnostic categories
#Text=Reduced attentional engagement contributes to deficits in prefrontal inhibitory control in schizophrenia
#Text=An improved framework for confound regression and filtering for control of motion artifact in the preprocessing of resting-state functional connectivity data
#Text=Antisaccade performance predicted by neuronal activity in the supplementary eye field
#Text=The angular gyrus: multiple functions and multiple subdivisions
#Text=Primate supplementary eye field.
155-1	30280-30290	References	_	
155-2	30291-30296	Basal	_	
155-3	30297-30320	ganglia-thalamocortical	_	
155-4	30321-30329	circuits	_	
155-5	30329-30330	:	_	
155-6	30331-30339	parallel	_	
155-7	30340-30350	substrates	_	
155-8	30351-30354	for	_	
155-9	30355-30360	motor	_	
155-10	30360-30361	,	_	
155-11	30362-30372	oculomotor	_	
155-12	30372-30373	,	_	
155-13	30374-30375	“	_	
155-14	30375-30385	prefrontal	_	
155-15	30385-30386	”	_	
155-16	30387-30390	and	_	
155-17	30391-30392	“	_	
155-18	30392-30398	limbic	_	
155-19	30398-30399	”	_	
155-20	30400-30409	functions	_	
155-21	30410-30423	Antipsychotic	_	
155-22	30424-30428	dose	_	
155-23	30429-30440	equivalents	_	
155-24	30441-30444	and	_	
155-25	30445-30455	dose-years	_	
155-26	30455-30456	:	_	
155-27	30457-30458	a	_	
155-28	30459-30471	standardized	_	
155-29	30472-30478	method	_	
155-30	30479-30482	for	_	
155-31	30483-30492	comparing	_	
155-32	30493-30501	exposure	_	
155-33	30502-30504	to	_	
155-34	30505-30514	different	_	
155-35	30515-30520	drugs	_	
155-36	30521-30531	Disruption	_	
155-37	30532-30534	of	_	
155-38	30535-30543	cortical	_	
155-39	30544-30555	association	_	
155-40	30556-30564	networks	_	
155-41	30565-30567	in	_	
155-42	30568-30581	schizophrenia	_	
155-43	30582-30585	and	_	
155-44	30586-30595	psychotic	_	
155-45	30596-30603	bipolar	_	
155-46	30604-30612	disorder	_	
155-47	30613-30627	Frontoparietal	_	
155-48	30628-30638	activation	_	
155-49	30639-30643	with	_	
155-50	30644-30655	preparation	_	
155-51	30656-30659	for	_	
155-52	30660-30672	antisaccades	_	
155-53	30673-30682	Isolation	_	
155-54	30683-30685	of	_	
155-55	30686-30693	saccade	_	
155-56	30694-30704	inhibition	_	
155-57	30705-30714	processes	_	
155-58	30714-30715	:	_	
155-59	30716-30721	rapid	_	
155-60	30722-30735	event-related	_	
155-61	30736-30740	fMRI	_	
155-62	30741-30743	of	_	
155-63	30744-30752	saccades	_	
155-64	30753-30756	and	_	
155-65	30757-30761	nogo	_	
155-66	30762-30768	trials	_	
155-67	30769-30772	The	_	
155-68	30773-30778	brain	_	
155-69	30778-30779	’	_	
155-70	30779-30780	s	_	
155-71	30781-30788	default	_	
155-72	30789-30796	network	_	
155-73	30796-30797	:	_	
155-74	30798-30805	origins	_	
155-75	30806-30809	and	_	
155-76	30810-30822	implications	_	
155-77	30823-30826	for	_	
155-78	30827-30830	the	_	
155-79	30831-30836	study	_	
155-80	30837-30839	of	_	
155-81	30840-30849	psychosis	_	
155-82	30850-30859	Different	_	
155-83	30860-30871	involvement	_	
155-84	30872-30874	of	_	
155-85	30875-30885	subregions	_	
155-86	30886-30892	within	_	
155-87	30893-30899	dorsal	_	
155-88	30900-30908	premotor	_	
155-89	30909-30912	and	_	
155-90	30913-30919	medial	_	
155-91	30920-30927	frontal	_	
155-92	30928-30934	cortex	_	
155-93	30935-30938	for	_	
155-94	30939-30942	pro	_	
155-95	30942-30943	-	_	
155-96	30944-30947	and	_	
155-97	30948-30960	antisaccades	_	
155-98	30961-30972	Frequencies	_	
155-99	30973-30985	contributing	_	
155-100	30986-30988	to	_	
155-101	30989-30999	functional	_	
155-102	31000-31012	connectivity	_	
155-103	31013-31015	in	_	
155-104	31016-31019	the	_	
155-105	31020-31028	cerebral	_	
155-106	31029-31035	cortex	_	
155-107	31036-31038	in	_	
155-108	31039-31040	“	_	
155-109	31040-31053	resting-state	_	
155-110	31053-31054	”	_	
155-111	31055-31059	data	_	
155-112	31060-31066	Neural	_	
155-113	31067-31075	networks	_	
155-114	31076-31083	related	_	
155-115	31084-31086	to	_	
155-116	31087-31099	pro-saccades	_	
155-117	31100-31103	and	_	
155-118	31104-31117	anti-saccades	_	
155-119	31118-31126	revealed	_	
155-120	31127-31129	by	_	
155-121	31130-31141	independent	_	
155-122	31142-31151	component	_	
155-123	31152-31160	analysis	_	
155-124	31161-31171	Volumetric	_	
155-125	31172-31178	neural	_	
155-126	31179-31189	correlates	_	
155-127	31190-31192	of	_	
155-128	31193-31204	antisaccade	_	
155-129	31205-31208	eye	_	
155-130	31209-31218	movements	_	
155-131	31219-31221	in	_	
155-132	31222-31235	first-episode	_	
155-133	31236-31245	psychosis	_	
155-134	31246-31252	Smooth	_	
155-135	31253-31260	pursuit	_	
155-136	31261-31264	and	_	
155-137	31265-31276	antisaccade	_	
155-138	31277-31280	eye	_	
155-139	31281-31290	movements	_	
155-140	31291-31293	in	_	
155-141	31294-31302	siblings	_	
155-142	31303-31313	discordant	_	
155-143	31314-31317	for	_	
155-144	31318-31331	schizophrenia	_	
155-145	31333-31349	Movement-related	_	
155-146	31350-31357	effects	_	
155-147	31358-31360	in	_	
155-148	31361-31365	fMRI	_	
155-149	31366-31377	time-series	_	
155-150	31378-31393	Hyperfrontality	_	
155-151	31394-31396	in	_	
155-152	31397-31405	patients	_	
155-153	31406-31410	with	_	
155-154	31411-31424	schizophrenia	_	
155-155	31425-31431	during	_	
155-156	31432-31439	saccade	_	
155-157	31440-31443	and	_	
155-158	31444-31455	antisaccade	_	
155-159	31456-31461	tasks	_	
155-160	31461-31462	:	_	
155-161	31463-31464	a	_	
155-162	31465-31470	study	_	
155-163	31471-31475	with	_	
155-164	31476-31480	fMRI	_	
155-165	31481-31487	Review	_	
155-166	31488-31490	of	_	
155-167	31491-31506	thalamocortical	_	
155-168	31507-31520	resting-state	_	
155-169	31521-31525	fMRI	_	
155-170	31526-31533	studies	_	
155-171	31534-31536	in	_	
155-172	31537-31550	schizophrenia	_	
155-173	31551-31563	Longitudinal	_	
155-174	31564-31571	studies	_	
155-175	31572-31574	of	_	
155-176	31575-31587	antisaccades	_	
155-177	31588-31590	in	_	
155-178	31591-31610	antipsychotic-naive	_	
155-179	31611-31624	first-episode	_	
155-180	31625-31638	schizophrenia	_	
155-181	31639-31647	Response	_	
155-182	31648-31659	suppression	_	
155-183	31660-31668	deficits	_	
155-184	31669-31671	in	_	
155-185	31672-31687	treatment-naive	_	
155-186	31688-31701	first-episode	_	
155-187	31702-31710	patients	_	
155-188	31711-31715	with	_	
155-189	31716-31729	schizophrenia	_	
155-190	31729-31730	,	_	
155-191	31731-31740	psychotic	_	
155-192	31741-31748	bipolar	_	
155-193	31749-31757	disorder	_	
155-194	31758-31761	and	_	
155-195	31762-31771	psychotic	_	
155-196	31772-31777	major	_	
155-197	31778-31788	depression	_	
155-198	31789-31799	Activation	_	
155-199	31800-31802	of	_	
155-200	31803-31817	frontoparietal	_	
155-201	31818-31826	cortices	_	
155-202	31827-31833	during	_	
155-203	31834-31843	memorized	_	
155-204	31844-31855	triple-step	_	
155-205	31856-31865	sequences	_	
155-206	31866-31868	of	_	
155-207	31869-31877	saccadic	_	
155-208	31878-31881	eye	_	
155-209	31882-31891	movements	_	
155-210	31891-31892	:	_	
155-211	31893-31895	an	_	
155-212	31896-31900	fMRI	_	
155-213	31901-31906	study	_	
155-214	31907-31917	Functional	_	
155-215	31918-31926	magnetic	_	
155-216	31927-31936	resonance	_	
155-217	31937-31944	imaging	_	
155-218	31945-31947	of	_	
155-219	31948-31960	sensorimotor	_	
155-220	31961-31976	transformations	_	
155-221	31977-31979	in	_	
155-222	31980-31988	saccades	_	
155-223	31989-31992	and	_	
155-224	31993-32005	antisaccades	_	
155-225	32006-32009	TMS	_	
155-226	32010-32014	over	_	
155-227	32015-32018	the	_	
155-228	32019-32023	left	_	
155-229	32024-32031	angular	_	
155-230	32032-32037	gyrus	_	
155-231	32038-32045	impairs	_	
155-232	32046-32049	the	_	
155-233	32050-32057	ability	_	
155-234	32058-32060	to	_	
155-235	32061-32073	discriminate	_	
155-236	32074-32078	left	_	
155-237	32079-32083	from	_	
155-238	32084-32089	right	_	
155-239	32090-32100	Functional	_	
155-240	32101-32115	specialization	_	
155-241	32116-32122	within	_	
155-242	32123-32130	macaque	_	
155-243	32131-32143	dorsolateral	_	
155-244	32144-32154	prefrontal	_	
155-245	32155-32161	cortex	_	
155-246	32162-32165	for	_	
155-247	32166-32169	the	_	
155-248	32170-32181	maintenance	_	
155-249	32182-32184	of	_	
155-250	32185-32189	task	_	
155-251	32190-32195	rules	_	
155-252	32196-32199	and	_	
155-253	32200-32209	cognitive	_	
155-254	32210-32217	control	_	
155-255	32218-32221	The	_	
155-256	32222-32233	antisaccade	_	
155-257	32234-32238	task	_	
155-258	32239-32241	as	_	
155-259	32242-32243	a	_	
155-260	32244-32252	research	_	
155-261	32253-32257	tool	_	
155-262	32258-32260	in	_	
155-263	32261-32276	psychopathology	_	
155-264	32276-32277	:	_	
155-265	32278-32279	a	_	
155-266	32280-32288	critical	_	
155-267	32289-32295	review	_	
155-268	32296-32305	Intrinsic	_	
155-269	32306-32318	Connectivity	_	
155-270	32319-32327	Provides	_	
155-271	32328-32331	the	_	
155-272	32332-32340	Baseline	_	
155-273	32341-32350	Framework	_	
155-274	32351-32354	for	_	
155-275	32355-32366	Variability	_	
155-276	32367-32369	in	_	
155-277	32370-32375	Motor	_	
155-278	32376-32387	Performance	_	
155-279	32387-32388	:	_	
155-280	32389-32390	A	_	
155-281	32391-32403	Multivariate	_	
155-282	32404-32410	Fusion	_	
155-283	32411-32419	Analysis	_	
155-284	32420-32422	of	_	
155-285	32423-32426	Low	_	
155-286	32426-32427	-	_	
155-287	32428-32431	and	_	
155-288	32432-32446	High-Frequency	_	
155-289	32447-32460	Resting-State	_	
155-290	32461-32473	Oscillations	_	
155-291	32474-32477	and	_	
155-292	32478-32489	Antisaccade	_	
155-293	32490-32501	Performance	_	
155-294	32502-32514	Quantitative	_	
155-295	32515-32528	meta-analysis	_	
155-296	32529-32531	of	_	
155-297	32532-32536	fMRI	_	
155-298	32537-32540	and	_	
155-299	32541-32544	PET	_	
155-300	32545-32552	studies	_	
155-301	32553-32560	reveals	_	
155-302	32561-32571	consistent	_	
155-303	32572-32582	activation	_	
155-304	32583-32585	in	_	
155-305	32586-32610	fronto-striatal-parietal	_	
155-306	32611-32618	regions	_	
155-307	32619-32622	and	_	
155-308	32623-32633	cerebellum	_	
155-309	32634-32640	during	_	
155-310	32641-32653	antisaccades	_	
155-311	32654-32657	and	_	
155-312	32658-32669	prosaccades	_	
155-313	32670-32680	Behavioral	_	
155-314	32681-32684	and	_	
155-315	32685-32691	Neural	_	
155-316	32692-32702	Plasticity	_	
155-317	32703-32705	of	_	
155-318	32706-32712	Ocular	_	
155-319	32713-32718	Motor	_	
155-320	32719-32726	Control	_	
155-321	32726-32727	:	_	
155-322	32728-32735	Changes	_	
155-323	32736-32738	in	_	
155-324	32739-32750	Performance	_	
155-325	32751-32754	and	_	
155-326	32755-32759	fMRI	_	
155-327	32760-32768	Activity	_	
155-328	32769-32778	Following	_	
155-329	32779-32790	Antisaccade	_	
155-330	32791-32799	Training	_	
155-331	32800-32807	Macaque	_	
155-332	32808-32820	dorsolateral	_	
155-333	32821-32831	prefrontal	_	
155-334	32832-32838	cortex	_	
155-335	32839-32843	does	_	
155-336	32844-32847	not	_	
155-337	32848-32856	suppress	_	
155-338	32857-32872	saccade-related	_	
155-339	32873-32881	activity	_	
155-340	32882-32884	in	_	
155-341	32885-32888	the	_	
155-342	32889-32897	superior	_	
155-343	32898-32908	colliculus	_	
155-344	32909-32913	Poor	_	
155-345	32914-32925	performance	_	
155-346	32926-32928	in	_	
155-347	32929-32935	smooth	_	
155-348	32936-32943	pursuit	_	
155-349	32944-32947	and	_	
155-350	32948-32960	antisaccadic	_	
155-351	32961-32973	eye-movement	_	
155-352	32974-32979	tasks	_	
155-353	32980-32982	in	_	
155-354	32983-32990	healthy	_	
155-355	32991-32999	siblings	_	
155-356	33000-33002	of	_	
155-357	33003-33011	patients	_	
155-358	33012-33016	with	_	
155-359	33017-33030	schizophrenia	_	
155-360	33031-33034	The	_	
155-361	33035-33043	positive	_	
155-362	33044-33047	and	_	
155-363	33048-33056	negative	_	
155-364	33057-33065	syndrome	_	
155-365	33066-33071	scale	_	
155-366	33072-33073	(	_	
155-367	33073-33078	PANSS	_	
155-368	33078-33079	)	_	
155-369	33080-33083	for	_	
155-370	33084-33097	schizophrenia	_	
155-371	33098-33105	Disease	_	
155-372	33106-33109	and	_	
155-373	33110-33114	drug	_	
155-374	33115-33122	effects	_	
155-375	33123-33125	on	_	
155-376	33126-33146	internally-generated	_	
155-377	33147-33150	and	_	
155-378	33151-33170	externally-elicited	_	
155-379	33171-33180	responses	_	
155-380	33181-33183	in	_	
155-381	33184-33189	first	_	
155-382	33190-33197	episode	_	
155-383	33198-33211	schizophrenia	_	
155-384	33212-33215	and	_	
155-385	33216-33225	psychotic	_	
155-386	33226-33233	bipolar	_	
155-387	33234-33242	disorder	_	
155-388	33243-33253	Functional	_	
155-389	33254-33262	magnetic	_	
155-390	33263-33272	resonance	_	
155-391	33273-33280	imaging	_	
155-392	33281-33288	studies	_	
155-393	33289-33291	of	_	
155-394	33292-33295	eye	_	
155-395	33296-33305	movements	_	
155-396	33306-33308	in	_	
155-397	33309-33314	first	_	
155-398	33315-33322	episode	_	
155-399	33323-33336	schizophrenia	_	
155-400	33336-33337	:	_	
155-401	33338-33344	smooth	_	
155-402	33345-33352	pursuit	_	
155-403	33352-33353	,	_	
155-404	33354-33362	visually	_	
155-405	33363-33369	guided	_	
155-406	33370-33378	saccades	_	
155-407	33379-33382	and	_	
155-408	33383-33386	the	_	
155-409	33387-33397	oculomotor	_	
155-410	33398-33405	delayed	_	
155-411	33406-33414	response	_	
155-412	33415-33419	task	_	
155-413	33420-33425	Norms	_	
155-414	33426-33429	and	_	
155-415	33430-33445	standardization	_	
155-416	33446-33448	of	_	
155-417	33449-33452	the	_	
155-418	33453-33458	Brief	_	
155-419	33459-33469	Assessment	_	
155-420	33470-33472	of	_	
155-421	33473-33482	Cognition	_	
155-422	33483-33485	in	_	
155-423	33486-33499	Schizophrenia	_	
155-424	33500-33501	(	_	
155-425	33501-33505	BACS	_	
155-426	33505-33506	)	_	
155-427	33507-33514	Effects	_	
155-428	33515-33517	of	_	
155-429	33518-33528	unilateral	_	
155-430	33529-33542	deactivations	_	
155-431	33543-33545	of	_	
155-432	33546-33558	dorsolateral	_	
155-433	33559-33569	prefrontal	_	
155-434	33570-33576	cortex	_	
155-435	33577-33580	and	_	
155-436	33581-33589	anterior	_	
155-437	33590-33599	cingulate	_	
155-438	33600-33606	cortex	_	
155-439	33607-33609	on	_	
155-440	33610-33618	saccadic	_	
155-441	33619-33622	eye	_	
155-442	33623-33632	movements	_	
155-443	33633-33643	Prefrontal	_	
155-444	33644-33650	cortex	_	
155-445	33651-33663	deactivation	_	
155-446	33664-33666	in	_	
155-447	33667-33675	macaques	_	
155-448	33676-33682	alters	_	
155-449	33683-33691	activity	_	
155-450	33692-33694	in	_	
155-451	33695-33698	the	_	
155-452	33699-33707	superior	_	
155-453	33708-33718	colliculus	_	
155-454	33719-33722	and	_	
155-455	33723-33730	impairs	_	
155-456	33731-33740	voluntary	_	
155-457	33741-33748	control	_	
155-458	33749-33751	of	_	
155-459	33752-33760	saccades	_	
155-460	33761-33773	Longitudinal	_	
155-461	33774-33781	Changes	_	
155-462	33782-33784	in	_	
155-463	33785-33798	Resting-State	_	
155-464	33799-33807	Cerebral	_	
155-465	33808-33816	Activity	_	
155-466	33817-33819	in	_	
155-467	33820-33828	Patients	_	
155-468	33829-33833	with	_	
155-469	33834-33847	First-Episode	_	
155-470	33848-33861	Schizophrenia	_	
155-471	33861-33862	:	_	
155-472	33863-33864	A	_	
155-473	33865-33866	1	_	
155-474	33866-33867	-	_	
155-475	33867-33871	Year	_	
155-476	33872-33881	Follow-up	_	
155-477	33882-33892	Functional	_	
155-478	33893-33895	MR	_	
155-479	33896-33903	Imaging	_	
155-480	33904-33909	Study	_	
155-481	33910-33925	Psychoradiology	_	
155-482	33925-33926	:	_	
155-483	33927-33930	the	_	
155-484	33931-33939	frontier	_	
155-485	33940-33942	of	_	
155-486	33943-33955	neuroimaging	_	
155-487	33956-33958	in	_	
155-488	33959-33969	psychiatry	_	
155-489	33970-33983	Resting-state	_	
155-490	33984-33989	brain	_	
155-491	33990-33998	function	_	
155-492	33999-34001	in	_	
155-493	34002-34015	schizophrenia	_	
155-494	34016-34019	and	_	
155-495	34020-34029	psychotic	_	
155-496	34030-34037	bipolar	_	
155-497	34038-34046	probands	_	
155-498	34047-34050	and	_	
155-499	34051-34056	their	_	
155-500	34057-34069	first-degree	_	
155-501	34070-34079	relatives	_	
155-502	34080-34083	The	_	
155-503	34084-34096	Contribution	_	
155-504	34097-34099	of	_	
155-505	34100-34107	Network	_	
155-506	34108-34120	Organization	_	
155-507	34121-34124	and	_	
155-508	34125-34136	Integration	_	
155-509	34137-34139	to	_	
155-510	34140-34143	the	_	
155-511	34144-34155	Development	_	
155-512	34156-34158	of	_	
155-513	34159-34168	Cognitive	_	
155-514	34169-34176	Control	_	
155-515	34177-34183	Neural	_	
155-516	34184-34194	correlates	_	
155-517	34195-34197	of	_	
155-518	34198-34208	refixation	_	
155-519	34209-34217	saccades	_	
155-520	34218-34221	and	_	
155-521	34222-34234	antisaccades	_	
155-522	34235-34237	in	_	
155-523	34238-34244	normal	_	
155-524	34245-34248	and	_	
155-525	34249-34262	schizophrenia	_	
155-526	34263-34271	subjects	_	
155-527	34272-34281	Measuring	_	
155-528	34282-34291	liability	_	
155-529	34292-34295	for	_	
155-530	34296-34309	schizophrenia	_	
155-531	34310-34315	using	_	
155-532	34316-34325	optimized	_	
155-533	34326-34337	antisaccade	_	
155-534	34338-34346	stimulus	_	
155-535	34347-34357	parameters	_	
155-536	34358-34359	A	_	
155-537	34360-34363	new	_	
155-538	34364-34374	depression	_	
155-539	34375-34380	scale	_	
155-540	34381-34389	designed	_	
155-541	34390-34392	to	_	
155-542	34393-34395	be	_	
155-543	34396-34405	sensitive	_	
155-544	34406-34408	to	_	
155-545	34409-34415	change	_	
155-546	34416-34427	Consistency	_	
155-547	34428-34430	of	_	
155-548	34431-34438	network	_	
155-549	34439-34446	modules	_	
155-550	34447-34449	in	_	
155-551	34450-34463	resting-state	_	
155-552	34464-34468	FMRI	_	
155-553	34469-34479	connectome	_	
155-554	34480-34484	data	_	
155-555	34485-34495	Functional	_	
155-556	34496-34508	neuroanatomy	_	
155-557	34509-34511	of	_	
155-558	34512-34523	antisaccade	_	
155-559	34524-34527	eye	_	
155-560	34528-34537	movements	_	
155-561	34538-34550	investigated	_	
155-562	34551-34555	with	_	
155-563	34556-34564	positron	_	
155-564	34565-34573	emission	_	
155-565	34574-34584	tomography	_	
155-566	34585-34592	Rostral	_	
155-567	34593-34596	and	_	
155-568	34597-34603	dorsal	_	
155-569	34604-34612	anterior	_	
155-570	34613-34622	cingulate	_	
155-571	34623-34629	cortex	_	
155-572	34630-34634	make	_	
155-573	34635-34646	dissociable	_	
155-574	34647-34660	contributions	_	
155-575	34661-34667	during	_	
155-576	34668-34679	antisaccade	_	
155-577	34680-34685	error	_	
155-578	34686-34696	commission	_	
155-579	34697-34705	Spurious	_	
155-580	34706-34709	but	_	
155-581	34710-34720	systematic	_	
155-582	34721-34733	correlations	_	
155-583	34734-34736	in	_	
155-584	34737-34747	functional	_	
155-585	34748-34760	connectivity	_	
155-586	34761-34764	MRI	_	
155-587	34765-34773	networks	_	
155-588	34774-34779	arise	_	
155-589	34780-34784	from	_	
155-590	34785-34792	subject	_	
155-591	34793-34799	motion	_	
155-592	34800-34811	Antisaccade	_	
155-593	34812-34823	performance	_	
155-594	34824-34826	in	_	
155-595	34827-34840	schizophrenia	_	
155-596	34841-34849	patients	_	
155-597	34849-34850	,	_	
155-598	34851-34856	their	_	
155-599	34857-34869	first-degree	_	
155-600	34870-34880	biological	_	
155-601	34881-34890	relatives	_	
155-602	34890-34891	,	_	
155-603	34892-34895	and	_	
155-604	34896-34905	community	_	
155-605	34906-34916	comparison	_	
155-606	34917-34925	subjects	_	
155-607	34925-34926	:	_	
155-608	34927-34931	data	_	
155-609	34932-34936	from	_	
155-610	34937-34940	the	_	
155-611	34941-34945	COGS	_	
155-612	34946-34951	study	_	
155-613	34952-34960	Neuronal	_	
155-614	34961-34970	substrate	_	
155-615	34971-34973	of	_	
155-616	34974-34977	the	_	
155-617	34978-34986	saccadic	_	
155-618	34987-34997	inhibition	_	
155-619	34998-35005	deficit	_	
155-620	35006-35008	in	_	
155-621	35009-35022	schizophrenia	_	
155-622	35023-35035	investigated	_	
155-623	35036-35040	with	_	
155-624	35041-35042	3	_	
155-625	35042-35043	-	_	
155-626	35043-35054	dimensional	_	
155-627	35055-35068	event-related	_	
155-628	35069-35079	functional	_	
155-629	35080-35088	magnetic	_	
155-630	35089-35098	resonance	_	
155-631	35099-35106	imaging	_	
155-632	35107-35115	Elevated	_	
155-633	35116-35127	antisaccade	_	
155-634	35128-35133	error	_	
155-635	35134-35138	rate	_	
155-636	35139-35141	as	_	
155-637	35142-35144	an	_	
155-638	35145-35157	intermediate	_	
155-639	35158-35167	phenotype	_	
155-640	35168-35171	for	_	
155-641	35172-35181	psychosis	_	
155-642	35182-35188	across	_	
155-643	35189-35199	diagnostic	_	
155-644	35200-35210	categories	_	
155-645	35211-35218	Reduced	_	
155-646	35219-35230	attentional	_	
155-647	35231-35241	engagement	_	
155-648	35242-35253	contributes	_	
155-649	35254-35256	to	_	
155-650	35257-35265	deficits	_	
155-651	35266-35268	in	_	
155-652	35269-35279	prefrontal	_	
155-653	35280-35290	inhibitory	_	
155-654	35291-35298	control	_	
155-655	35299-35301	in	_	
155-656	35302-35315	schizophrenia	_	
155-657	35316-35318	An	_	
155-658	35319-35327	improved	_	
155-659	35328-35337	framework	_	
155-660	35338-35341	for	_	
155-661	35342-35350	confound	_	
155-662	35351-35361	regression	_	
155-663	35362-35365	and	_	
155-664	35366-35375	filtering	_	
155-665	35376-35379	for	_	
155-666	35380-35387	control	_	
155-667	35388-35390	of	_	
155-668	35391-35397	motion	_	
155-669	35398-35406	artifact	_	
155-670	35407-35409	in	_	
155-671	35410-35413	the	_	
155-672	35414-35427	preprocessing	_	
155-673	35428-35430	of	_	
155-674	35431-35444	resting-state	_	
155-675	35445-35455	functional	_	
155-676	35456-35468	connectivity	_	
155-677	35469-35473	data	_	
155-678	35474-35485	Antisaccade	_	
155-679	35486-35497	performance	_	
155-680	35498-35507	predicted	_	
155-681	35508-35510	by	_	
155-682	35511-35519	neuronal	_	
155-683	35520-35528	activity	_	
155-684	35529-35531	in	_	
155-685	35532-35535	the	_	
155-686	35536-35549	supplementary	_	
155-687	35550-35553	eye	_	
155-688	35554-35559	field	_	
155-689	35560-35563	The	_	
155-690	35564-35571	angular	_	
155-691	35572-35577	gyrus	_	
155-692	35577-35578	:	_	
155-693	35579-35587	multiple	_	
155-694	35588-35597	functions	_	
155-695	35598-35601	and	_	
155-696	35602-35610	multiple	_	
155-697	35611-35623	subdivisions	_	
155-698	35624-35631	Primate	_	
155-699	35632-35645	supplementary	_	
155-700	35646-35649	eye	_	
155-701	35650-35655	field	_	
155-702	35655-35656	.	_	

#Text=II.
156-1	35657-35659	II	_	
156-2	35659-35660	.	_	

#Text=Comparative aspects of connections with the thalamus, corpus striatum, and related forebrain nuclei
#Text=Functional neuroanatomy of anticipatory behavior: dissociation between sensory-driven and memory-driven systems
#Text=Influence of the thalamus on spatial visual processing in frontal cortex
#Text=fMRI studies of eye movement control: investigating the interaction of cognitive and sensorimotor brain systems
#Text=Eye tracking abnormalities in schizophrenia: evidence for dysfunction in the frontal eye fields
#Text=Positron emission tomography study of voluntary saccadic eye movements and spatial working memory
#Text=Facing competition: Neural mechanisms underlying parallel programming of antisaccades and prosaccades
#Text=Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP)
#Text=Reduced functional connectivity in a right-hemisphere network for volitional ocular motor control in schizophrenia
#Text=Cortico-striatal disconnection within the cingulo-opercular network in schizophrenia revealed by intrinsic functional connectivity analysis: a resting fMRI study
#Text=Frontal eye field, where art thou?
157-1	35661-35672	Comparative	_	
157-2	35673-35680	aspects	_	
157-3	35681-35683	of	_	
157-4	35684-35695	connections	_	
157-5	35696-35700	with	_	
157-6	35701-35704	the	_	
157-7	35705-35713	thalamus	_	
157-8	35713-35714	,	_	
157-9	35715-35721	corpus	_	
157-10	35722-35730	striatum	_	
157-11	35730-35731	,	_	
157-12	35732-35735	and	_	
157-13	35736-35743	related	_	
157-14	35744-35753	forebrain	_	
157-15	35754-35760	nuclei	_	
157-16	35761-35771	Functional	_	
157-17	35772-35784	neuroanatomy	_	
157-18	35785-35787	of	_	
157-19	35788-35800	anticipatory	_	
157-20	35801-35809	behavior	_	
157-21	35809-35810	:	_	
157-22	35811-35823	dissociation	_	
157-23	35824-35831	between	_	
157-24	35832-35846	sensory-driven	_	
157-25	35847-35850	and	_	
157-26	35851-35864	memory-driven	_	
157-27	35865-35872	systems	_	
157-28	35873-35882	Influence	_	
157-29	35883-35885	of	_	
157-30	35886-35889	the	_	
157-31	35890-35898	thalamus	_	
157-32	35899-35901	on	_	
157-33	35902-35909	spatial	_	
157-34	35910-35916	visual	_	
157-35	35917-35927	processing	_	
157-36	35928-35930	in	_	
157-37	35931-35938	frontal	_	
157-38	35939-35945	cortex	_	
157-39	35946-35950	fMRI	_	
157-40	35951-35958	studies	_	
157-41	35959-35961	of	_	
157-42	35962-35965	eye	_	
157-43	35966-35974	movement	_	
157-44	35975-35982	control	_	
157-45	35982-35983	:	_	
157-46	35984-35997	investigating	_	
157-47	35998-36001	the	_	
157-48	36002-36013	interaction	_	
157-49	36014-36016	of	_	
157-50	36017-36026	cognitive	_	
157-51	36027-36030	and	_	
157-52	36031-36043	sensorimotor	_	
157-53	36044-36049	brain	_	
157-54	36050-36057	systems	_	
157-55	36058-36061	Eye	_	
157-56	36062-36070	tracking	_	
157-57	36071-36084	abnormalities	_	
157-58	36085-36087	in	_	
157-59	36088-36101	schizophrenia	_	
157-60	36101-36102	:	_	
157-61	36103-36111	evidence	_	
157-62	36112-36115	for	_	
157-63	36116-36127	dysfunction	_	
157-64	36128-36130	in	_	
157-65	36131-36134	the	_	
157-66	36135-36142	frontal	_	
157-67	36143-36146	eye	_	
157-68	36147-36153	fields	_	
157-69	36154-36162	Positron	_	
157-70	36163-36171	emission	_	
157-71	36172-36182	tomography	_	
157-72	36183-36188	study	_	
157-73	36189-36191	of	_	
157-74	36192-36201	voluntary	_	
157-75	36202-36210	saccadic	_	
157-76	36211-36214	eye	_	
157-77	36215-36224	movements	_	
157-78	36225-36228	and	_	
157-79	36229-36236	spatial	_	
157-80	36237-36244	working	_	
157-81	36245-36251	memory	_	
157-82	36252-36258	Facing	_	
157-83	36259-36270	competition	_	
157-84	36270-36271	:	_	
157-85	36272-36278	Neural	_	
157-86	36279-36289	mechanisms	_	
157-87	36290-36300	underlying	_	
157-88	36301-36309	parallel	_	
157-89	36310-36321	programming	_	
157-90	36322-36324	of	_	
157-91	36325-36337	antisaccades	_	
157-92	36338-36341	and	_	
157-93	36342-36353	prosaccades	_	
157-94	36354-36362	Clinical	_	
157-95	36363-36373	phenotypes	_	
157-96	36374-36376	of	_	
157-97	36377-36386	psychosis	_	
157-98	36387-36389	in	_	
157-99	36390-36393	the	_	
157-100	36394-36415	Bipolar-Schizophrenia	_	
157-101	36416-36423	Network	_	
157-102	36424-36426	on	_	
157-103	36427-36439	Intermediate	_	
157-104	36440-36450	Phenotypes	_	
157-105	36451-36452	(	_	
157-106	36452-36458	B-SNIP	_	
157-107	36458-36459	)	_	
157-108	36460-36467	Reduced	_	
157-109	36468-36478	functional	_	
157-110	36479-36491	connectivity	_	
157-111	36492-36494	in	_	
157-112	36495-36496	a	_	
157-113	36497-36513	right-hemisphere	_	
157-114	36514-36521	network	_	
157-115	36522-36525	for	_	
157-116	36526-36536	volitional	_	
157-117	36537-36543	ocular	_	
157-118	36544-36549	motor	_	
157-119	36550-36557	control	_	
157-120	36558-36560	in	_	
157-121	36561-36574	schizophrenia	_	
157-122	36575-36591	Cortico-striatal	_	
157-123	36592-36605	disconnection	_	
157-124	36606-36612	within	_	
157-125	36613-36616	the	_	
157-126	36617-36634	cingulo-opercular	_	
157-127	36635-36642	network	_	
157-128	36643-36645	in	_	
157-129	36646-36659	schizophrenia	_	
157-130	36660-36668	revealed	_	
157-131	36669-36671	by	_	
157-132	36672-36681	intrinsic	_	
157-133	36682-36692	functional	_	
157-134	36693-36705	connectivity	_	
157-135	36706-36714	analysis	_	
157-136	36714-36715	:	_	
157-137	36716-36717	a	_	
157-138	36718-36725	resting	_	
157-139	36726-36730	fMRI	_	
157-140	36731-36736	study	_	
157-141	36737-36744	Frontal	_	
157-142	36745-36748	eye	_	
157-143	36749-36754	field	_	
157-144	36754-36755	,	_	
157-145	36756-36761	where	_	
157-146	36762-36765	art	_	
157-147	36766-36770	thou	_	
157-148	36770-36771	?	_	

#Text=Anatomy, function, and non-invasive manipulation of frontal regions involved in eye movements and associated cognitive operations
#Text=Microstimulation of monkey dorsolateral prefrontal cortex impairs antisaccade performance
#Text=Disconnected and Hyperactive: A Replication of Sensorimotor Cortex Abnormalities in Patients With Schizophrenia During Proactive Response Inhibition
#Text=
#Text=A comprehensive assessment of regional variation in the impact of head micromovements on functional connectomics
#Text=A rating scale for mania: reliability, validity and sensitivity
#Text=Neurobiological basis of head motion in brain imaging
#Text=ALFF and FC measurements associated with antisaccade error rate in patients and controls.
158-1	36772-36779	Anatomy	_	
158-2	36779-36780	,	_	
158-3	36781-36789	function	_	
158-4	36789-36790	,	_	
158-5	36791-36794	and	_	
158-6	36795-36807	non-invasive	_	
158-7	36808-36820	manipulation	_	
158-8	36821-36823	of	_	
158-9	36824-36831	frontal	_	
158-10	36832-36839	regions	_	
158-11	36840-36848	involved	_	
158-12	36849-36851	in	_	
158-13	36852-36855	eye	_	
158-14	36856-36865	movements	_	
158-15	36866-36869	and	_	
158-16	36870-36880	associated	_	
158-17	36881-36890	cognitive	_	
158-18	36891-36901	operations	_	
158-19	36902-36918	Microstimulation	_	
158-20	36919-36921	of	_	
158-21	36922-36928	monkey	_	
158-22	36929-36941	dorsolateral	_	
158-23	36942-36952	prefrontal	_	
158-24	36953-36959	cortex	_	
158-25	36960-36967	impairs	_	
158-26	36968-36979	antisaccade	_	
158-27	36980-36991	performance	_	
158-28	36992-37004	Disconnected	_	
158-29	37005-37008	and	_	
158-30	37009-37020	Hyperactive	_	
158-31	37020-37021	:	_	
158-32	37022-37023	A	_	
158-33	37024-37035	Replication	_	
158-34	37036-37038	of	_	
158-35	37039-37051	Sensorimotor	_	
158-36	37052-37058	Cortex	_	
158-37	37059-37072	Abnormalities	_	
158-38	37073-37075	in	_	
158-39	37076-37084	Patients	_	
158-40	37085-37089	With	_	
158-41	37090-37103	Schizophrenia	_	
158-42	37104-37110	During	_	
158-43	37111-37120	Proactive	_	
158-44	37121-37129	Response	_	
158-45	37130-37140	Inhibition	_	
158-46	37142-37143	A	_	
158-47	37144-37157	comprehensive	_	
158-48	37158-37168	assessment	_	
158-49	37169-37171	of	_	
158-50	37172-37180	regional	_	
158-51	37181-37190	variation	_	
158-52	37191-37193	in	_	
158-53	37194-37197	the	_	
158-54	37198-37204	impact	_	
158-55	37205-37207	of	_	
158-56	37208-37212	head	_	
158-57	37213-37227	micromovements	_	
158-58	37228-37230	on	_	
158-59	37231-37241	functional	_	
158-60	37242-37254	connectomics	_	
158-61	37255-37256	A	_	
158-62	37257-37263	rating	_	
158-63	37264-37269	scale	_	
158-64	37270-37273	for	_	
158-65	37274-37279	mania	_	
158-66	37279-37280	:	_	
158-67	37281-37292	reliability	_	
158-68	37292-37293	,	_	
158-69	37294-37302	validity	_	
158-70	37303-37306	and	_	
158-71	37307-37318	sensitivity	_	
158-72	37319-37334	Neurobiological	_	
158-73	37335-37340	basis	_	
158-74	37341-37343	of	_	
158-75	37344-37348	head	_	
158-76	37349-37355	motion	_	
158-77	37356-37358	in	_	
158-78	37359-37364	brain	_	
158-79	37365-37372	imaging	_	
158-80	37373-37377	ALFF	_	
158-81	37378-37381	and	_	
158-82	37382-37384	FC	_	
158-83	37385-37397	measurements	_	
158-84	37398-37408	associated	_	
158-85	37409-37413	with	_	
158-86	37414-37425	antisaccade	_	
158-87	37426-37431	error	_	
158-88	37432-37436	rate	_	
158-89	37437-37439	in	_	
158-90	37440-37448	patients	_	
158-91	37449-37452	and	_	
158-92	37453-37461	controls	_	
158-93	37461-37462	.	_	

#Text=Dots identify the location of peak group differences within clusters (Table III).
159-1	37463-37467	Dots	_	
159-2	37468-37476	identify	_	
159-3	37477-37480	the	_	
159-4	37481-37489	location	_	
159-5	37490-37492	of	_	
159-6	37493-37497	peak	_	
159-7	37498-37503	group	_	
159-8	37504-37515	differences	_	
159-9	37516-37522	within	_	
159-10	37523-37531	clusters	_	
159-11	37532-37533	(	_	
159-12	37533-37538	Table	_	
159-13	37539-37542	III	_	
159-14	37542-37543	)	_	
159-15	37543-37544	.	_	

#Text=FEF frontal eye field region, SEF supplementary eye field region, THA thalamus, MFG middle frontal gyrus; IPG inferior parietal gyrus; PCUN precuneus; ANG angular gyrus; MTG middle temporal gyrus; PHG parahippocampal gyrus; FFG fusiform gyrus; L left; R right.
160-1	37545-37548	FEF	_	
160-2	37549-37556	frontal	_	
160-3	37557-37560	eye	_	
160-4	37561-37566	field	_	
160-5	37567-37573	region	_	
160-6	37573-37574	,	_	
160-7	37575-37578	SEF	_	
160-8	37579-37592	supplementary	_	
160-9	37593-37596	eye	_	
160-10	37597-37602	field	_	
160-11	37603-37609	region	_	
160-12	37609-37610	,	_	
160-13	37611-37614	THA	_	
160-14	37615-37623	thalamus	_	
160-15	37623-37624	,	_	
160-16	37625-37628	MFG	_	
160-17	37629-37635	middle	_	
160-18	37636-37643	frontal	_	
160-19	37644-37649	gyrus	_	
160-20	37649-37650	;	_	
160-21	37651-37654	IPG	_	
160-22	37655-37663	inferior	_	
160-23	37664-37672	parietal	_	
160-24	37673-37678	gyrus	_	
160-25	37678-37679	;	_	
160-26	37680-37684	PCUN	_	
160-27	37685-37694	precuneus	_	
160-28	37694-37695	;	_	
160-29	37696-37699	ANG	_	
160-30	37700-37707	angular	_	
160-31	37708-37713	gyrus	_	
160-32	37713-37714	;	_	
160-33	37715-37718	MTG	_	
160-34	37719-37725	middle	_	
160-35	37726-37734	temporal	_	
160-36	37735-37740	gyrus	_	
160-37	37740-37741	;	_	
160-38	37742-37745	PHG	_	
160-39	37746-37761	parahippocampal	_	
160-40	37762-37767	gyrus	_	
160-41	37767-37768	;	_	
160-42	37769-37772	FFG	_	
160-43	37773-37781	fusiform	_	
160-44	37782-37787	gyrus	_	
160-45	37787-37788	;	_	
160-46	37789-37790	L	_	
160-47	37791-37795	left	_	
160-48	37795-37796	;	_	
160-49	37797-37798	R	_	
160-50	37799-37804	right	_	
160-51	37804-37805	.	_	

#Text=Red lines indicate that stronger FC was associated with higher error rates while blue lines indicate that weaker FC was associated with higher error rates.
161-1	37806-37809	Red	_	
161-2	37810-37815	lines	_	
161-3	37816-37824	indicate	_	
161-4	37825-37829	that	_	
161-5	37830-37838	stronger	_	
161-6	37839-37841	FC	_	
161-7	37842-37845	was	_	
161-8	37846-37856	associated	_	
161-9	37857-37861	with	_	
161-10	37862-37868	higher	_	
161-11	37869-37874	error	_	
161-12	37875-37880	rates	_	
161-13	37881-37886	while	_	
161-14	37887-37891	blue	_	
161-15	37892-37897	lines	_	
161-16	37898-37906	indicate	_	
161-17	37907-37911	that	_	
161-18	37912-37918	weaker	_	
161-19	37919-37921	FC	_	
161-20	37922-37925	was	_	
161-21	37926-37936	associated	_	
161-22	37937-37941	with	_	
161-23	37942-37948	higher	_	
161-24	37949-37954	error	_	
161-25	37955-37960	rates	_	
161-26	37960-37961	.	_	

#Text=ALFF and FC measurements associated with latency of correct antisaccades in patients and controls.
162-1	37962-37966	ALFF	_	
162-2	37967-37970	and	_	
162-3	37971-37973	FC	_	
162-4	37974-37986	measurements	_	
162-5	37987-37997	associated	_	
162-6	37998-38002	with	_	
162-7	38003-38010	latency	_	
162-8	38011-38013	of	_	
162-9	38014-38021	correct	_	
162-10	38022-38034	antisaccades	_	
162-11	38035-38037	in	_	
162-12	38038-38046	patients	_	
162-13	38047-38050	and	_	
162-14	38051-38059	controls	_	
162-15	38059-38060	.	_	

#Text=Dots identify the location of peak group differences within clusters (Table III).
163-1	38061-38065	Dots	_	
163-2	38066-38074	identify	_	
163-3	38075-38078	the	_	
163-4	38079-38087	location	_	
163-5	38088-38090	of	_	
163-6	38091-38095	peak	_	
163-7	38096-38101	group	_	
163-8	38102-38113	differences	_	
163-9	38114-38120	within	_	
163-10	38121-38129	clusters	_	
163-11	38130-38131	(	_	
163-12	38131-38136	Table	_	
163-13	38137-38140	III	_	
163-14	38140-38141	)	_	
163-15	38141-38142	.	_	

#Text=FEF frontal eye field region, SEF supplementary eye field region, THA thalamus, MFG middle frontal gyrus; ACC, anterior cingulate gyrus; CUN cuneus; PCUN precuneus; FFG fusiform gyrus, L left; R right.
164-1	38143-38146	FEF	_	
164-2	38147-38154	frontal	_	
164-3	38155-38158	eye	_	
164-4	38159-38164	field	_	
164-5	38165-38171	region	_	
164-6	38171-38172	,	_	
164-7	38173-38176	SEF	_	
164-8	38177-38190	supplementary	_	
164-9	38191-38194	eye	_	
164-10	38195-38200	field	_	
164-11	38201-38207	region	_	
164-12	38207-38208	,	_	
164-13	38209-38212	THA	_	
164-14	38213-38221	thalamus	_	
164-15	38221-38222	,	_	
164-16	38223-38226	MFG	_	
164-17	38227-38233	middle	_	
164-18	38234-38241	frontal	_	
164-19	38242-38247	gyrus	_	
164-20	38247-38248	;	_	
164-21	38249-38252	ACC	_	
164-22	38252-38253	,	_	
164-23	38254-38262	anterior	_	
164-24	38263-38272	cingulate	_	
164-25	38273-38278	gyrus	_	
164-26	38278-38279	;	_	
164-27	38280-38283	CUN	_	
164-28	38284-38290	cuneus	_	
164-29	38290-38291	;	_	
164-30	38292-38296	PCUN	_	
164-31	38297-38306	precuneus	_	
164-32	38306-38307	;	_	
164-33	38308-38311	FFG	_	
164-34	38312-38320	fusiform	_	
164-35	38321-38326	gyrus	_	
164-36	38326-38327	,	_	
164-37	38328-38329	L	_	
164-38	38330-38334	left	_	
164-39	38334-38335	;	_	
164-40	38336-38337	R	_	
164-41	38338-38343	right	_	
164-42	38343-38344	.	_	

#Text=Red lines indicate that stronger FC was associated with longer latency while blue lines indicate that weaker FC was associated with longer latency.
165-1	38345-38348	Red	_	
165-2	38349-38354	lines	_	
165-3	38355-38363	indicate	_	
165-4	38364-38368	that	_	
165-5	38369-38377	stronger	_	
165-6	38378-38380	FC	_	
165-7	38381-38384	was	_	
165-8	38385-38395	associated	_	
165-9	38396-38400	with	_	
165-10	38401-38407	longer	_	
165-11	38408-38415	latency	_	
165-12	38416-38421	while	_	
165-13	38422-38426	blue	_	
165-14	38427-38432	lines	_	
165-15	38433-38441	indicate	_	
165-16	38442-38446	that	_	
165-17	38447-38453	weaker	_	
165-18	38454-38456	FC	_	
165-19	38457-38460	was	_	
165-20	38461-38471	associated	_	
165-21	38472-38476	with	_	
165-22	38477-38483	longer	_	
165-23	38484-38491	latency	_	
165-24	38491-38492	.	_	

#Text=Characteristics of patients with psychosis and healthy controls
#Text=\tPsychosis Patients N=88\tHealthy Controls N=50\tComparison\t \tAge, Mean (SD)\t33 (12.5)\t35.0 (12.5)\tn.s.
166-1	38493-38508	Characteristics	_	
166-2	38509-38511	of	_	
166-3	38512-38520	patients	_	
166-4	38521-38525	with	_	
166-5	38526-38535	psychosis	_	
166-6	38536-38539	and	_	
166-7	38540-38547	healthy	_	
166-8	38548-38556	controls	_	
166-9	38558-38567	Psychosis	_	
166-10	38568-38576	Patients	_	
166-11	38577-38578	N	_	
166-12	38578-38579	=	_	
166-13	38579-38581	88	_	
166-14	38582-38589	Healthy	_	
166-15	38590-38598	Controls	_	
166-16	38599-38600	N	_	
166-17	38600-38601	=	_	
166-18	38601-38603	50	_	
166-19	38604-38614	Comparison	_	
166-20	38617-38620	Age	_	
166-21	38620-38621	,	_	
166-22	38622-38626	Mean	_	
166-23	38627-38628	(	_	
166-24	38628-38630	SD	_	
166-25	38630-38631	)	_	
166-26	38632-38634	33	_	
166-27	38635-38636	(	_	
166-28	38636-38640	12.5	_	
166-29	38640-38641	)	_	
166-30	38642-38646	35.0	_	
166-31	38647-38648	(	_	
166-32	38648-38652	12.5	_	
166-33	38652-38653	)	_	
166-34	38654-38657	n.s	_	
166-35	38657-38658	.	_	

#Text=Sex (% Male)\t57%\t39%\tn.s
167-1	38661-38664	Sex	_	
167-2	38665-38666	(	_	
167-3	38666-38667	%	_	
167-4	38668-38672	Male	_	
167-5	38672-38673	)	_	
167-6	38674-38677	57%	_	
167-7	38678-38681	39%	_	
167-8	38682-38685	n.s	_	

#Text=.
168-1	38685-38686	.	_	

#Text=% Caucasian\t57%\t60%\tn.s
169-1	38689-38690	%	_	
169-2	38691-38700	Caucasian	_	
169-3	38701-38704	57%	_	
169-4	38705-38708	60%	_	
169-5	38709-38712	n.s	_	

#Text=.
170-1	38712-38713	.	_	

#Text=% African-American\t32%\t26%\tn.s.
171-1	38716-38717	%	_	
171-2	38718-38734	African-American	_	
171-3	38735-38738	32%	_	
171-4	38739-38742	26%	_	
171-5	38743-38746	n.s	_	
171-6	38746-38747	.	_	

#Text=WRAT 4 Word Readinga, Mean (SD)\t100.3 (16.1)\t103.5 (14.4)\tn.s.
172-1	38750-38754	WRAT	_	
172-2	38755-38756	4	_	
172-3	38757-38761	Word	_	
172-4	38762-38770	Readinga	_	
172-5	38770-38771	,	_	
172-6	38772-38776	Mean	_	
172-7	38777-38778	(	_	
172-8	38778-38780	SD	_	
172-9	38780-38781	)	_	
172-10	38782-38787	100.3	_	
172-11	38788-38789	(	_	
172-12	38789-38793	16.1	_	
172-13	38793-38794	)	_	
172-14	38795-38800	103.5	_	
172-15	38801-38802	(	_	
172-16	38802-38806	14.4	_	
172-17	38806-38807	)	_	
172-18	38808-38811	n.s	_	
172-19	38811-38812	.	_	

#Text=BACSb, Mean z-scores (SD)\t−1.1 (1.4)\t0.2 (1.0)\tt(136)=5.4; p<0.001\t \tPANSSc Positive, Mean (SD)\t15.8 (5.3)\t\t\t \tPANSSc Negative, Mean (SD)\t16.1 (6.0)\t\t\t \tPANSSc Total, Mean (SD)\t65.3 (16.4)\t\t\t \tYMRSd, Mean (SD)\t6.3 (6.1)\t\t\t \tMADRSe, Mean (SD)\t10.8 (8.9)\t\t\t \tMedication status\t\t\t\t \tChlorpromazine Equivalentsf, Mean (SD)\t325mg (296)\t\t\t \tAntidepressants, N (%)\t45 (51%)\t\t\t \tMood Stabilizer, N (%)\t39 (44%)\t\t\t \tAntisaccade performance\t\t\t\t \tError Rate, Mean (SD)\t31% (20)\t18% (12)\tt(136)=−4.35; p<0.001\t \tAntisaccade Latency, Mean (SD)\t385ms (74)\t386ms (54)\tn.s.
173-1	38815-38820	BACSb	_	
173-2	38820-38821	,	_	
173-3	38822-38826	Mean	_	
173-4	38827-38835	z-scores	_	
173-5	38836-38837	(	_	
173-6	38837-38839	SD	_	
173-7	38839-38840	)	_	
173-8	38841-38842	−	_	
173-9	38842-38845	1.1	_	
173-10	38846-38847	(	_	
173-11	38847-38850	1.4	_	
173-12	38850-38851	)	_	
173-13	38852-38855	0.2	_	
173-14	38856-38857	(	_	
173-15	38857-38860	1.0	_	
173-16	38860-38861	)	_	
173-17	38862-38863	t	_	
173-18	38863-38864	(	_	
173-19	38864-38867	136	_	
173-20	38867-38868	)	_	
173-21	38868-38869	=	_	
173-22	38869-38872	5.4	_	
173-23	38872-38873	;	_	
173-24	38874-38875	p	_	
173-25	38875-38876	<	_	
173-26	38876-38881	0.001	_	
173-27	38884-38890	PANSSc	_	
173-28	38891-38899	Positive	_	
173-29	38899-38900	,	_	
173-30	38901-38905	Mean	_	
173-31	38906-38907	(	_	
173-32	38907-38909	SD	_	
173-33	38909-38910	)	_	
173-34	38911-38915	15.8	_	
173-35	38916-38917	(	_	
173-36	38917-38920	5.3	_	
173-37	38920-38921	)	_	
173-38	38926-38932	PANSSc	_	
173-39	38933-38941	Negative	_	
173-40	38941-38942	,	_	
173-41	38943-38947	Mean	_	
173-42	38948-38949	(	_	
173-43	38949-38951	SD	_	
173-44	38951-38952	)	_	
173-45	38953-38957	16.1	_	
173-46	38958-38959	(	_	
173-47	38959-38962	6.0	_	
173-48	38962-38963	)	_	
173-49	38968-38974	PANSSc	_	
173-50	38975-38980	Total	_	
173-51	38980-38981	,	_	
173-52	38982-38986	Mean	_	
173-53	38987-38988	(	_	
173-54	38988-38990	SD	_	
173-55	38990-38991	)	_	
173-56	38992-38996	65.3	_	
173-57	38997-38998	(	_	
173-58	38998-39002	16.4	_	
173-59	39002-39003	)	_	
173-60	39008-39013	YMRSd	_	
173-61	39013-39014	,	_	
173-62	39015-39019	Mean	_	
173-63	39020-39021	(	_	
173-64	39021-39023	SD	_	
173-65	39023-39024	)	_	
173-66	39025-39028	6.3	_	
173-67	39029-39030	(	_	
173-68	39030-39033	6.1	_	
173-69	39033-39034	)	_	
173-70	39039-39045	MADRSe	_	
173-71	39045-39046	,	_	
173-72	39047-39051	Mean	_	
173-73	39052-39053	(	_	
173-74	39053-39055	SD	_	
173-75	39055-39056	)	_	
173-76	39057-39061	10.8	_	
173-77	39062-39063	(	_	
173-78	39063-39066	8.9	_	
173-79	39066-39067	)	_	
173-80	39072-39082	Medication	_	
173-81	39083-39089	status	_	
173-82	39095-39109	Chlorpromazine	_	
173-83	39110-39122	Equivalentsf	_	
173-84	39122-39123	,	_	
173-85	39124-39128	Mean	_	
173-86	39129-39130	(	_	
173-87	39130-39132	SD	_	
173-88	39132-39133	)	_	
173-89	39134-39139	325mg	_	
173-90	39140-39141	(	_	
173-91	39141-39144	296	_	
173-92	39144-39145	)	_	
173-93	39150-39165	Antidepressants	_	
173-94	39165-39166	,	_	
173-95	39167-39168	N	_	
173-96	39169-39170	(	_	
173-97	39170-39171	%	_	
173-98	39171-39172	)	_	
173-99	39173-39175	45	_	
173-100	39176-39177	(	_	
173-101	39177-39180	51%	_	
173-102	39180-39181	)	_	
173-103	39186-39190	Mood	_	
173-104	39191-39201	Stabilizer	_	
173-105	39201-39202	,	_	
173-106	39203-39204	N	_	
173-107	39205-39206	(	_	
173-108	39206-39207	%	_	
173-109	39207-39208	)	_	
173-110	39209-39211	39	_	
173-111	39212-39213	(	_	
173-112	39213-39216	44%	_	
173-113	39216-39217	)	_	
173-114	39222-39233	Antisaccade	_	
173-115	39234-39245	performance	_	
173-116	39251-39256	Error	_	
173-117	39257-39261	Rate	_	
173-118	39261-39262	,	_	
173-119	39263-39267	Mean	_	
173-120	39268-39269	(	_	
173-121	39269-39271	SD	_	
173-122	39271-39272	)	_	
173-123	39273-39276	31%	_	
173-124	39277-39278	(	_	
173-125	39278-39280	20	_	
173-126	39280-39281	)	_	
173-127	39282-39285	18%	_	
173-128	39286-39287	(	_	
173-129	39287-39289	12	_	
173-130	39289-39290	)	_	
173-131	39291-39292	t	_	
173-132	39292-39293	(	_	
173-133	39293-39296	136	_	
173-134	39296-39297	)	_	
173-135	39297-39298	=	_	
173-136	39298-39299	−	_	
173-137	39299-39303	4.35	_	
173-138	39303-39304	;	_	
173-139	39305-39306	p	_	
173-140	39306-39307	<	_	
173-141	39307-39312	0.001	_	
173-142	39315-39326	Antisaccade	_	
173-143	39327-39334	Latency	_	
173-144	39334-39335	,	_	
173-145	39336-39340	Mean	_	
173-146	39341-39342	(	_	
173-147	39342-39344	SD	_	
173-148	39344-39345	)	_	
173-149	39346-39351	385ms	_	
173-150	39352-39353	(	_	
173-151	39353-39355	74	_	
173-152	39355-39356	)	_	
173-153	39357-39362	386ms	_	
173-154	39363-39364	(	_	
173-155	39364-39366	54	_	
173-156	39366-39367	)	_	
173-157	39368-39371	n.s	_	
173-158	39371-39372	.	_	

#Text=Wide Range Achievement Test 4th - Edition: Reading 
#Text=Brief Assessment of Cognition in Schizophrenia, z-scores are given relative to norms
#Text=Positive and Negative Symptom Scale 
#Text=Montgomery Asberg Depression Rating Scale 
#Text=Young Mania Rating Scale 
#Text=According to 
#Text=Regions with altered ALFF values in whole brain analyses in patients with psychosis (N=88) compared to healthy controls (N=50)
#Text=\tMINI coordinates: peak voxel\tCluster size\tp-values*\t \tLocation\tx\ty\tz\t\t\t \tPatients < Controls\t\t\t\t\t\t \tFEF region, left\t−39\t−24\t54\t717\t<0.001\t \tFEF region, right\t63\t−12\t36\t339\t<0.001\t \tSEF region\t−6\t−12\t45\t152\t0.01\t \tThalamus, left\t−12\t−12\t3\t101\t0.03\t \tThalamus, right\t15\t−12\t9\t155\t0.01\t \tOrbitofrontal gyrus, left\t−15\t36\t−9\t113\t0.02\t \tSuperior temporal gyrus, left\t−54\t−36\t21\t107\t0.03\t \t
#Text=ALFF Amplitude of low frequency fluctuations, MNI Montreal Neurological Institute, SD standard deviation, FEF frontal eye fields, SEF supplementary eye fields
#Text=A threshold of p=0.05 after AlphaSim correction was used to correct for multiple comparisons using a minimum cluster size of 80 contiguous voxels significant individually at a threshold of p<0.01.
174-1	39376-39380	Wide	_	
174-2	39381-39386	Range	_	
174-3	39387-39398	Achievement	_	
174-4	39399-39403	Test	_	
174-5	39404-39407	4th	_	
174-6	39408-39409	-	_	
174-7	39410-39417	Edition	_	
174-8	39417-39418	:	_	
174-9	39419-39426	Reading	_	
174-10	39428-39433	Brief	_	
174-11	39434-39444	Assessment	_	
174-12	39445-39447	of	_	
174-13	39448-39457	Cognition	_	
174-14	39458-39460	in	_	
174-15	39461-39474	Schizophrenia	_	
174-16	39474-39475	,	_	
174-17	39476-39484	z-scores	_	
174-18	39485-39488	are	_	
174-19	39489-39494	given	_	
174-20	39495-39503	relative	_	
174-21	39504-39506	to	_	
174-22	39507-39512	norms	_	
174-23	39513-39521	Positive	_	
174-24	39522-39525	and	_	
174-25	39526-39534	Negative	_	
174-26	39535-39542	Symptom	_	
174-27	39543-39548	Scale	_	
174-28	39550-39560	Montgomery	_	
174-29	39561-39567	Asberg	_	
174-30	39568-39578	Depression	_	
174-31	39579-39585	Rating	_	
174-32	39586-39591	Scale	_	
174-33	39593-39598	Young	_	
174-34	39599-39604	Mania	_	
174-35	39605-39611	Rating	_	
174-36	39612-39617	Scale	_	
174-37	39619-39628	According	_	
174-38	39629-39631	to	_	
174-39	39633-39640	Regions	_	
174-40	39641-39645	with	_	
174-41	39646-39653	altered	_	
174-42	39654-39658	ALFF	_	
174-43	39659-39665	values	_	
174-44	39666-39668	in	_	
174-45	39669-39674	whole	_	
174-46	39675-39680	brain	_	
174-47	39681-39689	analyses	_	
174-48	39690-39692	in	_	
174-49	39693-39701	patients	_	
174-50	39702-39706	with	_	
174-51	39707-39716	psychosis	_	
174-52	39717-39718	(	_	
174-53	39718-39719	N	_	
174-54	39719-39720	=	_	
174-55	39720-39722	88	_	
174-56	39722-39723	)	_	
174-57	39724-39732	compared	_	
174-58	39733-39735	to	_	
174-59	39736-39743	healthy	_	
174-60	39744-39752	controls	_	
174-61	39753-39754	(	_	
174-62	39754-39755	N	_	
174-63	39755-39756	=	_	
174-64	39756-39758	50	_	
174-65	39758-39759	)	_	
174-66	39761-39765	MINI	_	
174-67	39766-39777	coordinates	_	
174-68	39777-39778	:	_	
174-69	39779-39783	peak	_	
174-70	39784-39789	voxel	_	
174-71	39790-39797	Cluster	_	
174-72	39798-39802	size	_	
174-73	39803-39811	p-values	_	
174-74	39811-39812	*	_	
174-75	39815-39823	Location	_	
174-76	39824-39825	x	_	
174-77	39826-39827	y	_	
174-78	39828-39829	z	_	
174-79	39834-39842	Patients	_	
174-80	39843-39844	<	_	
174-81	39845-39853	Controls	_	
174-82	39861-39864	FEF	_	
174-83	39865-39871	region	_	
174-84	39871-39872	,	_	
174-85	39873-39877	left	_	
174-86	39878-39879	−	_	
174-87	39879-39881	39	_	
174-88	39882-39883	−	_	
174-89	39883-39885	24	_	
174-90	39886-39888	54	_	
174-91	39889-39892	717	_	
174-92	39893-39894	<	_	
174-93	39894-39899	0.001	_	
174-94	39902-39905	FEF	_	
174-95	39906-39912	region	_	
174-96	39912-39913	,	_	
174-97	39914-39919	right	_	
174-98	39920-39922	63	_	
174-99	39923-39924	−	_	
174-100	39924-39926	12	_	
174-101	39927-39929	36	_	
174-102	39930-39933	339	_	
174-103	39934-39935	<	_	
174-104	39935-39940	0.001	_	
174-105	39943-39946	SEF	_	
174-106	39947-39953	region	_	
174-107	39954-39955	−	_	
174-108	39955-39956	6	_	
174-109	39957-39958	−	_	
174-110	39958-39960	12	_	
174-111	39961-39963	45	_	
174-112	39964-39967	152	_	
174-113	39968-39972	0.01	_	
174-114	39975-39983	Thalamus	_	
174-115	39983-39984	,	_	
174-116	39985-39989	left	_	
174-117	39990-39991	−	_	
174-118	39991-39993	12	_	
174-119	39994-39995	−	_	
174-120	39995-39997	12	_	
174-121	39998-39999	3	_	
174-122	40000-40003	101	_	
174-123	40004-40008	0.03	_	
174-124	40011-40019	Thalamus	_	
174-125	40019-40020	,	_	
174-126	40021-40026	right	_	
174-127	40027-40029	15	_	
174-128	40030-40031	−	_	
174-129	40031-40033	12	_	
174-130	40034-40035	9	_	
174-131	40036-40039	155	_	
174-132	40040-40044	0.01	_	
174-133	40047-40060	Orbitofrontal	_	
174-134	40061-40066	gyrus	_	
174-135	40066-40067	,	_	
174-136	40068-40072	left	_	
174-137	40073-40074	−	_	
174-138	40074-40076	15	_	
174-139	40077-40079	36	_	
174-140	40080-40081	−	_	
174-141	40081-40082	9	_	
174-142	40083-40086	113	_	
174-143	40087-40091	0.02	_	
174-144	40094-40102	Superior	_	
174-145	40103-40111	temporal	_	
174-146	40112-40117	gyrus	_	
174-147	40117-40118	,	_	
174-148	40119-40123	left	_	
174-149	40124-40125	−	_	
174-150	40125-40127	54	_	
174-151	40128-40129	−	_	
174-152	40129-40131	36	_	
174-153	40132-40134	21	_	
174-154	40135-40138	107	_	
174-155	40139-40143	0.03	_	
174-156	40147-40151	ALFF	_	
174-157	40152-40161	Amplitude	_	
174-158	40162-40164	of	_	
174-159	40165-40168	low	_	
174-160	40169-40178	frequency	_	
174-161	40179-40191	fluctuations	_	
174-162	40191-40192	,	_	
174-163	40193-40196	MNI	_	
174-164	40197-40205	Montreal	_	
174-165	40206-40218	Neurological	_	
174-166	40219-40228	Institute	_	
174-167	40228-40229	,	_	
174-168	40230-40232	SD	_	
174-169	40233-40241	standard	_	
174-170	40242-40251	deviation	_	
174-171	40251-40252	,	_	
174-172	40253-40256	FEF	_	
174-173	40257-40264	frontal	_	
174-174	40265-40268	eye	_	
174-175	40269-40275	fields	_	
174-176	40275-40276	,	_	
174-177	40277-40280	SEF	_	
174-178	40281-40294	supplementary	_	
174-179	40295-40298	eye	_	
174-180	40299-40305	fields	_	
174-181	40306-40307	A	_	
174-182	40308-40317	threshold	_	
174-183	40318-40320	of	_	
174-184	40321-40322	p	_	
174-185	40322-40323	=	_	
174-186	40323-40327	0.05	_	
174-187	40328-40333	after	_	
174-188	40334-40342	AlphaSim	_	
174-189	40343-40353	correction	_	
174-190	40354-40357	was	_	
174-191	40358-40362	used	_	
174-192	40363-40365	to	_	
174-193	40366-40373	correct	_	
174-194	40374-40377	for	_	
174-195	40378-40386	multiple	_	
174-196	40387-40398	comparisons	_	
174-197	40399-40404	using	_	
174-198	40405-40406	a	_	
174-199	40407-40414	minimum	_	
174-200	40415-40422	cluster	_	
174-201	40423-40427	size	_	
174-202	40428-40430	of	_	
174-203	40431-40433	80	_	
174-204	40434-40444	contiguous	_	
174-205	40445-40451	voxels	_	
174-206	40452-40463	significant	_	
174-207	40464-40476	individually	_	
174-208	40477-40479	at	_	
174-209	40480-40481	a	_	
174-210	40482-40491	threshold	_	
174-211	40492-40494	of	_	
174-212	40495-40496	p	_	
174-213	40496-40497	<	_	
174-214	40497-40501	0.01	_	
174-215	40501-40502	.	_	

#Text=Altered functional connectivity (FC) within oculomotor fronto-thalamo circuitry in patients with psychosis (N=88) compared to healthy controls (N=50)
#Text=\t\tMINI coordinates: of peak voxel\tCluster size\tp\t \tSeed area\tClusters with altered FC\tx\ty\tz\t\t\t \tPatients > Controls\t \tFEF region, left\tCaudate, bilateral\t15\t12\t−3\t4450\t<0.001\t \t\tInferior parietal gyrus, left\t−57\t−42\t39\t261\t0.007\t \t\tInferior parietal gyrus, right\t60\t−39\t48\t340\t0.003\t \t\tPrecuneus, right\t9\t−72\t45\t172\t0.022\t \t\tMiddle frontal gyrus, left\t−36\t48\t15\t281\t0.005\t \tFEF region, right\tThalamus, bilateral\t18\t−24\t6\t1310\t<0.001\t \tThalamus, left\tFEF region, bilateral\t−48\t−6\t21\t3721\t<0.001\t \tThalamus, right\tFEF region, bilateral\t−51\t−9\t24\t5574\t<0.001\t \t\tParahippocampus, right\t27\t−21\t−30\t218\t0.017\t \t\tCuneus, bilateral\t−12\t−75\t27\t256\t0.011\t \tSEF region\tThalamus, bilateral\t21\t−24\t3\t1212\t<0.001\t \t\tAnterior cingulate, bilateral\t9\t36\t21\t368\t0.002\t \tPatients < Controls\t \tFEF region, left\tAngular gyrus, left\t−48\t−75\t39\t273\t0.006\t \t\tSEF region\t−6\t−39\t75\t1362\t<0.001\t \t\tPrecuneus, bilateral\t−3\t−48\t9\t473\t0.001\t \t\tFusiform gyrus, right\t42\t−18\t−24\t204\t0.014\t \t\tMiddle temporal gyrus, left\t−57\t−27\t−3\t421\t0.001\t \tFEF region, right\tSuperior temporal gyrus, left\t−54\t−12\t6\t350\t0.003\t \tThalamus, right\tMiddlle frontal gyrus, right\t30\t57\t12\t506\t0.001\t \t\tMiddle frontal gyrus, left\t−36\t36\t48\t149\t0.043\t \t
#Text=MNI Montreal Neurological Institute, FEF frontal eye field, SEF supplementary eye field,
#Text=
#Text=          Associations of resting state activity with antisaccade measures in patients with psychotic disorders (N=88) and controls (N=50)
#Text=          *
#Text=        
#Text=Antisaccade error rate\t \tPatients\tBeta\tt\tp-value\t \tFC FEF region, left, to\tInferior parietal gyrus, left\t−0.16\t−1.68\t0.09\t \t\tAngular gyrus, left\t0.31\t3.10\t0.003\t \t\tPrecuneus, bilateral\t−0.38\t−3.54\t0.001\t \t\tGyrus fusiformis, right\t−0.23\t−2.42\t0.02\t \t\tMiddle temporal gyrus, left\t−0.19\t−1.93\t0.06\t \tFC SEF to\tThalamus, bilareral\t0.27\t2.90\t0.005\t \tFC Thalamus, right, to\tParahippocampus, right\t−0.43\t−4.41\t<0.001\t \t\tMiddle frontal gyrus, left\t−0.20\t−2.12\t0.04\t \tControls\t\t\t\t \tALFF in FEF region, left\t\t−0.27\t−2.03\t0.05\t \tALFF in Thalamus, left\t\t0.43\t3.27\t0.002\t \tLatency of correct antisaccades\t \tPatients\tBeta\tt\tp-value\t \tFC Thalamus, right, to\tCuneus, bilateral\t−0.25\t−2.44\t0.02\t \t\tMiddle frontal gyrus, left\t0.18\t1.74\t0.09\t \tControls\t\t\t\t \tFC FEF region, left, to\tPrecuneus, right\t−0.32\t−2.54\t0.02\t \t\tMiddle frontal gyrus, left\t0.38\t2.58\t0.01\t \t\tSEF\t−0.25\t−1.78\t0.08\t \t\tFusiform gyrus, right\t0.29\t2.07\t0.05\t \tFC SEF to\tThalamus, bilateral\t0.31\t2.13\t0.04\t \t\tAnterior cingulate, bilateral\t−0.50\t−3.25\t0.002\t \t
#Text=Table depicts results from backwards regression analyses using ALFF and FC values as independent variables to predict antisaccade error rate and latency of correct antisaccades, respectively.
175-1	40503-40510	Altered	_	
175-2	40511-40521	functional	_	
175-3	40522-40534	connectivity	_	
175-4	40535-40536	(	_	
175-5	40536-40538	FC	_	
175-6	40538-40539	)	_	
175-7	40540-40546	within	_	
175-8	40547-40557	oculomotor	_	
175-9	40558-40572	fronto-thalamo	_	
175-10	40573-40582	circuitry	_	
175-11	40583-40585	in	_	
175-12	40586-40594	patients	_	
175-13	40595-40599	with	_	
175-14	40600-40609	psychosis	_	
175-15	40610-40611	(	_	
175-16	40611-40612	N	_	
175-17	40612-40613	=	_	
175-18	40613-40615	88	_	
175-19	40615-40616	)	_	
175-20	40617-40625	compared	_	
175-21	40626-40628	to	_	
175-22	40629-40636	healthy	_	
175-23	40637-40645	controls	_	
175-24	40646-40647	(	_	
175-25	40647-40648	N	_	
175-26	40648-40649	=	_	
175-27	40649-40651	50	_	
175-28	40651-40652	)	_	
175-29	40655-40659	MINI	_	
175-30	40660-40671	coordinates	_	
175-31	40671-40672	:	_	
175-32	40673-40675	of	_	
175-33	40676-40680	peak	_	
175-34	40681-40686	voxel	_	
175-35	40687-40694	Cluster	_	
175-36	40695-40699	size	_	
175-37	40700-40701	p	_	
175-38	40704-40708	Seed	_	
175-39	40709-40713	area	_	
175-40	40714-40722	Clusters	_	
175-41	40723-40727	with	_	
175-42	40728-40735	altered	_	
175-43	40736-40738	FC	_	
175-44	40739-40740	x	_	
175-45	40741-40742	y	_	
175-46	40743-40744	z	_	
175-47	40749-40757	Patients	_	
175-48	40758-40759	>	_	
175-49	40760-40768	Controls	_	
175-50	40771-40774	FEF	_	
175-51	40775-40781	region	_	
175-52	40781-40782	,	_	
175-53	40783-40787	left	_	
175-54	40788-40795	Caudate	_	
175-55	40795-40796	,	_	
175-56	40797-40806	bilateral	_	
175-57	40807-40809	15	_	
175-58	40810-40812	12	_	
175-59	40813-40814	−	_	
175-60	40814-40815	3	_	
175-61	40816-40820	4450	_	
175-62	40821-40822	<	_	
175-63	40822-40827	0.001	_	
175-64	40831-40839	Inferior	_	
175-65	40840-40848	parietal	_	
175-66	40849-40854	gyrus	_	
175-67	40854-40855	,	_	
175-68	40856-40860	left	_	
175-69	40861-40862	−	_	
175-70	40862-40864	57	_	
175-71	40865-40866	−	_	
175-72	40866-40868	42	_	
175-73	40869-40871	39	_	
175-74	40872-40875	261	_	
175-75	40876-40881	0.007	_	
175-76	40885-40893	Inferior	_	
175-77	40894-40902	parietal	_	
175-78	40903-40908	gyrus	_	
175-79	40908-40909	,	_	
175-80	40910-40915	right	_	
175-81	40916-40918	60	_	
175-82	40919-40920	−	_	
175-83	40920-40922	39	_	
175-84	40923-40925	48	_	
175-85	40926-40929	340	_	
175-86	40930-40935	0.003	_	
175-87	40939-40948	Precuneus	_	
175-88	40948-40949	,	_	
175-89	40950-40955	right	_	
175-90	40956-40957	9	_	
175-91	40958-40959	−	_	
175-92	40959-40961	72	_	
175-93	40962-40964	45	_	
175-94	40965-40968	172	_	
175-95	40969-40974	0.022	_	
175-96	40978-40984	Middle	_	
175-97	40985-40992	frontal	_	
175-98	40993-40998	gyrus	_	
175-99	40998-40999	,	_	
175-100	41000-41004	left	_	
175-101	41005-41006	−	_	
175-102	41006-41008	36	_	
175-103	41009-41011	48	_	
175-104	41012-41014	15	_	
175-105	41015-41018	281	_	
175-106	41019-41024	0.005	_	
175-107	41027-41030	FEF	_	
175-108	41031-41037	region	_	
175-109	41037-41038	,	_	
175-110	41039-41044	right	_	
175-111	41045-41053	Thalamus	_	
175-112	41053-41054	,	_	
175-113	41055-41064	bilateral	_	
175-114	41065-41067	18	_	
175-115	41068-41069	−	_	
175-116	41069-41071	24	_	
175-117	41072-41073	6	_	
175-118	41074-41078	1310	_	
175-119	41079-41080	<	_	
175-120	41080-41085	0.001	_	
175-121	41088-41096	Thalamus	_	
175-122	41096-41097	,	_	
175-123	41098-41102	left	_	
175-124	41103-41106	FEF	_	
175-125	41107-41113	region	_	
175-126	41113-41114	,	_	
175-127	41115-41124	bilateral	_	
175-128	41125-41126	−	_	
175-129	41126-41128	48	_	
175-130	41129-41130	−	_	
175-131	41130-41131	6	_	
175-132	41132-41134	21	_	
175-133	41135-41139	3721	_	
175-134	41140-41141	<	_	
175-135	41141-41146	0.001	_	
175-136	41149-41157	Thalamus	_	
175-137	41157-41158	,	_	
175-138	41159-41164	right	_	
175-139	41165-41168	FEF	_	
175-140	41169-41175	region	_	
175-141	41175-41176	,	_	
175-142	41177-41186	bilateral	_	
175-143	41187-41188	−	_	
175-144	41188-41190	51	_	
175-145	41191-41192	−	_	
175-146	41192-41193	9	_	
175-147	41194-41196	24	_	
175-148	41197-41201	5574	_	
175-149	41202-41203	<	_	
175-150	41203-41208	0.001	_	
175-151	41212-41227	Parahippocampus	_	
175-152	41227-41228	,	_	
175-153	41229-41234	right	_	
175-154	41235-41237	27	_	
175-155	41238-41239	−	_	
175-156	41239-41241	21	_	
175-157	41242-41243	−	_	
175-158	41243-41245	30	_	
175-159	41246-41249	218	_	
175-160	41250-41255	0.017	_	
175-161	41259-41265	Cuneus	_	
175-162	41265-41266	,	_	
175-163	41267-41276	bilateral	_	
175-164	41277-41278	−	_	
175-165	41278-41280	12	_	
175-166	41281-41282	−	_	
175-167	41282-41284	75	_	
175-168	41285-41287	27	_	
175-169	41288-41291	256	_	
175-170	41292-41297	0.011	_	
175-171	41300-41303	SEF	_	
175-172	41304-41310	region	_	
175-173	41311-41319	Thalamus	_	
175-174	41319-41320	,	_	
175-175	41321-41330	bilateral	_	
175-176	41331-41333	21	_	
175-177	41334-41335	−	_	
175-178	41335-41337	24	_	
175-179	41338-41339	3	_	
175-180	41340-41344	1212	_	
175-181	41345-41346	<	_	
175-182	41346-41351	0.001	_	
175-183	41355-41363	Anterior	_	
175-184	41364-41373	cingulate	_	
175-185	41373-41374	,	_	
175-186	41375-41384	bilateral	_	
175-187	41385-41386	9	_	
175-188	41387-41389	36	_	
175-189	41390-41392	21	_	
175-190	41393-41396	368	_	
175-191	41397-41402	0.002	_	
175-192	41405-41413	Patients	_	
175-193	41414-41415	<	_	
175-194	41416-41424	Controls	_	
175-195	41427-41430	FEF	_	
175-196	41431-41437	region	_	
175-197	41437-41438	,	_	
175-198	41439-41443	left	_	
175-199	41444-41451	Angular	_	
175-200	41452-41457	gyrus	_	
175-201	41457-41458	,	_	
175-202	41459-41463	left	_	
175-203	41464-41465	−	_	
175-204	41465-41467	48	_	
175-205	41468-41469	−	_	
175-206	41469-41471	75	_	
175-207	41472-41474	39	_	
175-208	41475-41478	273	_	
175-209	41479-41484	0.006	_	
175-210	41488-41491	SEF	_	
175-211	41492-41498	region	_	
175-212	41499-41500	−	_	
175-213	41500-41501	6	_	
175-214	41502-41503	−	_	
175-215	41503-41505	39	_	
175-216	41506-41508	75	_	
175-217	41509-41513	1362	_	
175-218	41514-41515	<	_	
175-219	41515-41520	0.001	_	
175-220	41524-41533	Precuneus	_	
175-221	41533-41534	,	_	
175-222	41535-41544	bilateral	_	
175-223	41545-41546	−	_	
175-224	41546-41547	3	_	
175-225	41548-41549	−	_	
175-226	41549-41551	48	_	
175-227	41552-41553	9	_	
175-228	41554-41557	473	_	
175-229	41558-41563	0.001	_	
175-230	41567-41575	Fusiform	_	
175-231	41576-41581	gyrus	_	
175-232	41581-41582	,	_	
175-233	41583-41588	right	_	
175-234	41589-41591	42	_	
175-235	41592-41593	−	_	
175-236	41593-41595	18	_	
175-237	41596-41597	−	_	
175-238	41597-41599	24	_	
175-239	41600-41603	204	_	
175-240	41604-41609	0.014	_	
175-241	41613-41619	Middle	_	
175-242	41620-41628	temporal	_	
175-243	41629-41634	gyrus	_	
175-244	41634-41635	,	_	
175-245	41636-41640	left	_	
175-246	41641-41642	−	_	
175-247	41642-41644	57	_	
175-248	41645-41646	−	_	
175-249	41646-41648	27	_	
175-250	41649-41650	−	_	
175-251	41650-41651	3	_	
175-252	41652-41655	421	_	
175-253	41656-41661	0.001	_	
175-254	41664-41667	FEF	_	
175-255	41668-41674	region	_	
175-256	41674-41675	,	_	
175-257	41676-41681	right	_	
175-258	41682-41690	Superior	_	
175-259	41691-41699	temporal	_	
175-260	41700-41705	gyrus	_	
175-261	41705-41706	,	_	
175-262	41707-41711	left	_	
175-263	41712-41713	−	_	
175-264	41713-41715	54	_	
175-265	41716-41717	−	_	
175-266	41717-41719	12	_	
175-267	41720-41721	6	_	
175-268	41722-41725	350	_	
175-269	41726-41731	0.003	_	
175-270	41734-41742	Thalamus	_	
175-271	41742-41743	,	_	
175-272	41744-41749	right	_	
175-273	41750-41757	Middlle	_	
175-274	41758-41765	frontal	_	
175-275	41766-41771	gyrus	_	
175-276	41771-41772	,	_	
175-277	41773-41778	right	_	
175-278	41779-41781	30	_	
175-279	41782-41784	57	_	
175-280	41785-41787	12	_	
175-281	41788-41791	506	_	
175-282	41792-41797	0.001	_	
175-283	41801-41807	Middle	_	
175-284	41808-41815	frontal	_	
175-285	41816-41821	gyrus	_	
175-286	41821-41822	,	_	
175-287	41823-41827	left	_	
175-288	41828-41829	−	_	
175-289	41829-41831	36	_	
175-290	41832-41834	36	_	
175-291	41835-41837	48	_	
175-292	41838-41841	149	_	
175-293	41842-41847	0.043	_	
175-294	41851-41854	MNI	_	
175-295	41855-41863	Montreal	_	
175-296	41864-41876	Neurological	_	
175-297	41877-41886	Institute	_	
175-298	41886-41887	,	_	
175-299	41888-41891	FEF	_	
175-300	41892-41899	frontal	_	
175-301	41900-41903	eye	_	
175-302	41904-41909	field	_	
175-303	41909-41910	,	_	
175-304	41911-41914	SEF	_	
175-305	41915-41928	supplementary	_	
175-306	41929-41932	eye	_	
175-307	41933-41938	field	_	
175-308	41938-41939	,	_	
175-309	41951-41963	Associations	_	
175-310	41964-41966	of	_	
175-311	41967-41974	resting	_	
175-312	41975-41980	state	_	
175-313	41981-41989	activity	_	
175-314	41990-41994	with	_	
175-315	41995-42006	antisaccade	_	
175-316	42007-42015	measures	_	
175-317	42016-42018	in	_	
175-318	42019-42027	patients	_	
175-319	42028-42032	with	_	
175-320	42033-42042	psychotic	_	
175-321	42043-42052	disorders	_	
175-322	42053-42054	(	_	
175-323	42054-42055	N	_	
175-324	42055-42056	=	_	
175-325	42056-42058	88	_	
175-326	42058-42059	)	_	
175-327	42060-42063	and	_	
175-328	42064-42072	controls	_	
175-329	42073-42074	(	_	
175-330	42074-42075	N	_	
175-331	42075-42076	=	_	
175-332	42076-42078	50	_	
175-333	42078-42079	)	_	
175-334	42090-42091	*	_	
175-335	42101-42112	Antisaccade	_	
175-336	42113-42118	error	_	
175-337	42119-42123	rate	_	
175-338	42126-42134	Patients	_	
175-339	42135-42139	Beta	_	
175-340	42140-42141	t	_	
175-341	42142-42149	p-value	_	
175-342	42152-42154	FC	_	
175-343	42155-42158	FEF	_	
175-344	42159-42165	region	_	
175-345	42165-42166	,	_	
175-346	42167-42171	left	_	
175-347	42171-42172	,	_	
175-348	42173-42175	to	_	
175-349	42176-42184	Inferior	_	
175-350	42185-42193	parietal	_	
175-351	42194-42199	gyrus	_	
175-352	42199-42200	,	_	
175-353	42201-42205	left	_	
175-354	42206-42207	−	_	
175-355	42207-42211	0.16	_	
175-356	42212-42213	−	_	
175-357	42213-42217	1.68	_	
175-358	42218-42222	0.09	_	
175-359	42226-42233	Angular	_	
175-360	42234-42239	gyrus	_	
175-361	42239-42240	,	_	
175-362	42241-42245	left	_	
175-363	42246-42250	0.31	_	
175-364	42251-42255	3.10	_	
175-365	42256-42261	0.003	_	
175-366	42265-42274	Precuneus	_	
175-367	42274-42275	,	_	
175-368	42276-42285	bilateral	_	
175-369	42286-42287	−	_	
175-370	42287-42291	0.38	_	
175-371	42292-42293	−	_	
175-372	42293-42297	3.54	_	
175-373	42298-42303	0.001	_	
175-374	42307-42312	Gyrus	_	
175-375	42313-42323	fusiformis	_	
175-376	42323-42324	,	_	
175-377	42325-42330	right	_	
175-378	42331-42332	−	_	
175-379	42332-42336	0.23	_	
175-380	42337-42338	−	_	
175-381	42338-42342	2.42	_	
175-382	42343-42347	0.02	_	
175-383	42351-42357	Middle	_	
175-384	42358-42366	temporal	_	
175-385	42367-42372	gyrus	_	
175-386	42372-42373	,	_	
175-387	42374-42378	left	_	
175-388	42379-42380	−	_	
175-389	42380-42384	0.19	_	
175-390	42385-42386	−	_	
175-391	42386-42390	1.93	_	
175-392	42391-42395	0.06	_	
175-393	42398-42400	FC	_	
175-394	42401-42404	SEF	_	
175-395	42405-42407	to	_	
175-396	42408-42416	Thalamus	_	
175-397	42416-42417	,	_	
175-398	42418-42427	bilareral	_	
175-399	42428-42432	0.27	_	
175-400	42433-42437	2.90	_	
175-401	42438-42443	0.005	_	
175-402	42446-42448	FC	_	
175-403	42449-42457	Thalamus	_	
175-404	42457-42458	,	_	
175-405	42459-42464	right	_	
175-406	42464-42465	,	_	
175-407	42466-42468	to	_	
175-408	42469-42484	Parahippocampus	_	
175-409	42484-42485	,	_	
175-410	42486-42491	right	_	
175-411	42492-42493	−	_	
175-412	42493-42497	0.43	_	
175-413	42498-42499	−	_	
175-414	42499-42503	4.41	_	
175-415	42504-42505	<	_	
175-416	42505-42510	0.001	_	
175-417	42514-42520	Middle	_	
175-418	42521-42528	frontal	_	
175-419	42529-42534	gyrus	_	
175-420	42534-42535	,	_	
175-421	42536-42540	left	_	
175-422	42541-42542	−	_	
175-423	42542-42546	0.20	_	
175-424	42547-42548	−	_	
175-425	42548-42552	2.12	_	
175-426	42553-42557	0.04	_	
175-427	42560-42568	Controls	_	
175-428	42574-42578	ALFF	_	
175-429	42579-42581	in	_	
175-430	42582-42585	FEF	_	
175-431	42586-42592	region	_	
175-432	42592-42593	,	_	
175-433	42594-42598	left	_	
175-434	42600-42601	−	_	
175-435	42601-42605	0.27	_	
175-436	42606-42607	−	_	
175-437	42607-42611	2.03	_	
175-438	42612-42616	0.05	_	
175-439	42619-42623	ALFF	_	
175-440	42624-42626	in	_	
175-441	42627-42635	Thalamus	_	
175-442	42635-42636	,	_	
175-443	42637-42641	left	_	
175-444	42643-42647	0.43	_	
175-445	42648-42652	3.27	_	
175-446	42653-42658	0.002	_	
175-447	42661-42668	Latency	_	
175-448	42669-42671	of	_	
175-449	42672-42679	correct	_	
175-450	42680-42692	antisaccades	_	
175-451	42695-42703	Patients	_	
175-452	42704-42708	Beta	_	
175-453	42709-42710	t	_	
175-454	42711-42718	p-value	_	
175-455	42721-42723	FC	_	
175-456	42724-42732	Thalamus	_	
175-457	42732-42733	,	_	
175-458	42734-42739	right	_	
175-459	42739-42740	,	_	
175-460	42741-42743	to	_	
175-461	42744-42750	Cuneus	_	
175-462	42750-42751	,	_	
175-463	42752-42761	bilateral	_	
175-464	42762-42763	−	_	
175-465	42763-42767	0.25	_	
175-466	42768-42769	−	_	
175-467	42769-42773	2.44	_	
175-468	42774-42778	0.02	_	
175-469	42782-42788	Middle	_	
175-470	42789-42796	frontal	_	
175-471	42797-42802	gyrus	_	
175-472	42802-42803	,	_	
175-473	42804-42808	left	_	
175-474	42809-42813	0.18	_	
175-475	42814-42818	1.74	_	
175-476	42819-42823	0.09	_	
175-477	42826-42834	Controls	_	
175-478	42840-42842	FC	_	
175-479	42843-42846	FEF	_	
175-480	42847-42853	region	_	
175-481	42853-42854	,	_	
175-482	42855-42859	left	_	
175-483	42859-42860	,	_	
175-484	42861-42863	to	_	
175-485	42864-42873	Precuneus	_	
175-486	42873-42874	,	_	
175-487	42875-42880	right	_	
175-488	42881-42882	−	_	
175-489	42882-42886	0.32	_	
175-490	42887-42888	−	_	
175-491	42888-42892	2.54	_	
175-492	42893-42897	0.02	_	
175-493	42901-42907	Middle	_	
175-494	42908-42915	frontal	_	
175-495	42916-42921	gyrus	_	
175-496	42921-42922	,	_	
175-497	42923-42927	left	_	
175-498	42928-42932	0.38	_	
175-499	42933-42937	2.58	_	
175-500	42938-42942	0.01	_	
175-501	42946-42949	SEF	_	
175-502	42950-42951	−	_	
175-503	42951-42955	0.25	_	
175-504	42956-42957	−	_	
175-505	42957-42961	1.78	_	
175-506	42962-42966	0.08	_	
175-507	42970-42978	Fusiform	_	
175-508	42979-42984	gyrus	_	
175-509	42984-42985	,	_	
175-510	42986-42991	right	_	
175-511	42992-42996	0.29	_	
175-512	42997-43001	2.07	_	
175-513	43002-43006	0.05	_	
175-514	43009-43011	FC	_	
175-515	43012-43015	SEF	_	
175-516	43016-43018	to	_	
175-517	43019-43027	Thalamus	_	
175-518	43027-43028	,	_	
175-519	43029-43038	bilateral	_	
175-520	43039-43043	0.31	_	
175-521	43044-43048	2.13	_	
175-522	43049-43053	0.04	_	
175-523	43057-43065	Anterior	_	
175-524	43066-43075	cingulate	_	
175-525	43075-43076	,	_	
175-526	43077-43086	bilateral	_	
175-527	43087-43088	−	_	
175-528	43088-43092	0.50	_	
175-529	43093-43094	−	_	
175-530	43094-43098	3.25	_	
175-531	43099-43104	0.002	_	
175-532	43108-43113	Table	_	
175-533	43114-43121	depicts	_	
175-534	43122-43129	results	_	
175-535	43130-43134	from	_	
175-536	43135-43144	backwards	_	
175-537	43145-43155	regression	_	
175-538	43156-43164	analyses	_	
175-539	43165-43170	using	_	
175-540	43171-43175	ALFF	_	
175-541	43176-43179	and	_	
175-542	43180-43182	FC	_	
175-543	43183-43189	values	_	
175-544	43190-43192	as	_	
175-545	43193-43204	independent	_	
175-546	43205-43214	variables	_	
175-547	43215-43217	to	_	
175-548	43218-43225	predict	_	
175-549	43226-43237	antisaccade	_	
175-550	43238-43243	error	_	
175-551	43244-43248	rate	_	
175-552	43249-43252	and	_	
175-553	43253-43260	latency	_	
175-554	43261-43263	of	_	
175-555	43264-43271	correct	_	
175-556	43272-43284	antisaccades	_	
175-557	43284-43285	,	_	
175-558	43286-43298	respectively	_	
175-559	43298-43299	.	_	

#Text=Only results from final models that together best predicted antisaccade measures are shown.
176-1	43300-43304	Only	_	
176-2	43305-43312	results	_	
176-3	43313-43317	from	_	
176-4	43318-43323	final	_	
176-5	43324-43330	models	_	
176-6	43331-43335	that	_	
176-7	43336-43344	together	_	
176-8	43345-43349	best	_	
176-9	43350-43359	predicted	_	
176-10	43360-43371	antisaccade	_	
176-11	43372-43380	measures	_	
176-12	43381-43384	are	_	
176-13	43385-43390	shown	_	
176-14	43390-43391	.	_	
